Metabolic outcomes of islet transplantation and correlation of graft function with hepatic imaging and immune response by Brooks, Augustin Marchand Standish
  
Metabolic outcomes of islet transplantation 
and correlation of graft function with 
hepatic imaging and immune response 
 
 
 
 
 
 
 
 
Augustin Marchand Standish Brooks 
 
Thesis presented for the degree of MD in Cellular Medicine 2015 
 
Institute of Cellular Medicine 
University of Newcastle upon Tyne 
 
  
  
ii 
  
  
iii 
ABSTRACT 
Introduction 
Recipients of an islet transplant at all UK NHS-funded centres were invited to take part 
in an ethically approved experimental medicine follow-up study. Objectives were to 
determine metabolic outcomes post-intervention and identify potential surrogate 
markers for graft failure. 
Methods 
Assessment of islet recipients was undertaken pre-transplant, 1 month post-transplant 
and 3-6 monthly thereafter. Clinical review included HbA1c, hypoglycaemia frequency, 
insulin requirements, donor specific antibody (DSA) screening, magnetic resonance 
imaging (MRI) for hepatic fat assessment and continuous glucose monitoring (CGM) 
one week prior to standardised meal tolerance test (MTT). 
Results 
Twenty recipients received 35 islet infusions (single graft:n=7; two:n=11; three:n=2; 
transplant mass per recipient (median[IQR]) 8770(6536-13045) IEQ/kg), with all 
recipients receiving induction and maintenance immunosuppression. Graft function was 
maintained in 80% of recipients at 24(13.5-36) months. Frequency of severe 
hypoglycaemia reduced from 20(7-50) to 0.3(0-1.6) episodes per patient-year 
(p<0.001), with improved hypoglycaemia awareness (Gold score: pre-transplant 6(5-7); 
post-transplant 3(1.5-4.5); p<0.03) and HbA1c 6.2(5.7-8.4)% post-transplant, and 
cessation of exogenous insulin in 45% of recipients. In a single site sub-study, CGM 
demonstrated a continuous relationship between stimulated C-peptide and glucose 
variability, hyperglycaemia risk and hypoglycaemia risk. No significant difference in 
liver fat fraction was noted pre and post-transplant (p=0.94), and no direct correlation 
with 90 minute C-peptide on MTT at 12 months was identified. DSA was detected in 
5/23(21.7%) grafts in 14 recipients and was associated with rapid graft failure. 
Conclusions 
The primary goals of the UK islet transplant program to prevent recurrent life-
threatening hypoglycaemia and restore optimal glycaemic control in recipients have 
been attained up to 36 months post-transplant. Demonstration of a continuous 
relationship between endogenous C-peptide secretory capacity and parameters of 
glycaemic control has substantial implications for therapeutic interventions maintaining 
endogenous insulin production in individuals with type 1 diabetes. Therapeutic 
interventions preventing DSA formation post-transplant might improve graft outcomes.
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Chapter 1 - Introduction 
1.1  Diabetes: definition, classification and aetiology 
1.1.1 Definition of diabetes 
Diabetes mellitus is a heterogeneous group of disorders characterised by an increase in 
plasma glucose (Alberti and Zimmet, 1998). Its causation is complex and due to an 
interaction of genetic and environmental factors. Hyperglycaemia can occur as a 
consequence of a relative or absolute deficiency of endogenous insulin production. 
Persistent hyperglycaemia can cause serious health complications, including 
ketoacidosis in the short-term and increased risk of blindness, kidney failure, 
neuropathy (The Diabetes Control and Complications Trial Research Group (1993)), 
heart disease, stroke and peripheral vascular disease in the longer-term  (Zoungas et al., 
2012).  
 
1.1.2 Classification of diabetes 
The two most common forms of diabetes are type 1 and type 2 diabetes. Type 2 diabetes 
occurs as a consequence of insulin resistance, where the muscles and adipose cells do 
not respond adequately to insulin produced by intact  cells. By contrast, type 1 diabetes 
is a chronic autoimmune disorder that is triggered by environmental factors in 
genetically susceptible individuals, producing a state of insulin deficiency that results in 
hyperglycaemia and a greater predisposition to ketone formation. 
  
Major recent advances in the aetiology of diabetes have allowed further sub-
classification. Genetic analysis has unveiled monogenic forms of diabetes, and perhaps 
the most prominent example of this is the group of diabetes disorders classified as 
Maturity Onset Diabetes of the Young (MODY) (Hattersley, 1998). In addition, 
gestational diabetes can occur during pregnancy due to the tendency of the human body 
to become more insulin resistant whilst in the pregnant state (Catalano, 2010, 
International Association of et al., 2010). 
 
1.1.3 Prevalence and incidence of diabetes 
The American Centre for Disease Control states that 7.8 % of the United States 
population (23.6 million people) have a diagnosis of diabetes. In the US population, 1.6 
million new cases of diabetes were diagnosed in people aged 20 years or above in 2007.  
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The prevalence of type 1 diabetes for residents of the United States aged 19 years or less 
is 1.7/1000. The incidence of type 1 diabetes has been rising globally over recent 
decades. The number of new cases of type 1 diabetes in European children under the 
age of 5 years is expected to double between 2005 and 2020, whilst the prevalence of 
cases in individuals younger than 15 years will rise by 70% (Patterson et al., 2009). 
 
1.1.4 Aetiology of type 1 diabetes 
The aetiology of type 1 diabetes remains unclear. It is apparent that there is a genetic 
predisposition to the disorder (Todd and Farrall, 1996), although studies in identical 
twins demonstrate a concordance rate of less than 50% (Petersen et al., 1997), 
suggesting that environmental factors play a crucial role in its causation. 
 
Genetic factors  
Monogenic forms of type 1 diabetes 
Autoimmune diabetes is only rarely caused by mutational defects in a single gene but 
examples illustrate how genetic constitution might predispose an individual to diabetes 
through defects in immune tolerance mechanisms. 
 
Monogenic forms of type 1 diabetes are typically accompanied by other autoimmune 
conditions. The IPEX syndrome (immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked) occurs as a consequence of mutations in the Foxp3 transcription 
factor, which leads to dysfunction of regulatory T cells and multi-organ autoimmunity 
(Wildin et al., 2001); 80% of affected children develop diabetes. Autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy occurs as a result of mutations in 
an autoimmune regulator (AIRE). Deficiencies in AIRE inhibit expression of insulin in 
the thymus, allowing autoreactive T cells to enter the peripheral circulation: 20% of 
affected individuals develop autoimmune diabetes (Villasenor et al., 2005). 
 
Human Leukocyte Antigen associations with type 1 diabetes 
Type 1 diabetes has strong genetic links to the human leukocyte antigen (HLA) class II 
genes on chromosome 6p21 (IDDM1 locus) (Nerup et al., 1974). Molecular cloning and 
sequencing of HLA genes and class II proteins have made it possible to study genetic 
loci that may be associated with type 1 diabetes. HLA-DQB1*0302-A1*0301 has a 
greater association than any of the other HLA-DRB1*04 subtypes (Undlien et al., 
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1997).  DRB1*0401 confers a further additive risk (Kockum et al., 1996).  By contrast, 
the HLA-DRB1*1501-DQA1*0102-DQB1*0602 haplotype – found in 20% of the 
general population but only 1% of individuals with type 1 diabetes – confers dominant 
protection against type 1 diabetes (Erlich et al., 2008). The presence of HLA class II 
proteins associated with diabetes might promote antigen presentations that generate T-
helper cells responsible for an immune response to specific islet cell autoantigens. This 
in turn could lead to the formation of cytotoxic T cells which destroy insulin-producing 
 cells in islets of Langerhans, and the formation of islet autoantibodies. 
 
A less prominent association with type 1 diabetes has been found for HLA class I alleles 
(Fennessy et al., 1994). HLA-B*39 allele is a significant risk factor for type 1 diabetes, 
whilst HLA-A*02 increases the risk in individuals possessing the high-risk class II 
DR3/4-DQ8 haplotype. HLA-A*0201 is one of the most prevalent class I alleles, with a 
frequency of greater than 60% in individuals with type 1 diabetes. 
 
Other candidate genes for type 1 diabetes 
A recent Genome Wide Association Study focusing on type 1 diabetes found over 40 
different loci that affect the risk for type 1 diabetes (Cooper et al., 2008). 
 
A genetic predisposition to type 1 diabetes is conferred by the insulin gene region on 
chromosome 11 (IDDM2) (Bell et al., 1984). Susceptibility to diabetes lies in the 
variable number of tandem repeat (VNTR) polymorphisms in the promoter region of the 
insulin gene: VNTR type I alleles of the gene (26-63 repeats) predispose individuals to 
diabetes in a recessive type fashion; VNTR class III alleles (140 to more than 200 
repeats) appear to be dominantly protective. The protective effect may be explained by 
regulation of proinsulin mRNA in the thymus of class III allele carriers, which may 
enhance immune tolerance to preproinsulin, a key autoantigen in diabetes pathogenesis 
(Pugliese et al., 1997). 
 
A linkage to the cytotoxic T lymphocyte antigen (CTLA-4) gene on chromosome 2 
(IDDM12) is not fully understood (Nistico et al., 1996). CTLA-4 is critical to T cell 
apoptosis, and it has been speculated that long AT repeats in the encoding of the gene 
may lead to the CTLA-4 protein not being properly formed; this might result in 
increased survival of T cells responsible for  cell destruction. 
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Interferon-induced helicase 1 (IFIH1) encodes a helicase that contributes to the 
recognition of dsRNA from picornaviruses; it therefore acts as a cytoplasmic sensor for 
viral infection. A genetic defect encoding the helicase might interfere with the detection 
and clearance of viral infections, and this in turn might predispose an individual to a 
diabetogenic response. The presence of type 1 diabetes-associated polymorphisms has 
been reported in individuals with susceptible genotypes (Liu et al., 2009), and rare 
protective IFIH1 variants in type 1 diabetes have also been identified (Nejentsev et al., 
2009). 
 
Allelic variation in the interleukin-2 receptor  gene (IL2R) region has been 
implicated in type 1 diabetes causation (Lowe et al., 2007), with lower levels of IL2R 
possibly accounting for functional defects in regulatory T cells. 
 
The PTPN22 gene encodes lymphoid protein tyrosine phosphatase (LYP), and it is an 
important negative regulator of T cell receptor signalling. Functional variants of 
PTPN22 have been associated with type 1 diabetes (Bottini et al., 2004).  
 
Environmental factors 
Viral associations with type 1 diabetes 
The clinical manifestation of type 1 diabetes is a consequence of an underlying, 
sustained autoimmune process. A combination between susceptibility genes and 
environmental factors may initiate an autoimmune response that affects insulin-
producing  cells. The wide gap between the initiation of autoimmune damage and 
clinical onset of symptoms has posed a problem in looking for environmental triggers, 
of which several may be required before an autoimmune process against the  cells is 
invoked.  Lymphocytic infiltrates in pancreatic islets are a hallmark feature of type 1 
diabetes (Gepts, 1965), and abundant levels of HLA class I and IFN- in the islets of 
children with recent-onset diabetes suggested that beta-cell tropic infection might 
upregulate both HLA class I and IFN- to leave a molecular ‘viral signature’ in 
individuals with type 1 diabetes (Foulis et al., 1987).  
 
The seasonal variation in diabetes was first documented soon after the discovery of 
insulin (Adams, 1926), suggesting that viral infections may underpin causation of 
diabetes. Cytomegalovirus (Pak et al., 1988), parvovirus (Kasuga et al., 1996) and 
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encephalomyocarditis virus (Craighead and McLane, 1968) have all been associated 
with type 1 diabetes causation, although no direct evidence to diabetes causation has 
been identified. 
 
Extensive circumstantial evidence has suggested that enteroviruses – especially 
coxsackieviruses – may precipitate type 1 diabetes. Neutralising antibody titres in the 
serum of individuals recently diagnosed with type 1 diabetes were found to be higher 
than in healthy controls (Gamble et al., 1969), and this was confirmed in later studies 
using polymerase chain reaction (PCR) detection (Clements et al., 1995).  Prospective 
studies within the Finnish population have shown an association between enterovirus 
infection and diabetes development (Lonnrot et al., 2000). Coxsackie virus has striking 
protein sequence similarities to GAD, and this may contribute to molecular mimicry 
that is associated with HLA-DR3 susceptibility (Kaufman et al., 1992). 
 
Congenital rubella has been strongly associated with type 1 diabetes onset in affected 
children (Forrest et al., 1971, McIntosh and Menser, 1992) but any direct evidence for 
autoimmunity is scarce, and it may be that the virus interferes with  cell mass 
development rather than initiating the autoimmune process. In addition, rubella has 
largely been eliminated from the developed world by vaccination programmes, and yet 
the incidence of type 1 diabetes continues to increase. Multiple large studies have found 
no evidence linking vaccination programmes to the increased incidence of type 1 
diabetes (Hviid et al., 2004). 
 
Despite extensive research, no direct evidence for a particular viral strain causing type 1 
diabetes has been identified. Some indirect evidence warranting a focus on bacterial 
agents – most notably mycobacterium avium (Sechi et al., 2008) – has been proposed 
but no direct link to diabetes causation has been found. 
 
Other environmental associations with type 1 diabetes 
Cow’s milk 
The albumin content of cow’s milk has been proposed as a trigger for islet auto-
immunity, as a cross-reactivity was found between serum antibodies from individuals 
with type 1 diabetes and antibodies against the beta cell surface protein ICA-1 
(Karjalainen et al., 1992). However, subsequent reports have been unable to 
demonstrate any causal evidence (Norris et al., 1996).  
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Wheat gluten 
Increased peripheral blood T cell reactivity to wheat gluten was more frequently found 
in individuals with type 1 diabetes compared to controls (Klemetti et al., 1998) but no 
robust evidence to gluten initiating autoimmunity in diabetes has been found (Hummel 
et al., 2000). 
 
Vitamin D 
Vitamin D effectively inhibits dendritic cell differentiation and immune activation, and 
increased vitamin D intake has been reported to reduce the incidence of type 1 diabetes 
(Mathieu et al., 2005). Absence of vitamin D in childhood may contribute to poor 
expression of DRB1*0301 in the thymus, which has been associated with an increased 
risk of diabetes (Israni et al., 2009); vitamin D may therefore have an important role in 
inducing self-tolerance and protect against autoimmunity.
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Figure 1.1 Aetiology and pathogenesis of type 1 diabetes 
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1.1.5 Pathogenesis of type 1 diabetes 
The  cell decline hypothesis remains a widely referenced benchmark model for type 1 
diabetes (Eisenbarth, 1986). This model proposes that genetically susceptible 
individuals encounter an environmental trigger that initiates an autoimmune process, 
which subsequently leads to autoantibody formation and a linear decay in  cell mass. 
This is followed by hyperglycaemia and eventually a complete absence of endogenous 
C-peptide. 
  
Antibodies formed against prominent antigens in the pancreatic  cell are important 
markers of  cell autoimmunity in type 1 diabetes. The most significant are 
autoantibodies to insulin (micro IAA), glutamic acid decarboxylase (GAD65), 
insulinoma-associated antigen-2 (IA-2A) (Verge et al., 1998) and zinc transporter 8 
(ZnT8) (Wenzlau et al., 2007). Radioligand binding assays to these antibodies 
demonstrate high diagnostic sensitivity and specificity for type 1 diabetes, with many 
laboratories achieving a sensitivity of up to 80%. 
 
Autoantibody formation often precedes onset of hyperglycaemia and osmotic symptoms 
in type 1 diabetes. The early presence of autoantibodies clearly implicates a role for 
antibody-producing plasma B cells in the causation of type 1 diabetes, and they are 
likely to be active participants in the immune response because of their capacity to 
present antigen to other cells of the immune system. However, T cells are considered to 
be the final executors of  cell destruction. Cytotoxic CD8+ T cells have been found to 
be prominent in areas of insulitis in non-obese diabetic (NOD) mice, and can undertake 
cell-mediated  cell destruction upon activation by MHC class I expression on  cells. 
A deficiency in MHC class I expression due to a lack of beta-2 microglobulin has been 
shown to be sufficient to arrest diabetes development in NOD mice (Hamilton-Williams 
et al., 2003). CD4+ T helper cells are also likely to play an important role in the 
autoimmune process through cytokine production that assists the CD8+ T cell 
destruction of β cells. 
 
Studies have attempted to determine the predictive value of autoantibody presence in 
the later development of diabetes in healthy members of the population. The number of 
autoantibodies rather than the specificity of the autoantibody is thought to be most 
predictive of progression to overt diabetes. Whilst the presence of one autoantibody 
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alone may not be predictive of disease, almost all individuals expressing multiple 
diabetes associated autoantibodies progress to diabetes with long-term follow-up 
(Bingley et al., 1997, Achenbach et al., 2005). Relatives of patients with type 1 diabetes 
who are positive for two or more autoantibodies have a greater than 70% risk of 
developing diabetes over a seven year observation period (Sherr et al., 2008). 
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Figure 1.2 – Graphical illustration of the  cell decline hypothesis 
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1.2 Current treatments for type 1 diabetes 
1.2.1 Insulin treatment for type 1 diabetes 
The discovery of exogenous insulin therapy was a monumental achievement, 
transforming type 1 diabetes from a terminal disease to a manageable medical condition 
(Banting et al., 1922). However, although the previously fatal complication of diabetic 
ketoacidosis can now be readily treated, existing insulin formulations are unable to 
mimic the natural regulatory ability of the  cells of the endocrine pancreas. The 
Diabetes Control and Complications Trial (DCCT) confirmed that tight blood glucose 
control can reduce the incidence of complications (The Diabetes Control and 
Complications Trial Research Group (1993)) but regulation of blood glucose levels 
within the normal physiological range remains a challenge in even the most motivated 
patients. Nearly all individuals with type 1 diabetes remain prone to microvascular and 
macrovascular complications in the longer term (Genuth, 2006, Aronson, 2008). 
 
1.2.2 Burden of hypoglycaemia with insulin treatment in type 1 diabetes 
Hypoglycaemia is a potentially lethal side-effect of insulin treatment in patients who 
have labile blood glucose control or hypoglycaemia associated autonomic failure (Cryer 
et al., 2003). Repeated hypoglycaemia can result in impaired awareness of low blood 
glucose levels, leading to individuals being unable to take appropriate action when their 
blood glucose levels are low (Figure 1.3). Hypoglycaemia unawareness has been 
reported to affect 20-30% of unselected individuals with type 1 diabetes, and it is 
associated with an increased risk of severe hypoglycaemia requiring third party 
assistance (Clarke et al., 1995, Frier, 2008). One episode has potential implications 
regarding lifestyle choices and driving. Ultimately it can be truly life-threatening, as it 
potentially causes an inability to awaken from sleep when blood glucose levels are low, 
increasing the risk of ‘dead-in-bed’ syndrome and sudden death (Gill et al., 2009). Up to 
10% of the mortality in patients with type 1 diabetes may be as a consequence of 
hypoglycaemia unawareness (Cryer, 2008). Many patients with insulin-dependent type 
1 diabetes have some degree of hypoglycaemia unawareness, and as a consequence the 
benefits of stringent glycaemic control may be outweighed by the risk of a potentially 
fatal insulin overdose (Cryer, 2005). The frequency of hypoglycaemia unawareness has 
not declined in the past two decades (McCrimmon and Sherwin)(2010), and despite 
major advances in conventional insulin therapy (including structured education, insulin 
analogues, continuous subcutaneous insulin infusion pump therapy, continuous glucose 
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monitoring and even steps towards the closed loop bioartificial pancreas), there remains 
a group of patients in whom recurrent severe hypoglycaemia cannot be prevented 
without relaxation of overall glycaemic control. All adults with type 1 diabetes should 
be assessed for impaired awareness of hypoglycaemia, and this should take place at the 
individual’s annual care review. 
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Figure 1.3 – Vicious cycle of recurrent hypoglycaemia 
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1.2.3 Alternative approaches to treatment of type 1 diabetes 
Increased knowledge of the genetic susceptibility and ability to predict who might be at 
risk of developing type 1 diabetes has allowed clinicians to target interventions for 
diabetes management at three different stages during the pathogenesis of diabetes. 
Primary prevention aims to administer treatment to high risk individuals prior to their 
development of autoimmunity; secondary interventions might be administered when the 
development of autoimmunity is recognised; whilst tertiary interventions might be used 
soon after the clinical manifestations of diabetes become apparent when a significant 
number of  cells remain (Wherrett and Daneman, 2009). Research is therefore 
currently looking at alternative approaches to insulin management, and efforts have 
recently focused on immunosuppression trials in diabetes at the time of or shortly after 
diagnosis.  
 
1.2.4 Primary prevention trials for type 1 diabetes 
The TRIGR study (Trial to Reduce IDDM in the Genetically at Risk) is testing whether 
substitute milk products given whenever breast milk is not available in the first 6-8 
months of life decreases the risk of developing type 1 diabetes in genetically susceptible 
children (a first degree relative with type 1 diabetes and a high risk HLA allele) 
(Akerblom et al., 2005, Knip et al.). The trial is a double-blind, randomised control trial 
comparing hydrolysed infant formula to a cow’s milk-based formula. Early outcome 
results have shown that children receiving the extensively hydrolysed casein-based 
formula have less autoantibody positivity compared to those receiving the cow’s milk-
based formula (17% versus 30%), although to date there has been no impact on the 
incidence of type 1 diabetes onset; the trial is ongoing and due for completion in 
February 2017. 
 
The Diabetes Prevention Trial for type 1 diabetes investigated whether administration of 
oral or subcutaneous insulin prevented the onset of type 1 diabetes in genetically 
predisposed individuals (Pozzilli, 2002, Skyler et al., 2005, Barker et al., 2007). No 
impact on the incidence of type 1 diabetes was shown with either intervention by the 
trial. However, a post-hoc analysis of oral insulin administration demonstrated a 4-year 
delay in disease onset in subjects with higher titres of insulin autoantibodies. Further 
randomised trials in high-risk individuals are currently underway.  
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Intranasal insulin administration has also been tested as a preventative therapy in at risk 
individuals: a double-blind, placebo-controlled trial did not demonstrate a beneficial 
effect, even when intranasal insulin was administered soon after autoantibody 
seroconversion (Nanto-Salonen et al., 2008). 
 
1.2.5 Secondary and tertiary intervention trials in type 1 diabetes 
Secondary and tertiary intervention trials have the advantage over prevention trials in 
that potential trial entrants are more readily identified and efficacy can be evaluated 
within a much shorter timeframe. Secondary intervention involves screening for 
genetic, autoantibody and other markers associated with a risk of developing diabetes at 
birth, in school children or in adults. These interventions can be non-antigen specific - 
where the intervention used aims to modulate the immune response, preferably without 
negative effects on T regulatory cells - or aimed at a particular antigen that might be 
considered a target for halting the progression to the clinical onset of diabetes. 
 
Non-antigen specific trials 
The first non-antigen specific, double-blind, placebo-controlled clinical trial for type 1 
diabetes was with the calcineurin inhibitor cyclosporine A, which prevents interleukin-2 
(IL-2) transcription and reduces the function of effector T cells. During the trial, 
cyclosporine was administered to individuals with a clinical diagnosis of type 1 diabetes 
within 2 months of the initiation of insulin therapy. Cyclosporine induced remission of 
type 1 diabetes and insulin independence was achieved. However, its chronic use led to 
unacceptable side-effects – most notably nephrotoxicity – and its therapeutic effect 
vanished with cessation of the treatment (Stiller et al., 1983, Jenner et al., 1992). This 
demonstrated that cyclosporine did not therefore induce immune tolerance or 
immunoregulation, merely a state of non-specific immunosuppression. 
 
Other non-antigen specific approaches have been attempted with ketotifen (Bohmer et 
al., 1994) and nicotinamide (Gale et al., 2004) but each intervention has failed to 
improve clinical outcomes in type 1 diabetes long-term.  
 
Antigen specific trials 
The ultimate aim of antigen specific therapies is to promote regulatory T cell responses 
(active tolerance) or anergy of pathogenic T cells (passive tolerance) in order to induce 
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tolerance against multiple autoreactivities, thereby preventing an autoimmune attack on 
 cells. The selected antigen should be able to induce ‘bystander suppression’ by 
activating T regulatory cells to secrete cytokines that can dampen down immune 
function and modulate the response of antigen presenting cells (Tang and Bluestone, 
2008). 
 
Trials to induce tolerance against GAD 65 
Treatment of spontaneously non-obese diabetic (NOD) mice with GAD peptide reduced 
the incidence of diabetes onset (Tian et al., 1996). An aluminium hydroxide formulation 
of full length recombinant human GAD65 (GAD65-Alum) was subsequently developed 
and shown to preserve residual insulin secretion in subjects with late-onset autoimmune 
diabetes (Agardh et al., 2005). However, in phase III trials, GAD65-Alum failed to alter 
the natural history of C-peptide loss in individuals recently diagnosed with type 1 
diabetes (Wherrett et al., 2011). 
 
Trials using anti-CD3 monoclonal antibodies 
Anti-CD3 monoclonal antibodies cause short-term internalisation of the T cell receptor-
CD3 complex that makes cells ‘blind’ to antigens (Chatenoud et al., 1994). It alters T 
cell receptor-mediated signal transduction so that anergy or apoptosis is preferentially 
induced in activated T helper cells. Anti-CD3 treatment also results in regulatory T cell 
development (You et al., 2007), which protects against damage from effector T cells 
long after the drug has been eliminated from the body. 
 
Oxelizumab (Europe) and Teplizumab (US) are humanised anti-CD3 monoclonal 
antibodies that were used in open-label trials and showed that C-peptide production 
could be maintained for a longer duration in comparison to placebo in patients with 
newly diagnosed type 1 diabetes, and drug-treated subjects used less insulin while 
maintaining good glycaemic control (Herold et al., 2002, Keymeulen et al., 2010). 
However, drug recipients also experienced the side-effects of ‘cytokine storms’ and 
reactivation of Epstein-Barr virus. In an effort to prevent these side-effects occurring, 
later trials used lower doses of the anti-CD3 agents, with insulin dose combined with 
HbA1c improvement selected as the primary end-point over C-peptide production. No 
significant effect from anti-CD3 monoclonal antibody therapy was achieved when 
compared to placebo in the subsequent trials (Sherry et al., 2011).  
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Other trials using antigen–specific immunosuppressant therapies  
Rituximab is a CD20-specific monoclonal antibody that is used to deplete the antigen-
presenting B cell population (Hu et al., 2007). In a double-blind, placebo-controlled 
phase II trial, individuals receiving rituximab soon after a clinical diagnosis of type 1 
diabetes had a higher C-peptide at 1 year compared to placebo, with lower insulin 
requirements and better glycaemic control (Pescovitz et al., 2009). However, review of 
the risk-benefit ratio associated with the treatment meant that the clinical team leading 
the trial felt unable to recommend rituximab for clinical use in the management of type 
1 diabetes.  
 
Abatacept (a CTLA-4 Immunoglobulin) interferes with the stimulation of T cells, 
resulting in limited clonal expansion and induction of passive cell death (Salomon and 
Bluestone, 2001). In a phase II trial, subjects receiving monthly infusions of the drug 
had a significantly greater C-peptide level than those receiving placebo but reports also 
suggest that the effect is not sustained, and that a decline in C-peptide parallel to that of 
the placebo group occurs after 9 months (Orban et al., 2011). 
 
Combination immunotherapy  
Cancer therapy has benefitted from the use of combination therapies to treat 
malignancies, and a similar approach has been adopted in some immunotherapy trials 
aimed at reversal of type 1 diabetes. However, due to the possible side-effects of the 
drugs used, substantial regulatory and logistical hurdles exist for this approach in 
clinical practice, and extensive preclinical toxicity studies are needed before such 
regimens can be implemented in clinical trials. 
 
Basiliximab (chimeric mouse-human) and daclizumab (humanised IgG) are anti-CD25 
monoclonal antibodies that do not cause cytokine release syndrome and have been used 
in combination therapy regimens aimed at maintaining endogenous C-peptide 
production in patients with newly diagnosed type 1 diabetes. However, in a double 
blind, placebo-controlled trial, daclizumab in combination with mycophenolate mofetil 
failed to preserve β cell function 1 year post-therapy (Gottlieb et al., 2010). 
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Re-evaluation of the immunotherapy approach 
Immunotherapy used at the point of diagnosis of type 1 diabetes has not yet delivered 
convincing data to be considered for routine clinical use. Some research groups have 
suggested that better outcomes might be achieved if immune interventions are used as a 
secondary intervention in those at high risk of developing diabetes, in the hope that 
immunotherapy can be used to halt the pathogenesis of the autoimmune process that 
results in diabetes clinically (Greenbaum et al., 2012, Staeva et al., 2013). However, this 
is likely to be a high-risk approach and the risk-benefit ratio is such that immune 
interventions have not yet provided sufficient evidence for their routine use as a 
secondary intervention to be warranted at the current time. More information is required 
regarding the long-term effects of the immunosuppressants used: high-dose / high-risk 
immunosuppressive treatments may have untoward effects, whilst low-dose / low-risk 
therapies may simply be ineffective. Given that in ideal cases, life expectancy might be 
only shortened by 10 years with exogenous insulin therapy, a high safety bar has been 
set for immune-based interventions, and they must achieve long-lasting outcomes with 
minimal side-effects to replace insulin therapy. 
 
1.2.6 The demand to know benefits of maintained endogenous C-peptide 
What has arisen from many of the immunosuppression trials is that the potential clinical 
benefits of maintained endogenous insulin production - as reflected by measurements of 
C-peptide – are not yet fully known. The benefits of endogenous insulin production 
were confirmed in the DCCT, in which the intensively treated group could be 
subdivided according to residual C-peptide secretion at entry into the trial: the subgroup 
with the highest stimulated C-peptide (>0.2 pmol/ml) had a significantly lower HbA1c 
over the first four years of the study, 50% less risk of progression of retinopathy and 
65% less risk for severe hypoglycaemia with seizure or coma (The Diabetes Control and 
Complications Trial Research Group (1998)).  
 
Beyond outcomes from the DCCT, the evidence base for the advantages of maintained 
C-peptide production is scarce. It has been suggested that individuals with long-
standing type 1 diabetes may be protected from vascular complications if endogenous 
insulin production is maintained (Sjoberg et al., 1987, Panero et al., 2009). These 
clinical findings have led to the development of a ‘legacy effect’ concept, that suggest 
that maintenance of endogenous insulin production might offer protection from vascular 
complications in the later life of a patient with type 1 diabetes.  
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Many authors have subsequently called on research to define these benefits in greater 
detail, as expressed in the following quotations selected from published literature:  
 
“As yet there is no formal proof that long term maintenance of C-peptide responses will 
decrease morbidity and mortality but the indirect evidence makes this a justifiable 
inference. One current limitation is that we do not know what constitutes a ‘protective’ 
residual C-peptide response.” 
(Kolb and Gale, 2001) 
‘Does partial preservation of residual beta-cell function justify immune intervention in 
recent onset Type 1 diabetes?’ 
Diabetologia (2001);44:1349-1353. 
 
 
“ . . . the degree and duration of endogenous C-peptide likely to provide a minimum or 
maximum benefit is unknown. Thus, parallel with clinical trials to test the therapeutic 
effects on β cell function, studies evaluating the relationship of C-peptide secretion . . . 
whether the clinical course is easier to manage in those with residual β cell function are 
needed.” 
(Greenbaum et al., 2012) 
‘Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 
Diabetes’  
Diabetes (2012);61:1323-1330 
 
“In the long-term, it will be important to correlate preservation of C-peptide with 
improved clinical outcomes, such as short-term and long-term insulin dose 
requirements, HbA1c level, glycaemic variability and time in range, frequency of 
hypoglycaemia, and decreased occurrence of microvascular and macrovascular 
complications…. A major challenge will be to demonstrate to regulators and payers 
that preservation of C-peptide in T1D [type 1 diabetes], even for a limited period of 
time, with immune interventions provides clinical benefit.” 
(Staeva et al., 2013) 
‘Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes 
Immunotherapy Trials.’ 
Diabetes (2013);62:9-17. 
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Whilst immunotherapy intervention at the time of a clinical diagnosis of type 1 diabetes 
appears to be at a crossroads, it is clear that all research groups would benefit from a 
greater knowledge of the short-term and long-term clinical benefits of maintaining 
endogenous C-peptide production, and the level of C-peptide production required to 
achieve these benefits.
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Figure 1.4 – Treatment interventions for type 1 diabetes
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1.3 Transplantation therapies in type 1 diabetes 
Transplantation interventions in the management of type 1 diabetes are currently 
indicated in patients who have recurrent severe hypoglycaemia with loss of 
hypoglycaemia awareness. The patient must feel that their quality of life is affected by 
the recurrent severe hypoglycaemia to such a degree that they are willing to take on the 
risks of a transplantation procedure and the subsequent risks of immunosuppression 
therapy that are required to maintain transplant function. Two transplant interventions 
are currently available in the management of type 1 diabetes: pancreas transplantation 
and islet transplantation. 
 
1.3.1 Pancreas transplantation 
The first successful pancreas transplant was a simultaneous kidney-pancreas transplant 
in two patients with end-stage diabetic nephropathy (Kelly et al., 1967). One of the 
patients achieved near-normal glycaemia for two months post-transplant. Success rates 
for simultaneous pancreas-kidney transplants (SPK), pancreas-after kidney (PAK) 
transplant and pancreas-transplant alone (PTA) have since improved considerably. 
Whole organ pancreas transplantation can deliver insulin independence without 
significant hypoglycaemia but a 3-5% first year mortality is unavoidable with this major 
intervention. Patient mortality has been reported to be greater at 4 years following a 
pancreas-after-kidney transplant than in a matched cohort receiving a kidney transplant 
and on the waiting list for a pancreas transplant (Venstrom et al., 2003). SPK pancreas 
graft survival rates are approximately 70% at 5 years post-transplant, but 5 year graft 
survival rates for PAK and PTA are considerably lower at approximately 50% 
(Gruessner, 2011). A recent United Network for Organ Sharing (UNOS) study reported 
that SPK pancreas graft survival has not improved since 1995 (Waki et al.).  
 
Pancreas transplantation is a major surgical intervention with significant short-term 
morbidity and mortality, the risks of which are unacceptable to some patients and their 
clinicians for it to be considered as a routine intervention in the management of type 1 
diabetes. This has encouraged the search for alternative interventions in the 
management of patients affected by recurrent severe hypoglycaemia. 
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1.3.2 Islet transplantation 
Islets can be isolated from a donor pancreas and transplantation of allogeneic isolated 
pancreatic islets offers beta-cell replacement for type 1 diabetes through a minimally 
invasive percutaneous infusion into the hepatic portal vein under radiological guidance. 
Islet transplantation has the advantage over pancreatic transplantation that peri-
procedural complications are estimated to have a 20-fold lower morbidity risk, with the 
commonest complication rates reported to be an 8% risk of bleeding, a 3% risk of portal 
venous thrombosis and a 1% risk of bile leakage (Ryan et al., 2005a). 
 
Successful reversal of diabetes by isolated islet transplantation was achieved in animal 
models in 1972 (Ballinger and Lacy, 1972). Subsequent development of the procedure 
centred on the selection of the portal vein and the liver as the site of delivery for isolated 
islets (Kemp et al., 1973). The introduction of an automated method for the isolation of 
human pancreatic islets (Ricordi et al., 1988) and improvements in the collagenase 
enzymes used for islet isolation and purification has enabled islet transplantation to 
become a clinical intervention for the restoration of endogenous C-peptide production in 
patients with type 1 diabetes.
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Figure 1.5 – Islet transplantation: from donor to recipient 
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Early outcomes in islet transplantation 
In the landmark Edmonton study on islet transplantation (Shapiro et al., 2000), seven 
individuals with recurrent severe hypoglycaemia and a mean type 1 diabetes duration of 
35 years all attained insulin independence and freedom from severe hypoglycaemia 
after multiple islet infusions at a median follow-up of 11.9 months. The trial utilised an 
induction immunosuppression regimen using daclizumab (monoclonal antibody to the 
IL-2 receptor) but its revolutionary breakthrough was to use a maintenance 
immunosuppression regimen that was glucocorticoid-free: steroid treatment as part of a 
maintenance immunosuppression regimen is common in transplant medicine but steroid 
therapy is believed to be particularly detrimental to transplanted islet function. Instead, 
the Edmonton team used the calcineurin inhibitor tacrolimus with the mTOR 
(mammalian target of rapamycin) inhibitor sirolimus for maintenance immunotherapy.  
 
Following its tremendous initial success, later follow-up of the Edmonton cohort 
revealed progressive loss of β cell function and recurrence of diabetes. Islet 
transplantation in 65 patients conducted by the Edmonton group showed that only 10% 
of patients remained insulin-independent at 5 years, although partial graft function 
persisted in 80% (Ryan et al., 2005a). 
 
A subsequent trial utilising the Edmonton protocol in 36 patients at nine international 
academic centres (six in North America, three in Europe) was unable to replicate the 
successes achieved by the Edmonton team (Shapiro et al., 2006). Twenty-one of the 36 
islet recipients achieved insulin independence post-transplantation. At one year’s 
follow-up, 16 of 36 islet recipients achieved the study’s primary end-point and were 
insulin independent; 10 had partial graft function and 10 patients had complete graft 
loss. At three years follow-up, only one patient remained insulin independent. 
Nonetheless, patients with partial graft function had substantial clinical benefits 
compared to pre-transplant, including improved glycaemic control and freedom from 
severe hypoglycaemia.  
 
In light of the successes achieved by the Edmonton team, clinical islet transplant centres 
have been set up across the world. A glucocorticoid-free, low tacrolimus, sirolimus-
based immunosuppression regimen has been shown to be efficacious in a Swiss study 
reporting outcomes in nine recipients with type 1 diabetes and end-stage renal failure 
undergoing combined islet-kidney transplantation (Lehmann et al., 2004). Five patients 
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achieved insulin independence and none experienced severe hypoglycaemia following 
transplantation after a mean follow-up of over two years. The ongoing challenge for 
transplant centres has been to elucidate the mechanisms that might be responsible for 
islet graft failure, and to identify predictors of graft failure that might allow a clinical 
intervention to be made at a sufficiently early stage so that graft function might be 
maintained. In 2004, the Clinical Islet Transplantation Registry (CITR) was established 
under the guidance of the National Institutes of Health and the US Food and Drug 
Administration. The Consortium is collecting outcome data on islet transplantation from 
academic centres around the world, with the aim of identifying factors that might 
improve islet transplant outcomes. 
 
Developments in immunosuppression used with islet transplantation 
Since the initial Edmonton trials, improvements in induction and maintenance 
immunotherapy have been made. Anti-thymocyte globulin (ATG) is a polyclonal 
antibody used at induction with the capacity to delete and inhibit T cells that might be 
responsible for the alloimmune and autoimmune responses made against transplanted 
islets (Bonnefoy-Berard et al., 1998). An alternative induction agent is Campath 
(alemtuzumab); a recombinant humanised monoclonal antibody that binds to the CD52 
antigen to cause cell mediated lysis of T and B lymphocytes. TNF-α antagonists such as 
etanercept are now being used alongside induction agents to reduce the inflammatory 
responses in the peri-transplant period (Farney et al., 1993, Froud et al., 2005). 
Sirolimus has been associated with nephrotoxicity, and may inhibit β cell function; its 
use has therefore been replaced by mycophenolate mofetil in most maintenance 
immunosuppression regimens. 
 
The risk-benefit ratio in having to take immunosuppression in patients undergoing islet 
transplantation differs from that substantially in comparison to patients with newly 
diagnosed type 1 diabetes. The majority of patients with type 1 diabetes are unlikely to 
develop hypoglycaemia unawareness and problematic recurrent severe hypoglycaemia. 
However, patients undergoing islet transplantation are often selected for the procedure 
on the grounds that they have developed hypoglycaemia unawareness and are 
experiencing recurrent severe hypoglycaemia that has a significant impact on their 
quality of life; they often meet the criteria to undergo an islet transplant because their 
pre-transplant clinical status carries with it a significant mortality risk due to 
hypoglycaemia. This group of patients therefore have much more to gain from an 
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intervention that necessarily requires the use of immunosuppressant therapy, whereas in 
individuals with a new diagnosis of type 1 diabetes, the risk-benefit ratio from 
immunosuppression therapies is less clear-cut. 
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1.4 Assessment of islet graft function 
In order to make an assessment of the clinical success of an islet transplant in re-
establishing endogenous insulin production in an individual recipient, and to be able to 
compare clinical outcomes from transplantation between centres, a method of assessing 
islet graft function must be selected. 
 
1.4.1 Glycated haemoglobin (HbA1c) 
HbA1c is a measure of the level of glycated haemoglobin in red blood cells, and gives a 
reflection of a patient’s overall blood glucose control over the previous 6 to 12 weeks 
preceding measurement, and achieving a near-normal HbA1c reflects excellent 
glycaemic control (Higgins, 2012). However, HbA1c is influenced by exogenous 
insulin doses and caution is required in using the result as a measure of islet transplant 
function. Even insulin independent islet recipients with a normal HbA1c post-
transplantation have been shown to have impaired glucose tolerance that was only 
detected on additional metabolic testing (Shapiro and Lakey, 2000). 
 
1.4.2 Insulin requirement 
The initial goal of many islet transplant studies was for patients with diabetes to achieve 
insulin independence but this target is not always attained, especially in the longer term. 
Even if insulin independence is not reached, many patients achieve a significant 
reduction in exogenous insulin dose as their overall blood glucose control improves 
with endogenous insulin production by transplanted β cells. A reduction in the 
magnitude of exogenous insulin required is therefore a measure of insulin transplant 
function, and this has been recognised by many groups that develop scoring systems to 
assess transplanted β cell function.  
 
1.4.3 Assessment of endogenous insulin secretion by C-peptide 
Measurement of C-peptide is one of the simplest methods of assessing endogenous 
insulin production and therefore islet function. C-peptide is a breakdown product in the 
formation of insulin from proinsulin, secreted on an equimolar basis to insulin and - 
unlike the latter – it is not removed in first-pass metabolism through the liver (Palmer et 
al., 2004). The high reproducibility and close relationship of C-peptide measurements to 
endogenously secreted insulin makes it a suitable monitoring tool for β-cell function. 
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Exogenous insulin does not contain C-peptide and therefore C-peptide measurement 
reflects endogenous insulin production only.  
 
A barrier to the use of C-peptide in clinical care is a lack of available reference ranges 
for specific populations with diabetes. Data quoted in published research may relate to 
different assays or populations and is rarely presented as a reference range. Optimal 
standardization of C-peptide measurement between laboratories has yet to be achieved, 
meaning C-peptide results produced by different methods may not be comparable (Little 
et al., 2008, Wiedmeyer et al., 2007).  
 
1.4.4 Stimulation tests for assessment of endogenous C-peptide production 
Stimulation tests can be used to assess islet response to a standardised stimulus. They 
are more complicated to perform than assessments of random or basal levels of 
metabolic markers but often provide much more information than one-off blood tests. 
Correlations between fasting C-peptide and post-stimulation C-peptide are high in 
insulin-treated patients, although the use of stimulated C-peptide appears to offer 
modestly better clinical utility (Greenbaum et al., 2008b, Gjessing et al., 1987).  
Furthermore, the DCCT evidence used stimulation tests to report that increased C-
peptide levels in patients with type 1 diabetes were directly associated with improved 
glycaemic control, reduced incidence of hypoglycaemia and decreased microvascular 
risk; the DCCT made no analysis of associations with fasting C-peptide (The Diabetes 
Control and Complications Trial Research Group (1998)). Stimulation tests are typically 
performed after a period of fasting and discontinuation of exogenous insulin for at least 
12 hours, although individual groups have many variations on the preparation period 
prior to the test. Patients on insulin pump treatments have been permitted to continue 
their insulin infusion at a basal rate throughout the test, whilst some groups allow rapid 
acting insulin to be given subcutaneously up to 4 hours before commencing a 
stimulation test. Stimulation testing can be divided into two groups: those that use a 
glucose stimulus and those that use direct pharmacological stimulation. 
 
The Meal tolerance test (MTT) 
The MTT assesses endogenous insulin production in response to ingestion of a 
standardised meal. The ‘meal’ is typically a commercial caloric supplement that 
contains between 350-500 kcal and 50 to 65 g of carbohydrate. Blood samples are 
typically taken at 0, 15, 30, 60, 90, 120, 150, 180, 210, 240, 270 and 300 minutes post-
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ingestion for glucose, C-peptide and insulin. The use of very different measurement 
units for reporting C-peptide values can lead to confusion in clinical care. C-peptide is 
commonly reported in nmol/l, pmol/l or ng/ml (1 nmol/l = 1000 pmol/l = 3 ng/ml). C-
peptide response to the meal tolerance test in subjects without diabetes has been 
reported to be an increase from a fasting level of 0.80±0.36 to 2.63±0.78 nmol/l post-
stimulus (Hovorka et al., 1998). Traditionally, the most important value from the test is 
the 90 minute C-peptide (often deemed to be the ‘peak’ C-peptide in healthy subjects), 
although time to peak C-peptide response has been shown to variable in subjects 
without diabetes (Pozzan et al., 1997).  
 
The MTT has been widely used to study the response to therapeutic interventions in 
type 1 diabetes, and in a cross-sectional study of 259 patients aged 8-35 years with a 
mean diabetes duration of 1.5 years, C-peptide was shown to peak at 90 min during an 
MTT (Greenbaum et al., 2008b). Subsequently, 90 minute C-peptide has been shown to 
be a highly sensitive and specific measure of peak C-peptide in children and adolescents 
with type 1 diabetes (Besser et al., 2013). 
 
The MTT has been used extensively to monitor the function of transplanted islets 
(Baidal et al., 2009, Berney and Toso, 2006, Rickels et al., 2005, Ryan et al., 2005a, 
Alejandro et al., 1997). The 90 minute glucose is considered to be a good measure of β 
cell reserve following islet transplantation, and it provides an assessment of the 
homeostatic ability of an individual to handle a secretagogue load; a level of <10.0 
mmol/L (180 mg/dL) at 90 minutes indicates good graft function (Ryan et al., 2005a). 
 
Hyperglycaemic clamp studies 
Hyperglycaemic clamp studies have been used to assess insulin response in islet 
transplant patients (Luzi et al., 1996, Luzi, 1999). Concerns have been expressed that 
prolonged exposure to hyperglycaemia might cause β cell stress in transplanted islets, 
and the studies are not routinely used in the investigation of islet transplant subjects. 
 
Oral glucose tolerance test (OGTT) 
The OGTT is well known throughout the diabetes community, as it is still the only 
stimulation test listed in the American Diabetes Association’s criteria for the diagnosis 
of diabetes (American Diabetes Association (2011)). At the start of the test, subjects 
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consume 75 g of oral glucose and blood samples are taken at 0, 30, 60, 90 and 120 
minutes for assessment of the blood glucose response. 
 
Intravenous glucose tolerance test (IV GTT) 
In this test, subjects are given 300 mg/kg of 50 % dextrose. Blood samples are taken at -
10, 0, 3, 4, 5, 7, 10, 15, 20, 25, 30 and 60 minutes for glucose, insulin and C-peptide.  
Acute response to glucose for C-peptide and insulin release can then be calculated by 
the mean of their values at 3, 4 and 5 minutes minus the mean of their baseline values at 
-10 and 0 minutes.   
 
The glucagon stimulation test (GST) 
In the GST, blood samples for insulin, C-peptide and glucose are collected after the 
intravenous administration of 1 mg of glucagon. 
 
Comparison of the MTT to the GST as a stimulation test for C-peptide 
The MTT has been compared to the GST in the stimulation of C-peptide production in 
266 patients with a recent diagnosis (within 4 years) of type 1 diabetes (Greenbaum et 
al., 2008a). The MTT produced a significantly higher C-peptide response in comparison 
to the GST, and was therefore felt to be a more sensitive test of residual β-cell function. 
For this reason, it might be preferred as a test of graft function in islet transplant 
subjects. The greater sensitivity of the MTT might be due to the incretin effect produced 
by the oral food bolus during the test, whereby glucagon-like peptide 1 production will 
produce additional insulin release. 
 
The GST does have the advantage that it takes less time to perform: time to peak C-
peptide has been reported at 6 minutes in the GST, compared to 80 to 90 minutes in the 
MTT (Greenbaum et al., 2008a). However, although the peak C-peptide in both tests is 
positively associated with fasting C-peptide, only the MTT peak C-peptide has been 
shown to be inversely associated with fasting glucose. The GST is also associated with 
a higher frequency of adverse effects, with nausea reported in 75-81 % of subjects. Most 
importantly, the results from an MTT have been reported to be significantly more 
reproducible than those of the GST. The MTT therefore appears to have considerable 
advantages over the GST to both the assessor and the test subject in the assessment of 
stimulated C-peptide production. 
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The Arginine stimulation test (AST) 
In the AST, 0.07 mg/kg of arginine hydrochloride (up to a maximum of 5 g) is 
administered over 30 seconds and blood samples are taken at -10, 0, 2, 3, 4, 5, 7, and 10 
minutes (Dupre et al., 1969). The AST has the advantage over the GST that it is 
clinically well tolerated and does not provoke nausea. Acute response to arginine for C-
peptide and insulin release can then be calculated by the mean of their values at 2, 3, 4 
and 5 minutes minus the mean of their baseline values at -10 and 0 minutes. The area 
under the curve for insulin above the mean of the baseline values is a reflection of islet 
mass.  
 
Glucose potentiated arginine stimulation tests (GP AST) 
The glucose potentiated arginine stimulation test allows determination of the maximal 
acute secretory response (ARmax) as a measure of β cell secretory capacity. The test 
involves the subject undertaking an arginine stimulation test whilst a hyperglycaemic 
clamp is used to achieve a raised plasma glucose, with the aim of increasing β cell 
insulin release during the AST at increased blood glucose levels. 
 
 
Comparison of the MTT to the AST as a stimulation test for C-peptide 
The AST has been compared to the MTT for the assessment of residual C-peptide 
production in 19 subjects with a recent diagnosis (1 to 42 months) of type 1 diabetes 
(Greenbaum et al., 2004). No difference in peak C-peptide value was observed for the 
MTT and AST, and there was a strong relationship between the obtained mean and peak 
C-peptide values from both the AST and MTT. A strong inverse relationship also 
existed between time to peak on the MTT and the amplitude of the arginine stimulated 
C-peptide response. No relationship between basal glucose and stimulated C-peptide 
was found in the arginine tests but a weak relationship between basal glucose and mean 
C-peptide was found in the MTT results. The MTT therefore has a reported sensitivity 
for stimulated C-peptide that is equivalent to the AST and provides a similar measure of 
 cell function when used in the assessment of patients with recent onset type 1 
diabetes. 
 
Previous use of the MTT in islet transplant patients 
The MTT has previously been used in the metabolic assessment of islet graft function 
post-transplant (Ryan et al., 2005a, Barton et al., 2012). Marked metabolic 
 35 
abnormalities during an MTT have been shown to be detectable early in the post-
transplant period which can act as markers for islet graft dysfunction, and the MTT has 
emerged as a preferred test in the monitoring of islet graft function post-transplant. 
 
1.4.5 Assessment of Glucose Variability - Continuous glucose monitoring 
Continuous glucose monitoring (CGM) provides a continuous data stream to give 
information on the rate and direction of blood glucose fluctuations. The impact of 
therapeutic interventions on blood glucose variability - and the subsequent risk of hypo 
or hyperglycaemia – can accordingly be quantified in a way that cannot be provided by 
self-monitoring blood glucose devices (SMBG).  
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1.4.6 Scoring indices of islet graft function 
Work with metabolic function tests in islet transplant recipients has led to the 
conclusion that no single metabolic measurement provides an exhaustive evaluation of 
the clinical success of a transplant. Research groups have therefore attempted to create 
scoring indices using the metabolic data that can be used clinically to provide a rapid 
assessment of current – and possibly future – islet graft function. 
 
The β-score 
The β-score is a composite scoring system designed to provide clinicians with more 
than just a statement about whether the graft is producing insulin or not (Ryan et al., 
2005b). The score can be between 0 and 8, and its calculation is based on scoring each 
of the four factors of fasting plasma glucose, HbA1c, daily insulin requirement and 90 
minute stimulated C-peptide MTT with 0, 1 or 2, based on their values. 
 
Using stepwise regression analysis, it has been shown that the β-score could be 
predicted from linear combination of each of the four independent variables in islet 
transplant patients. In the original paper stating its use, only 16% of transplant patients 
achieved a score of 8/8, with most patients achieving a score of 6-7 once adequate islet 
mass and insulin independence was achieved. A prospective longitudinal study in 14 
transplant patients has suggested that calculation of the β-score might have a role in 
predicting future graft survival (Vantyghem et al., 2009).  
 
C-peptide/glucose (CP/G) index 
Plasma C-peptide levels fluctuate according to the degree of glycaemia at the time they 
are measured. Any plasma C-peptide may indicate good graft function if glucose levels 
are normal but they may be inappropriately low if glucose levels are high. The CP/G 
therefore corrects for high glycaemic values, and it is calculated by: 
C-peptide / glucose ratio = [Fasting C-peptide (ng/ml) x 100] / [Glucose (mg/dL] 
A retrospective analysis on results from 22 islet transplant patients was used to 
determine whether C-peptide or the CP/G might best predicted a high 90 minute glucose 
during an MTT (Faradji et al., 2007). CP/G was found to be superior to C-peptide, and 
also had a significant negative correlation with 90 minute glucose during MTTs at 3, 6, 
9, 12, 15 and 18 months post-transplant. Multiple logistic regression for all time points 
revealed that a CP/G of >1.0 was associated with having a lower 90 minute glucose 
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level (<10 mmol/L), a higher acute insulin response during an intravenous glucose 
tolerance test and a higher β-score (>6). CP/G may therefore be more indicative of graft 
dysfunction and clinical outcome than C-peptide alone. 
 
Transplant Estimated Function (TEF) 
TEF estimates daily insulin secretion by the transplant and is simpler to calculate than 
the β-score (Caumo et al., 2008). Stepwise multiple regression analysis was carried out 
on β-scores measured in islet transplant patients and daily insulin requirement was 
found to be the best predictor of the β-score, whilst HbA1c and fasting glucose had a 
lesser influence on β-score prediction. C-peptide values were reported to have only a 
marginal significance on the β-score. ‘Transplant Estimated Function’ therefore only 
uses the daily insulin requirement (DIR) and HbA1c for its calculation. It was reasoned 
that a change in total daily insulin would influence glycaemic control, such that: 
∆HbA1c = k.∆DIR 
where: ‘k’ is the sensitivity of glycaemic control to insulin supply 
As a transplant recipient has two sources of insulin supply (exogenous insulin and 
endogenous β cell secretion from islets), the change in HbA1c can be calculated as: 
∆HbA1c = k.[∆DIR+TEF] 
where: TEF is insulin produced by the transplanted islets 
TEF can therefore be calculated by: 
TEF = a.DIR + b.HbA1c + c 
where: ‘a’ = -1, ‘b’ =1/k and ‘c’ is a constant dependent on pre-transplant DIR & 
HbA1c, calculated by c = - a.DIR(pre-Tx) - b.HbA1c(pre-Tx) 
These calculations are all dependent on having a value for ‘k’, which has been given as 
a population value estimated from ∆HbA1c and ∆DIR recorded in a group of patients 
with type 1 diabetes: ‘k’ is calculated to be -5.43. Once TEF is known, ‘Islet Estimated 
Function’ (IEF) can be calculated by dividing TEF by the number of infused islets. An 
advantage of the TEF calculation over the β score is that it does not require the results 
of an MTT. However, a major limitation of the TEF is that by use of a population value 
for parameter ‘k’, it assumes the same degree of insulin sensitivity in all patients. The 
group proposing use of TEF state that a 50% variation in ‘k’ does not alter its calculated 
correlations with insulin response during metabolic tests. 
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Secretory unit of islet transplant objects (SUITO) index 
The SUITO index also estimates engrafted islet mass (Matsumoto et al., 2005). It can be 
calculated by: 
Fasting C-peptide [ng/dL) / [Fasting blood glucose (mg/dL) – 63] x 1500 
A score of 100 is equal to 100% of pancreatic β cell function, and a score of greater than 
25 is required for insulin independent status. It has been suggested that calculation of 
the SUITO index within 1 month of allogeneic (Matsumoto et al., 2009) or autologous 
(Matsumoto, 2011) islet transplantation is an excellent predictor of insulin 
independence. 
 
Which scoring index should be used to assess islet graft function? 
There is no consensus on which test is best to monitor β cell mass and function in islet 
transplant patients. A comparative evaluation of each of the simple indices (β-score, C-
peptide/glucose ratio, TEF and SUITO) has been attempted (Caumo et al., 2011) but 
concluded that no index outperformed the others. 
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1.5 Assessment of hypoglycaemia in islet recipients 
At present, none of the scoring systems assessing islet graft function comment on the 
outcome that is used to determine whether a patient should have an islet transplant in 
the first place; that of a reduction in the frequency of severe hypoglycaemia.  This is a 
major shortfall and separate assessments for hypoglycaemia frequency and quality of 
life are required post-transplantation. Current scoring systems for the assessment of 
hypoglycaemia awareness aim to predict impaired awareness and increased risk of 
severe hypoglycaemia. 
 
1.5.1 The Gold Score 
This scoring system is based on the response to a single question: ‘Do you know when 
your hypos are commencing?’. Results are expressed by a 7-point Likert scale, where 1 
= ‘always aware’ and 7 = ‘never aware’. Impaired awareness of hypoglycaemia is 
suggested by a value of ≥4. This score is based on results from a prospective case-
control study with 60 participants and 12 months follow-up (Gold et al., 1994); 29 
participants were noted to have impaired awareness and 31 participants had normal 
awareness of hypoglycaemia. Participants with impaired awareness of hypoglycaemia 
had an increased frequency of severe hypoglycaemia episodes (≥1 severe 
hypoglycaemia episodes in 66% with impaired awareness versus 26% with normal 
awareness; higher incidence of severe hypoglycaemia episodes per patient per year: 2.8 
with impaired awareness versus 0.5 with normal awareness). 
 
1.5.2 The Clarke Score 
This score is made up of eight questions characterising an individual’s exposure to 
episodes of moderate and severe hypoglycaemia to assess the glycaemic threshold for 
and symptomatic response to hypoglycaemia. The assessment gives a score where a 
value of ≥4 indicates impaired awareness of hypoglycaemia. The scoring system is 
derived from a prospective case series study in 78 subjects with 9-12 months follow-up 
(Clarke et al., 1995). Thirty-eight of the subjects were classified as having impaired 
awareness of hypoglycaemia, defined as being less able to detect biochemical 
hypoglycaemia (<3.9 mmol/L), with less autonomic and neuroglycopenic symptoms in 
response to hypoglycaemia. Frequency of severe hypoglycaemia events was increased 
in subjects with impaired awareness. 
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1.5.3 The HYPO Score 
This is a composite hypoglycaemia score based on the frequency, severity and degree of 
impaired awareness of hypoglycaemia that provides a measure of the extent of problems 
with hypoglycaemia to complement an assessment of problems with glucose control 
(Ryan et al., 2004). The score is developed from an assessment of glucose readings 
collected from patients over a 4 week period (minimum of two capillary glucose 
readings a day), noting details of each hypoglycaemic event (glucose <3.0 mmol/L), the 
number of occurrences of hypoglycaemia, and a completed questionnaire about the 
frequency and severity of hypoglycaemia episodes over the previous year. In particular, 
emphasis is placed on which symptoms occur and whether outside help from a third 
party was obtained to either recognise or treat a hypoglycaemic event. A score of ≥433 
is representative of problematic hypoglycaemia, ≥1,047 is indicative of very serious 
unawareness of hypoglycaemia. 
 
1.5.4 The DAFNE Hypoglycaemia awareness rating 
This score is a three question hypoglycaemia assessment that is used in the national 
DAFNE database. It asks patients to rate their awareness of hypoglycaemia by stating 
whether they (1) usually recognised that they were hypoglycaemic at a blood glucose 
concentration ≥3 mmol/L; (2) <3 mmol/L or (3) not at all. Patients rating themselves in 
categories 2 and 3 were defined as having impaired awareness and had reported a mean 
of 3.6 severe hypoglycaemia episodes during the preceding year; compared to 0.87 in 
patients rating themselves as aware at blood glucose concentrations of 3 mmol/L or 
higher (Hopkins et al.). 
 
1.5.5 The Pedersen-Bjergaard Score 
Impaired awareness of hypoglycaemia is assessed by the question ‘Can you feel when 
you are low?’, with the respondent selecting one answer of ‘always’, ‘usually’, 
‘sometimes/occasionally’ or ‘never’. A response of ‘usually’ implies impaired 
awareness of hypoglycaemia, whilst the responses of ‘sometimes/occasionally’ or 
‘never’ imply severely impaired awareness of hypoglycaemia. This scoring system was 
developed from a questionnaire assessing the occurrence of hypoglycaemia and aspects 
of hypoglycaemia unawareness in 230 participants, 47% of whom were classified as 
having impaired awareness (Pedersen-Bjergaard et al., 2001). Groups with impaired 
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awareness were found to have a 5.1 to 9.6 increased risk of severe hypoglycaemia 
compared to groups defined as having normal awareness. 
 
1.5.6 Correlation between scoring systems for assessment of impaired awareness of 
hypoglycaemia 
Two studies have undertaken comparison of scoring systems for impaired awareness of 
hypoglycaemia (Geddes et al., 2007, Hoi-Hansen et al.). The studies undertook direct 
comparison of the Clarke, Gold and Pedersen-Bjergaard scores with focus given to their 
correlation and ability to predict severe hypoglycaemia. Gold and Clarke scores defined 
24-28% of study participants as having impaired awareness of hypoglycaemia and both 
scores correlated well in both studies. The Pedersen-Bjergaard score defined 13-15% of 
subjects as having impaired awareness of hypoglycaemia. However, correlation with 
Clarke and Gold score assessments was poor, suggesting the possibility that the 
Pedersen-Bjergaard score might not necessarily be picking up cases of impaired 
hypoglycaemia awareness. The studies concluded that Clarke and Gold questionnaires 
might be better discriminators for impaired awareness of hypoglycaemia in comparison 
to the Pedersen-Bjergaard questionnaire. 
 
1.5.7 Scores as predictors of hypoglycaemia and severe hypoglycaemia 
One study has reported that more episodes of biochemical hypoglycaemia are predicted 
with use of Clarke and Gold scoring, whilst no significant difference in hypoglycaemia 
frequency was noted in subjects assessed by the Pedersen-Bjergaard score (Geddes et 
al., 2007). Gold and Clarke scores predicted reduced autonomic warning symptoms 
during biochemical hypoglycaemia but again no significant difference was noted with 
Pedersen-Bjergaard scoring. All three testing methods did predict an increased rate of 
severe hypoglycaemia episodes. 
 
In a second study in 518 study participants (Geddes et al., 2008), the Gold score 
classified 101 participants as having impaired hypoglycaemia awareness: rate of severe 
hypoglycaemia per person was six-fold in this group, with lower intensity of autonomic 
symptoms reported. A further study reported that Gold scoring (Schopman et al.) 
predicted an increased rate of severe hypoglycaemia in study participants. 
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Clarke and Gold scores have been used to assess impaired awareness of hypoglycaemia 
during continuous glucose monitoring (CGM) (Gimenez et al., 2009, Choudhary et al.). 
More episodes of hypoglycaemia and an increased incidence of severe hypoglycaemia 
were recorded with use of CGM in patients defined as having impaired awareness 
according to their Clarke and Gold scores in comparison to controls. Clarke scoring has 
also been found to correlate with clamp study outcomes investigating impaired 
hypoglycaemia awareness in 19 study participants (Janssen et al., 2000). 
 
1.5.8 Choice of scoring system for assessment of impaired awareness of 
hypoglycaemia 
Gold and Clarke scores correlate well in studies and have a high concordance with 
increased frequency of severe hypoglycaemia episodes. The Pedersen-Bjergaard score 
has less correlation with Gold and Clarke scores and not such a good concordance with 
prediction of severe hypoglycaemia episodes. The HYPO score has a good concordance 
with frequency of severe hypoglycaemia. However, the baseline data required and the 
method of its interpretation for the score’s calculation is complex, favouring the use of 
Gold and Clarke scores for assessment of impaired awareness of hypoglycaemia. 
 
1.5.9 Impact of islet transplantation on hypoglycaemia awareness 
Although islet transplantation prevents severe hypoglycaemia (Froud et al., 2005), 
metabolic studies using hypoglycaemic clamp data for the assessment of restoration of 
hypoglycaemia awareness are not conclusive (Rickels et al., 2007, Paty et al., 2002).  
 
A retrospective study on 31 islet transplant patients (Leitao et al., 2008) used the Clarke 
score pre and post-transplant to assess hypoglycaemia awareness, with a score of 4 
indicating hypoglycaemia unawareness. The proportion of patients with hypoglycaemia 
unawareness decreased from 87% to 13%, and the threshold for glycaemic awareness 
was increased from 41.4 +/- 17.6 mg/dL to 58.4 +/- 10.3 mg/dL.  Such improvements in 
hypoglycaemia awareness were sustained regardless of classification of graft function 
post-transplant, although an increase in post-transplant hypoglycaemia score was 
observed in patients with loss of graft function.  It was also noted that a lower 
hypoglycaemia score correlated with better β cell function according to stimulated C-
peptide levels in an MTT. Improvements in hypoglycaemia score were therefore 
obtained post-transplant even if the graft was considered to have ‘failed’ on an MTT 
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post-transplant.  The study demonstrated that metabolic data may not be able to account 
for all of the clinical improvements observed post islet transplantation.  It may be that 
avoidance of hypoglycaemia during the early post-transplant period produces increased 
hypoglycaemia awareness, which is maintained even if graft function is lost. This 
conclusion highlights the need to utilise alternatives to metabolic testing - such as the 
Clarke and Gold hypoglycaemia scores - to assess some of the clinical benefits of islet 
transplantation. 
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1.6 The need to develop novel markers of islet transplant attrition 
The reasons for attrition in islet transplant function are currently unknown. It has been 
suggested that innate immunity, autoimmune responses, alloimmune responses and 
choice of immunosuppression (Lacotte et al., 2011, Van Belle and von Herrath, 2008) 
may all affect outcome. There may be unidentified mechanisms that result in islet graft 
dysfunction, and it may be that inflammatory changes occur at the transplantation site in 
the liver, leading to a reduction in functioning islet cell mass. 
 
Donor pancreas and isolated islet characteristics have been previously analysed to 
assess whether they have any impact on clinical outcome (Nano et al., 2005). Islet yield 
has been significantly associated with donor age and body mass index (BMI). A high 
BMI is a marker of insulin resistance and high metabolic demand, both of which are a 
stimulus for islet neogenesis and a consequent increase in overall β cell mass. The 
presence of fatty tissue or of a thick capsule around the islets during digestion further 
improves isolation outcomes, as it limits the exposure of free islets to collagenase in 
solution, preserving islet integrity and survival. Good pancreas condition and weight are 
also associated with improved islet yield. 
 
Multivariate analysis of single islet preparations used for transplantation has shown that 
reduction in insulin requirement was significantly associated with morphological 
aspects of islets (Nano et al., 2005). ‘Round-shaped’ islets were shown to have 
maintained morphology and a large portion of their peripheral capsule, whilst 
‘fragmented’ islets had architectural disorganisation with irregular borders and free 
chains of cells protruding from the periphery. One month C-peptide post-transplant 
correlated positively with islet purity, higher transplanted islet equivalents per kilogram 
(IEQ/kg), and preparations with predominantly round-shaped islets. 
 
After transplantation, early losses of graft function are primarily non-specifically 
immunological, thought to be the result of damage sustained during the isolation 
procedure or in the graft micro-environment within the liver. The principal problem of 
current metabolic tests is that they are late markers of islet graft dysfunction and reflect 
changes when it might no longer be possible to salvage a failing graft. Assessment of 
alternative markers post-transplantation might provide a novel marker of rejection that 
identifies islet stress at an early stage and allows rescue therapies to prevent complete 
graft failure. 
 45 
Techniques for monitoring graft function must address four aims: 
1. Understanding when grafts are damaged 
2. Understanding by which mechanisms grafts are damaged 
3. Detection of damage early enough to allow intervention for graft salvage 
4. Allow immunosuppression to be tailored according to risk of immune events 
 
Ultimately, one of the requirements of islet monitoring tests should be that they provide 
prognostic information if there is concern that the graft might be failing, and allow 
tailoring of strategies to overcome graft dysfunction. 
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1.6.1 Development of hepatic steatosis following islet transplantation 
Physiological consequences of localised insulin production by transplanted islets 
might result in hepatic steatosis 
Hepatic intraportal islet transplantation for patients with type 1 diabetes has the 
theoretical advantage of more closely mimicking natural insulin release in subjects 
without diabetes by promoting insulin delivery to a site close to the hepatic portal vein. 
This avoids the systemic hyperinsulinaemia associated with exogenous insulin delivery 
but localised insulin delivery in the liver has a powerful lipogenic response in 
hepatocytes, and may cause them to become overloaded with triacylglycerol. 
Lipohypertrophy has long been recognised to be a consequence of the promotion of 
local accumulation of triglyceride when insulin is delivered subcutaneously (Hu and 
Kan, 2013). In the liver, insulin upregulates the expression of lipogenic enzymes 
(Kakuma et al., 2000) and local lipoprotein lipase hydrolyses triacylglycerol to create an 
excess of fatty acids. 
 
Hepatic steatosis occurs in recipients post-islet transplantation 
Periportal steatosis following islet transplantation has been previously reported 
(Eckhard et al., 2004, Markmann et al., 2003, Bhargava et al., 2004).  The Edmonton 
team have been at the forefront of developments in islet transplantation for many years 
and have examined the liver by ultrasound and magnetic resonance imaging (MRI) 
post-transplantation. Post-transplant scans showed fatty changes on MRI in 20% of 
subjects (median follow-up time 402 days, range 117 to 1190 days) (Bhargava et al., 
2004).   
 
Potential impact of steatosis on graft function 
Hepatic steatosis is an abnormal and excessive intracellular accumulation of fat in 
hepatocytes (Basaranoglu et al.). Free fatty acids can trigger cell death by induction of 
oxidative stress and activation of apoptosis, which can potentially result in progressive 
hepatic disease. Steatosis is the histological hallmark of non-alcoholic fatty liver disease 
(NAFLD) (Matteoni et al., 1999), and its presence has a causative role in many hepatic 
and systemic disorders. A significant proportion of individuals with steatosis 
subsequently develop type 2 diabetes and its presence may interfere with insulin 
signalling (Semple et al., 2009). Lipotoxicity has been shown to have an acute effect on 
islet function and a chronic effect on islet cell mass in patients with type 2 diabetes 
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(Poitout and Robertson, 2002). It is possible that exposure to high local concentration of 
fatty acids may damage transplanted islets.  
 
1.6.2 Role of the humoral immune response in transplant graft rejection 
Accumulated evidence from the field of transplantation suggests that the humoral 
immune response may have an integral role in graft rejection, with the development of 
donor specific antibodies associated with graft failure (Cai and Terasaki, 2005). The 
humoral immune response may cause damage to graft endothelium by activation of the 
complement system, recruitment of inflammatory cells and direct antibody-mediated 
cell cytotoxicity. Following endothelial damage, platelet activation may lead to 
thrombosis, whilst humoral and cellular infiltrates mediate ongoing graft tissue damage. 
These events produce irreversible ischaemic changes that could result in graft loss. 
 
The finding of preformed antibodies in recipient serum to donor graft tissue underpins 
the concept of hyperacute rejection (Kissmeyer-Nielsen et al., 1966, Terasaki et al., 
1971). Pre-formed Human Leukocyte Antigen (HLA) antibodies should be 
characterised pre-transplant to aid selection of the optimal donor for transplantation. 
HLA typing and screening for HLA antibodies is systematically undertaken in all 
candidates awaiting organ or cellular transplantation, with T and B cell cross-matches 
between recipient and donor tissue routinely performed pre-transplant. 
 
Association of de novo DSA with graft rejection in renal transplantation 
De novo HLA antibody and Donor Specific Antibody (DSA) development post-
transplant are associated with reduced graft survival in renal transplants (Morris et al., 
1969), with graft loss greatest in recipients with DSA (Lachmann et al., 2009, Everly et 
al., 2013). The central diagnostic criterion of antibody-mediated rejection of renal 
transplants is the demonstration of complement activation marker C4d in inflamed 
peritubular capillaries (Feucht, 2003). Renal transplant studies in cynomolgus monkeys 
have shown that DSA precedes C4d deposition and subsequent transplant 
glomerulopathy, suggesting that DSA might be the trigger for graft failure (Smith et al., 
2008). 
 
A cross-sectional prospective international trial assessing the impact of HLA antibodies 
and DSA on graft outcome in 1014 deceased kidney transplant recipients (Lachmann et 
al., 2009) found that 30% of recipients had HLA antibodies at a mean time of 6 years 
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post-transplant, of which 31% were DSA positive. In the presence of antibodies, median 
time to graft failure was 989 days (435-1591) post-assessment, compared to 1294 days 
(791-1952) in recipients without antibodies. Kaplan-Meier survival probability at 5.5 
years post-assessment was 49% with DSA and 70% with non-DSA, versus 83% in 
recipients with no antibodies. 
 
In a second study, 189 non-HLA identical primary kidney recipients known to be DSA 
negative pre-transplant were screened annually for DSA. DSA developed in 24.8% of 
recipients, with the greatest incidence in the first year post-transplant (11.2%) (Everly et 
al., 2013). DSA positive recipients experienced an acute rejection episode in 33% of 
cases, versus 23% of DSA negative recipients. In recipients with graft loss, 56% had 
DSA and all DSA negative chronic rejections were HLA antibody positive. From the 
onset of DSA, 24% of recipients lost graft function within 3 years, compared to a 96% 
five year survival rate for those without DSA. The relative risk of allograft loss was six 
to nine times higher for DSA positive recipients compared to DSA negative recipients. 
 
Association of de novo DSA with graft rejection in other fields of organ 
transplantation 
HLA antibody and DSA have been associated with poor outcome in other fields of 
organ transplantation. Cardiac antibody mediated rejection was first described in 1989 
(Hammond et al., 1989), and diagnosis is based on the triad of clinical evidence of 
allograft dysfunction, serological evidence of DSA and endomysial antibody features 
(Kobashigawa et al., 2011). Both symptomatic and asymptomatic antibody mediated 
rejection has been shown to be associated with poor prognosis (Kfoury et al., 2009, 
Irving et al., 2011). In lung transplant recipients, the presence of DSA has been 
associated with a reduced survival rate (Hachem et al., 2010).  Liver transplants are 
generally regarded as not being susceptible to antibody mediated rejection. However, 
CDC positive cross-match recipients were reported to have a one year graft survival rate 
of 29%, compared to 72% of cross-match negative recipients (Muro et al., 2005b). 
Preformed DSA has been associated with a 1.58 increased risk hazard ratio of early 
rejection after liver transplantation (O'Leary et al., 2013). Acute rejection rate in 
simultaneous pancreas-kidney recipients has been reported to be 45% among patients 
with anti-HLA antibodies versus 8% in recipients without HLA antibodies (Cantarovich 
et al., 2008). In a nine year follow-up of 167 consecutive pancreas transplant recipients 
(152 simultaneous pancreas-kidney, 15 pancreas-transplant alone) (Cantarovich et al.), 
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40 recipients developed anti-HLA antibodies, with 26 developing DSA. More rejection 
episodes were observed in recipients with positive anti-HLA antibodies than in those 
without (42.5% versus 11%), with the highest incidence of rejection reported in 
recipients developing DSA (53.8% incidence of rejection). Graft survival was 
significantly lower in DSA positive recipients (75% for DSA positive kidney and 75% 
for DSA positive pancreas grafts versus 100% for pancreas non-DSA and 95% for 
kidney non-DSA grafts).   
 
The accumulated evidence suggests that DSA development is associated with reduced 
graft survival, and its detection may therefore be a useful prognostic marker in islet 
recipients. 
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1.7 Project Aims 
1.7.1 Aim 1: Assess clinical outcomes in the UK islet transplant program 
An integrated UK islet transplant network was commissioned in 2008 (Aldibbiat A, 
2012) and fully-funded by the National Health Service (NHS) as a clinical intervention 
with proven efficacy for life-threatening recurrent severe hypoglycaemia freely 
available at the point-of-care. The service was endorsed by the National Institute for 
Health and Clinical Excellence (NICE), with the stated aims of preventing recurrent 
severe hypoglycaemia (Workgroup on Hypoglycaemia, 2005), attaining HbA1c <7.0% 
(<58 mmol/mol), reducing exogenous insulin requirement and also quantifying graft 
function by C-peptide secretion (NICE, 2008). 
 
From the inception of the National Health Service (NHS) funded UK program, all 
recipients have been invited to participate in a prospective follow-up study to determine 
biomedical and psychosocial outcomes. The objectives of the current analysis were to: 
 
1. Determine metabolic outcomes post-intervention over the first 3 years of the NHS-
funded UK islet transplant program. The following clinical outcomes were assessed: 
a. Rate of severe hypoglycaemia 
b. Glycaemic control 
c. Insulin dose  
d. Duration of graft function 
 
2. Assess whether NICE treatment targets for islet transplantation were achieved at 12 
months post-intervention over the first 3 years of the UK program. 
 
3. Establish whether equity of access to transplantation could be realised by the 
achievement of equivalent outcomes with both locally isolated and transported 
preparations. 
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1.7.2 Aim 2: Use continuous glucose monitoring to relate measures of blood glucose 
control to endogenous C-peptide production 
Mainstream diabetes therapies have aimed at exogenous insulin replacement for blood 
glucose control in individuals with type 1 diabetes (The Diabetes Control and 
Complications Trial Research Group (1993)). However, preserved endogenous insulin 
secretion soon after diagnosis of type 1 diabetes is a therapeutic goal for new disease 
modifying therapies (Michels and Eisenbarth, 2011, Greenbaum et al., 2012, Staeva et 
al., 2013). Immunotherapy used at the point of diagnosis of type 1 diabetes has 
delivered prolongation of endogenous insulin production but long-term consequences 
on clinical outcomes are unclear; little data exists regarding what improvements in 
blood glucose control might be anticipated if a level of endogenous insulin production 
can be maintained beyond the anticipated honeymoon period. There is a need to define 
the short-term and long-term clinical benefits of maintained endogenous C-peptide 
production in greater detail (Kolb and Gale, 2001, Greenbaum et al., 2012), particularly 
the relationship between C-peptide preservation and glycaemic control and variability 
(Staeva et al., 2013). This study therefore aimed to: 
 
1. Define the duration of time spent within defined blood glucose ranges following 
islet transplantation, using continuous glucose monitoring to assess blood glucose 
control. 
 
2. Correlate blood glucose control with level of endogenous insulin production 
achieved post-transplantation, using stimulated C-peptide during meal tolerance 
testing as a measure of graft function.  
 
3. Give a detailed assessment of blood glucose variability, hyperglycaemia risk and 
hypoglycaemia risk and investigate for any possible relationship with the level of 
endogenous insulin production in islet recipients. 
 
Detailed glucose time series obtained by CGM have been previously used to assess 
blood glucose control pre- and post-islet transplantation (Kessler et al., 2002, 
Vantyghem et al., 2012, Geiger et al., 2005, Paty et al., 2006, Faradji et al., 2006). 
However, these studies are limited by a basic assessment of CGM outcomes that does 
not utilise CGM analysis to its full potential: CGM analysis can provide a number of 
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measures of blood glucose variability (Hill et al., 2011), as well as an assessment of 
hyperglycaemia and hypoglycaemia risk (Clarke and Kovatchev, 2009). 
 
The aim of this work was to use CGM in islet recipients to determine whether 
restoration of beta-cell function at a given level is intrinsically associated with benefits 
in glycaemic control and prevention of hypoglycaemia. Defining the level of C-peptide 
at which clinical outcomes are achieved could have substantial implications for present 
and future therapeutic interventions aimed at maintaining or restoring endogenous 
insulin production. 
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1.7.3 Aim 3: Assessment of hepatic fat in UK islet recipients 
Whether fatty changes in the liver are merely an incidental consequence of a 
successfully functioning islet transplant in a minority of patients, or whether the 
changes might predict future transplant failure is currently unclear. No consensus has 
yet been reached on whether the development of steatosis impacts on graft function. 
 
This project aimed to use Magnetic Resonance Imaging (MRI) to make the first 
quantitative assessment of liver fat in islet recipients. The specific aims were: 
 
1) To identify whether intra-hepatic islet transplantation results in morphological fatty 
change within the liver, using chemical shift based water-fat separation MRI. 
 
2) To accurately quantify the distribution of fatty liver changes on magnetic resonance 
images obtained in islet transplant patients. 
 
3) To compare images of the liver obtained in islet recipients with two control groups: 
patients with a known diagnosis of NAFLD and patients with type 1 diabetes on 
continuous subcutaneous insulin infusions. 
 
4) To assess the impact of any fatty change in islet recipients on graft function. 
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1.7.4 Aim 4: Determination of de novo Donor Specific Antibody development in 
islet transplant recipients  
The alloimmune response and anti-HLA antibody formation have been associated with 
reduced islet graft functional outcomes (Mohanakumar et al., 2006). Islet 
transplantation is associated with a relatively high rate of de novo DSA development 
(Campbell et al., 2007b), and association with immunosuppression withdrawal after 
graft failure has been previously confirmed. Prospective studies are required to elucidate 
the temporal relationship between DSA development and graft dysfunction, and this 
study aimed to: 
 
1) Screen for de novo DSA development at regular intervals during the first 12 months 
following an islet transplant. 
 
2) Assess the impact of de novo DSA development on graft function. 
 
3) Assess whether available donor information (age, body mass index, HLA match, 
pancreas condition, harvesting and cold ischaemia time) has any association with 
DSA formation or graft outcome. 
 
Islet cell transplantation also provides a unique opportunity to monitor recurrent 
autoimmune mediated islet destruction, and this study aimed to measure fluctuations in 
autoimmune antibody formation alongside alloimmune testing to determine the 
temporal relationships of the immune response with any graft dysfunction. The aim of 
the work was to identify potential surrogate markers that might predict islet graft 
failure. 
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Chapter 2 - Methods 
2.1 Assessment of clinical outcomes in the UK islet transplant program 
2.1.1 The UK islet recipient population – indications for transplantation 
Recipients of a first islet transplant between April 2008 and March 2011 at all NHS-
funded centres (Edinburgh, King’s College London, Royal Free London, Manchester, 
Newcastle and Oxford (including patients assessed and followed up in Bristol)) were 
invited to take part in an ethically-approved experimental medicine follow-up study 
following informed written consent. Inclusion criteria included C-peptide-negative type 
1 diabetes complicated by recurrent severe hypoglycaemia (≥1 event over the preceding 
12 months requiring assistance to actively administer carbohydrate, glucagon, or other 
resuscitative actions (Workgroup on Hypoglycaemia, 2005)) despite optimised 
conventional management. Contraindications included insulin resistance (insulin 
requirement >0.7 units/kg to achieve HbA1c <9.0% (<75 mmol/mol)), BMI >28 kg/m2 
and any contraindications to immunosuppression therapy (including impaired renal 
function with isotopic GFR <60 mls/min/1.73m2 or albumin excretion rate >300 
mg/24hr (unless previous renal transplant)) (See Appendix One). 
 
2.1.2 Donor tissue for transplantation 
Pancreases from donors without diabetes were allocated to the best-matched ABO-
compatible recipient at the top of the national waiting list following negative cross-
match. Following standardised procurement, the pancreas was transported in ice-cold 
University of Wisconsin solution to the designated isolation facility according to 
geographical proximity / on-call rota. The service was initially commissioned for 
England alone with central isolation sites in Oxford and London (King’s College and 
Royal Free Hospitals sharing the London commitment). A separately commissioned 
service for Scotland was launched in 2009 with isolation and transplantation in 
Edinburgh. Isolation for recipients throughout the UK is now shared between Oxford, 
King’s College London and Edinburgh, with Royal Free Hospital continuing as a non-
isolating satellite transplant centre. 
 
2.1.3 Islet isolation from a donor pancreas 
Following digestion with Collagenase NB 6 GMP Grade (Serva, Heidelberg, Germany), 
islets were purified, cultured (0-24 hours), quality-assessed and product-released 
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(Aldibbiat A, 2012, Huang et al., 2004).  Islet preparations allocated to a recipient at a 
distant transplant centre were transported by road (maximum journey time 8 hours) in 
cooled standard 500 ml blood transfusion bags (Huang et al., 2004). Following 
confirmation of satisfactory temperature maintenance and negative Gram stain, 
maintained integrity and viability were confirmed from a side-arm sample prior to 
infusion directly from the transport bag. Confirmation of a minimum isolate mass of 
3,000 IEQ/kg with islet viability >70% and purity >30% was required for 
transplantation.  
 
2.1.4 Peri-operative management of islet transplant recipients 
Islets were transplanted by percutaneous transhepatic delivery into the portal vein under 
radiological visualisation. Recipients received adjuvant intravenous insulin and heparin 
infusions perioperatively, followed by self-administered low molecular weight heparin 
for 7 days according to published protocols (Koh et al.)(2010). Intensified insulin 
regimens were continued in all post-discharge, with the goal being maintenance of 
optimal glycaemic control. Islet recipients were defined as having received ‘transported’ 
islets if ≥1 of their islet preparations had been isolated at a separate geographical 
location in the UK and required transport to a second site prior to transplantation. 
 
2.1.5 Study protocol for the follow-up of islet transplant recipients 
Severe hypoglycaemia over the preceding 12 months was recorded pre-transplant with 
careful prospective collection of all severe hypoglycaemic events post-transplant. 
Formal metabolic assessment was undertaken pre-transplant, at 1 month after each 
transplant and 3-6 monthly thereafter up to 36 months post-transplant (see Appendix 
Two). Clinical review included hypoglycaemia awareness assessment (by Clarke/ Gold 
questionnaires (score ≥4 = impaired awareness of hypoglycaemia)) (Clarke et al., 1995, 
Gold et al., 1994), HbA1c (TOSOH G7/G8 analyser, Reddich, UK with NGSP (DCCT) 
standardization until June 2009 and transition to IFCC standardization thereafter), total 
daily insulin dose and weight, and a standardised Meal Tolerance Test (Greenbaum et 
al., 2008a) with centralised glucose and C-peptide assay (Perkin Elmer AutoDELFIA, 
Massachusetts, USA until December 2011; Siemens Immulite 2000, Erlangen, Germany 
from December 2011; equivalence confirmed including excellent correlation (Pearson’s 
R2 = 0.98)). Ongoing graft function was defined as stimulated serum C-peptide >50 
pmol/L. Participants attended fasted and, if on exogenous insulin therapy, were advised 
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to withhold their pre-breakfast short-acting insulin dose on the day of assessment, with 
all tests organised to commence at 9 am. The decision to stop insulin therapy post-
transplantation was made following review of blood glucose levels by the clinical team, 
and insulin independence was defined as cessation of insulin for >14 days. 
 
2.1.6 Statistics for the assessment of clinical outcomes in recipients receiving 
transported and non-transported islet preparations 
Data are reported as median and interquartile range. The Wilcoxon Signed Rank test 
was used to compare pre- versus post-transplant clinical outcomes. Outcomes between 
groups of recipients receiving transported versus non-transported islet preparations were 
compared using the Mann-Whitney U-test. 
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2.2 Continuous glucose monitoring in islet recipients to assess relationship between 
glycaemic control and endogenous insulin secretion 
2.2.1 Continuous glucose monitoring in islet recipients 
Recipients of an islet transplant between October 2008 and December 2012 at 
Newcastle-upon-Tyne Hospitals NHS Foundation Trust were invited to take part in an 
ethically-approved experimental medicine follow-up study following informed written 
consent.  
 
In the week preceding metabolic assessments, an iPro continuous glucose monitor 
(iPro1; Medtronic, Minneapolis, USA) was placed on the anterior abdominal wall of 
islet recipients. The system registers glucose concentration every 10s and stores an 
average value every five minutes, within a range of 2.2-22.2 mmol/L (40-400 mg/dL). 
Participants were blinded to CGM data but were provided with a One Touch blood 
glucose meter (Lifescan, High Wycombe, UK) with standardized instructions on 
checking blood glucose at least once every 12 hours to enable standardized CGM 
calibration. A 3 to 5 day continuous blood glucose monitoring record was obtained in 
recipients prior to each metabolic assessment, with device removal prior to each meal-
tolerance test.  
 
2.2.2 Analysis of CGM records 
Data from the sensor and calibration blood glucose meter were uploaded to a computer 
using Medtronic Solutions software (Medtronic, Minneapolis, USA). Records where 
mean absolute difference (MAD) between sensor glucose and capillary blood glucose 
readings exceeded 28% over a 24 hour period of CGM were considered to be at high 
risk of reflecting inaccurate blood glucose recordings, and were excluded from analysis. 
Periods of time where the sensor failed to record blood glucose values due to study 
participants not undertaking sensor calibration were also excluded from analysis. 
 
Duration of normoglycaemia (3-10 mmol/L), hypoglycaemia (<3 mmol/L) and 
hyperglycaemia (>10 mmol/L) were calculated from the blood glucose sensor record 
and expressed as percentages of total blood glucose recording time. 
 
Measures of blood glucose variability and estimates of hypo and hyperglycaemia risk 
were calculated by inputting blood glucose records in the Xcel format into the Easy 
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GV© computer program (available free for non-commercial use at www.easygv.co.uk) 
(Hill et al., 2011). Standard deviation of blood glucose (SD), average daily risk ratio 
(ADRR) (Kovatchev et al., 2006), low blood glucose index (LBGI) and high blood 
glucose index (HBGI) (Kovatchev et al., 2003) were calculated using this program. 
 
2.2.3 Statistical Analysis of CGM records and assessment of relationship with 
endogenous insulin secretion in islet recipients 
All statistical analysis was undertaken in collaboration with the Newcastle University 
Department of Statistics. 
 
Relationship of stimulated C-peptide, metabolic status and CGM glucose profile was 
explored by cross-sectional analysis of all post-transplant assessments.  Graft function 
was determined by the level of stimulated C-peptide achieved at 90 minutes post-
stimulus during the meal tolerance test. Beta-cell function was categorised into four pre-
defined groups: ‘low function’ C-peptide <200 pmol/L; ‘moderate function’ 200-500 
pmol/L; ‘good function’ 500-1000 pmol/L; ‘excellent function’ >1000 pmol/L. C-
peptide <200 pmol/L is a historically important cut-off point given previous clinical 
outcomes reported by DCCT (The Diabetes Control and Complications Trial Research 
Group (1997)); other cut-off points were selected to allow comparison of CGM outputs 
in groups of approximately equal size at increasing levels of endogenous C-peptide.  
 
Results for individual recipients are reported as median (minimum to maximum range), 
results for group comparisons as median (interquartile range). Outcomes obtained from 
CGM records when graft function was ‘moderate’, ‘good’ or ‘excellent’ were compared 
to CGM outcomes when graft function was ‘low’ using the Mann-Whitney U-test; the 
non-parametric Jonckheere-Terpstra test was used to compare CGM outcomes across all 
groups. 
 
The relationship between C-peptide and blood glucose control was investigated using a 
mixed Poisson regression model (Stata 12 data analysis and statistical software, Texas, 
USA). The dependent variable in each analysis was the measure of blood glucose 
control, either fitted directly or after an appropriate transformation. Variation between 
patients and variation between observations within patients were included as a random 
effects; C-peptide was included as a fixed effect. These models were used to generate 
plots of predicted values of the indicator against a range of C-peptide values. 
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Proportion of time spent within normoglycaemic range (3-10 mmol/L) was modelled by 
considering the proportion of time spent outside this range. The dependent variable was 
the number of 5 minute blocks of time where blood glucose levels were either <3.0 
mmol/L or >10.0 mmol/L. A Poisson error structure was assumed for the variation 
between observations within patients; variation between subjects was assumed to follow 
a gamma distribution. The total number of blocks observed during a particular 
observation interval was included as an exposure variable (loge [total number of blocks] 
was included as a covariate with the regression coefficient constrained to 1). 
 
Plots of blood glucose variability against C-peptide suggested a non-linear relationship 
between the two variables: standard deviation cannot be less than zero and therefore a 
linear relationship was not plausible. Taking a log transformation resulted in a plausible 
model and plots that were consistent with a linear trend on the log scale. For the log 
transformed observations, normal distributions were assumed for both variation 
between patients and variation between observations within patients. 
 
The analyses of average daily risk ratio, high blood glucose index and low blood 
glucose index were based on log transformed values. For the low blood glucose index, 
one was added to all values prior to taking the log transformation. 
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2.3 Hepatic steatosis assessment in islet recipients 
2.3.1 Magnetic resonance imaging in islet recipients 
All recipients of an islet transplant between April 2008 and March 2013 at all NHS-
funded centres were invited to take part in an ethically approved experimental medicine 
follow-up study following informed written consent.  
 
All scans were undertaken at the Magnetic Resonance Research Centre, Newcastle 
University. Primary aims of the study were to invite all participants for post-transplant 
magnetic resonance imaging to assess hepatic fat content, and to determine the 
incidence of steatosis post-islet transplantation. Secondary aims were to investigate 
whether quantity of hepatic fat content had any impact on future graft function. A subset 
of patients from Newcastle and Manchester were invited for an additional pre-transplant 
scan for baseline assessment of pre-transplant liver fat content, and for further scans at 
multiple time-points post-transplant to assess the evolution of any variations in hepatic 
fat content post-transplantation. 
 
As part of their routine clinical care, islet recipients underwent a liver ultrasound pre-
transplant (to assess liver architecture for any abnormalities prior to islet 
transplantation), one day post-transplant (to assess for thrombosis or haemorrhage) and 
prior to any further islet transplant (to reassess liver architecture prior to re-
transplantation). 
 
2.3.2 Control groups for hepatic steatosis assessment 
Liver fat assessment in islet recipients was compared to two recruited control groups: 
subjects with a previous clinical diagnosis of NAFLD and adults with type 1 diabetes on 
continuous subcutaneous insulin infusion (CSII). Both control groups provided 
informed written consent and underwent a single magnetic resonance imaging scan for 
hepatic fat assessment. A history of hepatic disease, substance abuse or daily 
consumption of more than one alcoholic drink daily (>20 g/L) were exclusion criteria 
for recruitment into control groups. At the time of scanning, BMI and waist 
circumference were recorded and blood was taken for DCCT-aligned HbA1c, lipid 
profile and liver function tests. Participants with type 1 diabetes had an additional blood 
sample taken for endogenous C-peptide assessment (Siemens Immulite 2000 assay).  
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2.3.3 Magnetic resonance imaging protocol 
Imaging was performed using a 3.0 T Philips Achieva (Philips, Best, NL) with a six-
channel phased array cardiac coil. Multi-slice, two-dimensional spoiled gradient echo 
sequences were acquired from the liver, with three echoes in separate repetition times. 
TR= 50 ms, TE = 3.45/4.60/5.75 ms, flip angle = 5o, bandwidth = 435 Hz/pixel, field-
of-view 400 x 280 mm, matrix 160 x 156, zero-filled to 1.4 x 1.0 mm resolution, slice 
thickness = 10 mm. To image the whole liver, three acquisitions were made in separate 
17 second expiration breath-holds, acquiring slices per breath-hold.  The use of a low 
flip angle minimised T1 weighting in the images and hence bias, since the T1 of hepatic 
fat is lower than that of water. 
 
Separate fat and water images were computed using the hierarchical IDEAL algorithm 
of Tsao and Jiang on the complex data acquired (Tsao and Jiang), using a fixed fat 
model containing 6 resonances to model the spectral complexity of fat at chemical shift 
(Hamilton et al., 2011). The proton density fat fraction was computed from the separate 
fat and water images using a magnitude discrimination method (Liu et al., 2007) to 
preclude noise-related bias. All computations were performed in MATLAB 
(Mathworks, UK). 
 
2.3.4 Fat map analysis 
Proton density fat fraction maps were viewed utilising ImageJ software (Research 
Services Branch, National Institute of Mental Health, Bethesda, Maryland, USA) for 
subsequent quantitative region-of-interest (ROI) analysis. Each magnetic resonance 
scan typically provided 18 axial fat maps of the liver. The three fat maps providing the 
largest cross-sectional area of liver available for analysis were selected from each set, 
and a ROI was created for each fat map. The ROI for analysis was selected manually 
and aimed to cover the largest possible area of liver whilst avoiding visible vessels, 
hepatic ducts, liver capsule and falciform ligament (which have a higher fat content than 
neighbouring hepatocytes). ImageJ software was used to generate a histogram of hepatic 
fat fractions according to pixel shade intensity within the ROI. Mean, minimum, 
maximum and standard deviation of fat fraction were calculated for each MRI scan 
following analysis of three ROIs from separate fat maps to provide a quantitative 
assessment of hepatic fat content (See Appendix Three). 
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Fat map analysis was undertaken by two assessors (AA and AB) independently to check 
for reproducibility of quantitative hepatic fat assessment using the method described. 
Bland-Altman analysis (Bland and Altman, 1986) was used to assess inter-user 
variability. AB’s measurements were used for all other outcome analyses. 
 
Hepatic fat outcomes are reported as median (interquartile range). Comparisons of 
hepatic fat between groups were assessed using the Mann-Whitney U-test, whilst 
comparisons across groups were made using the Kruskal-Wallis test. 
 
2.3.5 Calculation of a heterogeneity index in islet recipients with focal steatosis 
changes 
Two islet recipients were noted to have focal steatosis changes on their post-transplant 
scans. A method of quantifying this pattern of steatosis was sought, with the aim of 
producing a measure of heterogeneity for hepatic fat that would differentiate the islet 
recipient scans with focal steatosis changes from scans with an equivalent hepatic fat 
content where hepatic fat distribution was more homogeneous. Two areas of 
approximately 1 cm radius were subjectively selected on three fat maps for each scan: 
one area was selected to obtain the highest fat concentration possible on the fat map, 
whilst the second was selected to obtain the lowest possible fat concentration. The mean 
high fat fraction result for three fat maps was divided by the mean low fat fraction to 
give a ‘heterogeneity index’. Outcomes were compared to MRI scans from two control 
subjects with type 2 diabetes identified to have homogeneous hepatic fat distributions 
and matched for total hepatic fat content to the two islet recipients with focal steatosis 
changes. 
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2.4 De novo donor specific antibody assessment in islet recipients and assessment 
of impact on graft function 
Recipients of an islet transplant between October 2008 and March 2013 at Newcastle-
upon-Tyne Hospitals NHS Foundation Trust were invited to take part in an ethically-
approved experimental medicine follow-up study following informed written consent.  
 
Pancreases from donors without diabetes were allocated to best-matched ABO-
compatible recipients according to a national waiting list following a negative cross-
match. All previously detected HLA antibodies had been listed as unacceptable 
mismatches preventing transplantation from donors who expressed antigens to which 
antibodies had previously been detected. Islet recipients received induction 
immunotherapy with alemtuzumab, basiliximab or daclizumab pre-transplant; 
tacrolimus (Prograf: trough 8-12 ng/ml) and mycophenolate (500 mg - 2 g daily) were 
used for maintenance immunosuppression post-transplant. 
 
2.4.1 Pre-transplantation cross-matching 
Crossmatching and HLA antibody screening were performed at the Histocompatibility 
and Immunogenetics laboratory at the National Health Service Blood and Transplant 
facility in Newcastle (NHSBT, Newcastle, UK). A T and B cell complement dependent 
cytotoxicity (CDC) and flow cytometric cross-match was performed pre-transplant. 
 
In the CDC crossmatch, lymphocytes extracted from donor spleen were incubated with 
patient serum; Dithiothreitol (DTT) was used to determine differential reactivity 
between IgG and IgM antibodies. A selection of pre-transplant serum samples reflecting 
the recipient’s immunological profile over this time was used for crossmatching, with a 
positive IgG T cell cross-match a contraindication to transplantation.  
 
Flow cytometric crossmatching using lymphocytes extracted from donor spleen was 
performed using a fluorescein isothiocyanate (FITC) anti-human IgG conjugate (Sigma-
Aldrich, Dorset, UK). T and B cell populations were separated using Phycoerythrin 
conjugated CD3 or CD20 (Beckman Coulter, CA, USA) respectively. The Flow 
cytometry cross-match was considered positive if the mean value of the test sera was 
greater than the mean plus two standard deviations of six negative controls. 
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In keeping with UK kidney transplant data, the total number of HLA mismatches was 
calculated by measuring the mismatches to HLA A, B and DR antigens. Some islet 
recipients received islets from two donors and therefore recipients could be exposed to 
up to twelve mismatches at HLA-A, B and DR (2 HLA-A, 2 HLA-B, 2 HLA-DR per 
transplant). If an HLA-antigen was a repeat mismatch, this was only counted as one 
mismatch. HLA-C, HLA-DQ and HLA-DP mismatches were also assessed but not 
included in the conventional total mismatch count. 
 
2.4.2 HLA antibody and DSA assessment 
Sera were drawn prospectively pre-transplant, one month after each received islet 
infusion and at 1, 3, 6, 9 and 12 months post-first transplant for antibody assessment.  
 
Tests were performed to determine the presence or absence of IgG HLA antibodies to 
HLA-A, B, C, DR, DQ and DP using a Luminex 200 flow cytometer (Luminex Inc., 
Austin, TX, USA). HLA binding to microparticles coated with HLA molecules was 
determined using a two-stage screening and identification protocol. All samples were 
initially screened for the presence or absence of HLA antibodies with the Luminex 
cytometer using Labscreen mixed HLA antibody screening kits (One Lambda Inc., 
Canoga Park, CA, USA). A positive result for this mixed screen assay was determined 
using the manufacturer’s recommended guidelines of more than 1.5 times the negative 
control bead as positive and 1.2-1.5 times as reactive. HLA antibody specificities were 
then further determined in any tests that were positive or reactive using Labscreen 
single antigen kits (One Lambda Inc.). Standard manufacturer’s guidelines were 
followed to determine a positive reaction, with median fluorescence intensity (MFI) 
>1000 used as a cut-off value for a positive result. De novo antibodies were defined as a 
new HLA specificity post-transplant that was not detectable prior to the first islet 
infusion. 
 
2.4.3 Autoantibody measurement 
All available sera drawn for antibody sampling were tested for antibodies to Glutamic 
acid decarboxylase (GAD), Insulinoma-associated protein 2 antigen (IA-2A) and Islet 
cell antibody (ICA). 
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The threshold for GAD positivity was the 99th percentile of control subjects, equivalent 
to >9.9 arbitrary units (Triturus analyser, ELISA assay supplied by Euroimmun UK, 
London). 
 
The threshold for IA-2A positivity was the 99th percentile of control subjects, equivalent 
to >10.0 arbitrary units (ELISA assay, Euroimmun UK, London). 
 
ICA was recorded as ‘negative’, ‘weakly positive’ or ‘positive’ (Indirect 
Immunofluorescence, monkey pancreas substrate, conjugate used FITC IgG, INOVA 
diagnostics, San Diego, CA, US). 
 
2.4.4 Statistical analysis of DSA outcome data 
Descriptive statistics are presented as median (interquartile range). Clinical outcomes 
are reported for each individual graft post-transplantation, comparing outcomes for graft 
with a DSA positive response versus a DSA negative response. Comparisons were 
performed using the Mann-Whitney U-test, with p<0.05 considered to be significant. 
Graft failure was defined as stimulated serum C-peptide <100 pmol/L at 90 minutes 
during MTT assessment. Subsequent investigation of factors that might underlie DSA 
development in grafts with a DSA positive response versus those without a DSA 
response was also undertaken using the Mann-Whitney U-test. 
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Chapter 3 - Clinical outcomes in the integrated UK islet transplant 
program with locally isolated and transported preparations 
3.1 Introduction 
3.1.1 Islet transplantation restores endogenous insulin production 
Restoration of endogenous insulin secretion in C-peptide-negative type 1 diabetes by 
deceased donor pancreatic islet allograft transplantation has been confirmed (Shapiro et 
al., 2000, Ryan et al., 2005a). Success has been replicated in centres internationally and 
clinical outcomes have continued to improve (Barton et al., 2012). Nevertheless, islet 
transplantation remains an experimental procedure in the majority of programs with 
widespread availability limited by the expense and complexity of establishing validated 
cell isolation facilities accessible to all potential recipients (Khan and Harlan, 2009). 
 
3.1.2 The UK islet transplant network 
An integrated UK islet transplant network fully funded by the NHS was commissioned 
in 2008 (Aldibbiat A, 2012) as a clinical intervention for life-threatening recurrent 
severe hypoglycaemia (See Appendix One). Islet transplantation has been approved by 
NICE, with the stated treatment aims of prevention of recurrent severe hypoglycaemia 
(Workgroup on Hypoglycaemia, 2005), achievement of HbA1c <7.0% (<53 mmol/mol), 
reduction in exogenous insulin requirement and quantification of graft function by 
assessment of C-peptide secretion (NICE, 2008). In contrast to other islet transplant 
programs (Ryan et al., 2005a, Vantyghem et al., 2009) achievement of insulin 
independence is not a primary goal.  
 
Equity of access is a cornerstone of the NHS islet transplant program, with all potential 
recipients joining a single national waiting list following completion of assessment and 
offered organs that are optimally procured throughout the UK by the National Organ 
Retrieval Service. Islets are purified at a designated specialist isolation centre with local 
transplantation or transport to a distant centre according to patient location.  
 
The islet program has been integrated with the vascularised pancreas transplant program 
from the outset, with a national agreement for deceased donor organ sharing. Organs 
procured from donors with a body mass index (BMI) of >30 and <40 kg/m2 were used 
in preference for islet isolation, although organs from donors with a BMI of <30kg/m2 
not placed for whole organ pancreas transplantation were also offered for clinical islet 
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isolation. The goal was transplantation of a total transplant mass of >10,000 islet 
equivalents (IEQ)/kg recipient weight within 12 months of the first transplant, with no 
further grafts once this mass had been exceeded.  
 
3.1.3 Assessment of clinical outcomes in the UK islet transplant program 
From the inception of the NHS-funded UK program, islet recipients have been invited 
to participate in a prospective follow-up study to determine clinical outcomes following 
transplantation. The objectives of the current analysis were to determine whether 
metabolic outcome goals were achieved post-intervention over the first 3 years of the 
UK program, and whether equity of access to transplantation might be realised if 
equivalent outcomes were achieved with both locally isolated and transported 
preparations. 
 
3.2 Methods 
See section 2.1 entitled ‘Assessment of clinical outcomes in the UK islet transplant 
program’ for a description of study methods (See also Appendix Two). 
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3.3 Results 
3.3.1 Islet recipients in the first three years of the UK islet transplant program 
A total of 24 individuals received islet transplants over the first three years of the 
integrated UK islet transplant program. Data are reported in 20 recipients, as two had 
received initial islet transplants prior to April 2008, one had post-pancreatectomy 
diabetes and one did not provide research consent. 
 
There were 16 islet transplant alone and 4 islet after kidney transplant recipients; 15 
females and 5 males. Age was 49(44-54) years and diabetes duration 30(17-39) years 
with weight 61.0(55.5-76.0) kg. 12 month metabolic outcomes were obtained in all 
recipients, and at a median follow-up 24(13.5-36) months (see Table 3.1).   
 
Participants received a total of 35 islet infusions (single graft: n=7; two: n=11; three: 
n=2). For recipients of a second graft, time to second transplant was 5(3-8.5) months. 
Donor age was 45(38-53) years with BMI 30.7(26.6-33.4) kg/m2. There were 33 donors 
after brain death (DBD) and 2 donors after circulatory death (DCD) with cause of death 
intracranial haemorrhage in 67%. Total transplant mass per recipient was 8770(6536-
13045) IEQ/kg.  
 
For first transplants, induction was with alemtuzumab (n=13); daclizumab/ basiliximab 
(n=6); or anti-thymocyte globulin (n=1). For second transplants, alemtuzumab (n=6), 
daclizumab/ basiliximab (n=4) or no induction agent (n=3) was used. For third 
transplants, basiliximab was used at induction in one recipient and alemtuzumab in the 
other. Initial maintenance immunosuppression was tacrolimus (Prograf: trough 8-12 
ng/ml)/ mycophenolate mofetil (500 mg - 2 g daily) (n=18); tacrolimus/ sirolimus 
(n=1); or ciclosporin/ mycophenolate mofetil (n=1)
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Table 3.1 – UK islet recipient metabolic outcomes 12 months from time of first islet transplant and median 24 (13.5-36) months post-transplant
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3.3.2 Graft function survival and clinical outcomes 
Graft function was maintained in 80% of recipients at 24 (13.5-36) months (Figures 3.1 
and 3.2).  
 
Severe hypoglycaemia was reduced post-transplant from 20 (7-50) to 0.3 (0-1.6) 
episodes per patient-year (p<0.001) (Table 3.1 and Figure 3.3A). This includes 
recipients who had lost graft function, who experienced 0.7 (0.4-1.5) episodes per 
patient during follow-up. Whereas all participants had experienced severe 
hypoglycaemia in the 12 months prior to transplantation, 60% of all recipients 
experienced no recurrent severe hypoglycaemia over 24 (13.5-36) months post-
transplant. Hypoglycaemia awareness improved (pre-transplant: Gold score 6 (5-7); 24 
(13.5-36) months: Gold score 3 (1.5-4.5); p<0.03).  
 
Significant improvement in overall glycaemic control was achieved with post-transplant 
HbA1c 6.2 (5.7-8.4)% (Figure 3.3B). HbA1c target of <7.0% was attained in 70% of 
recipients.  
 
There was a reduction in insulin dose of >50% at 24 (13.5-36) months (pre-transplant: 
0.5 (0.4-0.6) units/kg; 24 (13.5-36) months: 0.2 (0-0.4); p<0.001), with cessation of 
exogenous insulin in 45% of recipients. Rate of graft survival exceeded 70% in both 
insulin independent and insulin requiring islet recipients (see Figure 3.3A), and of the 9 
recipients achieving insulin independence, 3 remained off exogenous insulin at 24 
(13.5-36) months (see Figure 3.1). 
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Figure 3.1 – Bar chart showing graft function up to 36 months post-transplant, indicating timing of subsequent transplants, duration of insulin 
independence, prevention of recurrent severe hypoglycaemia and maintenance of HbA1c <7.0%.
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Figure 3.2 - Kaplan-Meier plots of graft survival up to 36 months post-transplant (n=20). 
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Figure 3.3 - Box plots of severe hypoglycaemia incidence (A) and HbA1c (B) in all 
recipients pre- and 24 (13.5-36) months post-first islet transplant (n=20). Box indicates 
median, upper quartile and lower quartile ranges. Whiskers plotted with the lowest 
datum within 1.5 times the interquartile range of the lower quartile and the highest 
datum within 1.5 times the interquartile range of the upper quartile. *P < 0.001 vs. pre-
transplant, Wilcoxon Signed Rank test.  
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3.3.3 Comparison of clinical outcomes in recipients receiving transported versus non-
transported islet preparations 
Nine recipients (45%) received ≥1 transported islet preparation (Table 3.2). Pre-
transplant, recipients of solely locally isolated islets were well-matched with those who 
received transported preparations, with the exception of significantly higher HbA1c in 
the group receiving transported islets. Donor age, number of islet infusions and islet 
transplant mass were not significantly different between groups, although donor BMI 
was noted to be higher in recipients receiving transported islets. Islets were transported 
prior to transplantation from both DCD donors. Islet viability was high in both groups 
(median ≥90%), although higher in recipients of local islets. No difference in islet purity 
was noted. 
 
No significant difference in metabolic outcomes was noted in recipients of transported 
and only locally isolated islets at 12 months follow-up (Table 3.2), with graft function 
well maintained in both groups up to 36 months post-transplant (Figure 3.4B). 
 
Three of the 9 recipients who received transported islet preparations also received a 
locally isolated preparation. To further investigate whether islet transport had any 
influence on metabolic outcome, a reanalysis of outcomes from the six individuals 
(30%) who had received only transported islets was undertaken. These patients 
achieved a reduction in severe hypoglycaemia (35(4-50) events/year pre-transplant vs 
0(0-4) events/year post-transplant); and HbA1c (9.6(8.8-10.3)% pre-transplant vs 
6.4(5.9-9.1%) post-transplant). There were no significant differences in metabolic 
outcomes compared to the 11 recipients receiving solely locally isolated preparations 
(p-value for between-group differences: 12-month severe hypoglycaemia rate: p=1.00; 
HbA1c: p=0.65).  
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Table 3.2 – Recipient metabolic outcomes 12 months following first transplant: Locally isolated islet preparations versus ≥ 1 transported islet preparation. 
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Figure 3.4 - Kaplan-Meier plots of graft survival comparisons up to first 36 months post-
transplant. Figure 3.4A is a comparison of recipients achieving insulin independence 
(interrupted line) (n=9) versus those requiring insulin throughout follow-up (solid line) (n=11); 
Figure 3.4B is a comparison of those receiving only locally isolated (interrupted line) (n=11) 
versus transported (solid line) (n=9) islet preparations.
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3.3.4 Complications and renal function post-transplant 
There were no episodes of significant haemorrhage, thrombosis or other major peri-
operative adverse events.  Following discharge from hospital, one participant received 
granulocyte colony stimulating factor (GCSF) for asymptomatic neutropenia. One 
participant was treated for shingles and a second for folliculitis but none developed 
systemic sepsis over the first 12 months post-transplant. No new neoplastic disease was 
detected. Renal function was not altered significantly at 24 (13.5-36) months post-
transplant (creatinine: pre-transplant 85 (75-104) μmol/l, post-transplant 103(85-133) 
μmol/l; p=0.91).  
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3.4 Discussion 
3.4.1 Primary goals of the UK islet transplant program achieved: prevention of 
recurrent severe hypoglycaemia with improvement in glycaemic control 
The primary goals of the UK islet transplantation program are to prevent recurrent life-
threatening hypoglycaemia and restore optimal overall glycaemic control in recipients, 
regardless of geographical proximity to an isolation facility. This study has shown that 
these goals have been attained up to 36 months post-transplant. 
 
Since definitive confirmation of the potential for at least short term insulin 
independence following islet transplantation by the Edmonton group, the debate has 
continued around whether the primary goal should be freedom from exogenous insulin 
replacement (Hering et al., 2005) or prevention of debilitating severe hypoglycaemia 
without sacrificing overall glycaemic control (Lehmann et al., 2008).  
 
The UK health service made a decision to make this therapy available to patients with 
type 1 diabetes who have life-threatening hypoglycaemia and loss of hypoglycaemia 
awareness, with the primary goal being elimination of severe hypoglycaemia requiring 
third-party intervention. To underpin equitable sharing of the restricted potential donor 
pool between solid pancreas and isolated islet transplant recipients, it was agreed that no 
more than two transplants per recipient would be undertaken, in the absence of 
exceptional circumstances.    
 
Further agreement has been reached nationally on congruent indications for pancreas 
and islet transplantation alone, with the primary listing criterion being recurrent severe 
hypoglycaemia despite optimised conventional self-management. Individuals are 
assessed for both procedures, with the majority rapidly reaching a definitive decision 
about whether they wish the more invasive procedure of pancreatic transplantation with 
increased mortality risk but prospect of long-term insulin independence (White et al., 
2009), or the lower risk procedure of islet transplantation with the prospect of optimal 
metabolic control despite maintained insulin therapy. With the focus on freedom from 
severe hypoglycaemia, transplant physicians in the UK tend to intensify diabetes self-
management post-islet transplantation rather than to attempt insulin withdrawal in all 
recipients, as we believe that maintained exogenous insulin may preserve islet 
transplant function and provide longer term metabolic benefits.  
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The UK program has realised its commitment to limit number of islet infusions per 
recipient, with 35% receiving single grafts. Given this and overall transplant mass of 
<10,000 IEQ/kg, insulin independence rate of <50% is not unexpected (Ryan et al., 
2005a). In one recent single centre study, insulin independence was achieved in 14 
consecutive islet recipients (Vantyghem et al., 2009). This necessitated a mean of 2.7 
grafts per recipient with overall transplant mass 12,479 IEQ/kg. After median follow-up 
of 3.3 years, insulin independence had fallen to 58% of recipients. Notably, in that study 
all transplants for a single recipient were completed within less than 3.5 months. In 
contrast, median time to second transplant in the UK cohort was 5 months, with a range 
of 1-13 months. 
 
The alternative paradigm with primary goal of optimal glycaemic control and avoidance 
of severe hypoglycaemia as opposed to insulin independence has been adopted by the 
Zurich group (Lehmann et al., 2008). This group reported equivalent metabolic 
outcomes to solid organ transplantation after simultaneous islet kidney transplantation 
(Gerber et al., 2008). Although one year insulin independence rate was lower in islet 
recipients (31% versus 96% in simultaneous pancreas kidney recipients), incidence of 
serious adverse events was also much lower. In that study, 38% of islet recipients 
received three or more infusions with a maximum of five and mean of 2.2±1.3 
transplants per recipient.  
 
3.4.2 Equivalent clinical outcomes achieved with transported and non-transported 
islet preparations, allowing equity of access to islet transplantation across the UK 
Clinical success has previously been reported with transported islets (Kessler et al., 
2004, Barshes et al., 2004) but a direct comparison of local and distant recipients who 
have been transplanted according to nationally agreed congruent protocols has not been 
published before. 
 
Existing programs have been configured around a single isolation facility providing 
islets for both local and distant recipients. The UK program is unique in being fully 
integrated, dependent on the isolation facilities transplanting both locally isolated islets 
and preparations transported from another facility. This has enabled equitable allocation 
of donor pancreas directly to the most appropriate recipient nationally, regardless of 
which isolation facility is on-call. Establishment of a successful integrated islet and 
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vascularised pancreas transplant program has facilitated implementation of a unique 
organ pancreas allocation scheme, with equitable provision of organs to both whole 
organ and isolated islet recipients on a common national waiting list. This was launched 
in December 2010, and it is hoped the updated scheme will lead to further 
improvements in UK islet transplant outcomes through the provision of higher quality 
donor organs than those rejected for whole organ transplantation. Islet recipients 
awaiting a second transplant will be given enhanced priority under the new scheme, 
reducing time between transplants. Alongside changes to the allocation scheme, the 
impact of adjuvant peri-transplant anti-tumour necrosis factor-alpha therapy - associated 
with higher insulin independence rates in leading centres internationally (Bellin et al., 
2012) - is now being evaluated in UK recipients. 
 
3.4.3 Limitations in the clinical outcomes study 
Limitations of the study include absence of an intensified conventional therapy control 
group. Nevertheless, listing for islet transplantation can only be considered following 
specialist diabetologist confirmation that fully optimised medical management has not 
been successful in preventing recurrent severe hypoglycaemia. Evidence of the severity 
of risk in UK prospective islet transplant recipients has been underlined by death of 
three patients on the national waiting list – all due to hypoglycaemic crisis. Numbers 
remain relatively low for definitive comparison of transported versus non-transported 
preparations. However, the current study provides sufficient evidence of metabolic 
success for UK recipients of both locally isolated and transported islets to justify 
ongoing central funding. 
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CHAPTER FOUR 
Endogenous C-peptide determines 
blood glucose control outcomes in 
islet recipients
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Chapter 4 - Endogenous C-peptide determines blood glucose control 
outcomes in islet recipients assessed by  
continuous blood glucose monitoring 
4.1 Introduction 
4.1.1 Residual endogenous insulin secretion is associated with a reduced incidence of 
microvascular complications in individuals with type 1 diabetes 
Type 1 diabetes is widely considered to be a disease of absolute insulin deficiency after 
the honeymoon period but it has long been recognised that small amounts of retained 
endogenous insulin production are associated with reduced risk of complications and 
hypoglycaemia (The Diabetes Control and Complications Trial Research Group (1997), 
(1998)), (Steffes et al., 2003). The Diabetes Control and Complications Trial noted that 
individuals with ongoing endogenous insulin production had a reduced rate of 
microvascular complications and were less prone to experiencing hypoglycaemia (The 
Diabetes Control and Complications Trial (1997)). Complication rates remained 
reduced if endogenous insulin production was maintained by achievement of tight 
glycaemic control in the years following diagnosis of type 1 diabetes (The Diabetes 
Control and Complications Trial Research Group (1998)). These clinical findings 
suggest a legacy effect, where individuals with type 1 diabetes may have improved 
blood glucose control and be protected from vascular complications in later life if 
endogenous insulin production is maintained (Sjoberg et al., 1987, Panero et al., 2009). 
 
4.1.2 Islet recipients are a unique population in which to explore the relationship 
between endogenous insulin production and glycaemic control 
Transplantation of isolated pancreatic islets offers beta-cell replacement for individuals 
with type 1 diabetes through a minimally invasive percutaneous infusion into the 
hepatic portal vein. Stimulated C-peptide levels are frequently measured in islet 
recipients and can be assessed alongside intensive glucose monitoring within an 
individual. Graft function in islet recipients can vary according to the quality and 
number of islets received, and therefore stimulated endogenous insulin production 
varies between individuals. In addition, insulin production within an individual varies 
with time from transplantation, and can decline in the years following transplantation 
(Ryan et al., 2005a). Previous studies have shown that increased insulin production is 
associated with improved clinical outcomes in islet transplant recipients (Vantyghem et 
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al., 2012, Ryan et al., 2005a), with evidence suggesting that even low levels of 
endogenous C-peptide restoration may be associated with a reduction in hypoglycaemia 
risk and awareness (Leitao et al., 2008, Vantyghem et al., 2009). The relationship 
between a measured level of endogenous insulin production and its impact on day-to-
day glycaemic control has yet to be defined. 
 
4.1.3 Continuous glucose monitoring for the assessment of blood glucose control and 
the risk of hyperglycaemia or hypoglycaemia 
Continuous glucose monitoring (CGM) is used to give a measure of glycaemic control 
by providing a detailed glucose time series (288 readings / 24hrs). Scores developed to 
assess hyperglycaemia and hypoglycaemia risk (Kovatchev et al., 2006, Hill et al., 
2007, Kovatchev et al., 1998, Kovatchev et al., 2002) can be calculated from CGM 
records (Hill et al., 2011). They provide further information about the impact an 
intervention can have on clinical outcomes than merely the duration of time spent 
hyperglycaemic and hypoglycaemic: they are especially relevant to our islet recipients, 
given that we are undertaking an intervention to reduce the risk of severe 
hypoglycaemia.  
 
Risk indices - like the low blood glucose index (LBGI) and high blood glucose index 
(HBGI) (Clarke and Kovatchev, 2009) - try to overcome the dilemmas of 
hyperglycaemia and hypoglycaemia influence on measures of blood glucose variability. 
The LBGI and HBGI split the overall glucose variation into two independent sections 
related to excursions into hypo and hyperglycaemia, equalising the amplitude of the 
excursions with respect to the risk they carry. In a patient with diabetes, a drop in 
glucose levels does not have to be large to increase the risk of hypoglycaemia 
substantially, whilst increases in blood glucose have to be large prior to the patient 
being put at risk of a clinical event. LBGI is a summary statistic obtained from blood 
glucose readings that increases as frequency and extent of hypoglycaemia episodes 
increase. It has been used to predict future severe hypoglycaemia (Kovatchev et al., 
1998) but its use is specifically designed to assess hypoglycaemia risk. Similarly, the 
HBGI is designed specifically to assess hyperglycaemia risk (Kovatchev et al., 2002). 
 
The average daily risk range (ADRR) (Kovatchev et al., 2006) takes into account the 
asymmetric nature of the blood glucose scale and provides a measure of event severity. 
As a result, it does not just predict outlier blood glucose readings but is also linearly 
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associated with progressively higher frequency and severity of events according to 
blood glucose level. This overcomes the insensitivity to hypoglycaemia and inherent 
bias towards hyperglycaemia of some blood glucose variability measures. 
 
4.1.4 Aims of CGM assessment in islet recipients 
The relationship between endogenous C-peptide secretory capacity and parameters of 
glycaemic control was assessed by undertaking CGM in islet recipients one week prior 
to a mixed meal C-peptide response (Palmer et al., 2004) at multiple time intervals post-
transplant. As well as defining the duration of time spent within defined blood glucose 
ranges, a detailed assessment of blood glucose variability, hyperglycaemia risk and 
hypoglycaemia risk was undertaken to show how this related to endogenous insulin 
production. 
 
4.2 Methods 
See section 2.2 entitled ‘Continuous glucose monitoring in islet recipients to assess 
relationship between glycaemic control and endogenous insulin secretion’ for a 
description of study methods. 
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4.3 Results 
4.3.1 Islet recipient characteristics and collected CGM data 
Twelve consecutive islet transplant recipients were recruited (9 islet transplant alone, 3 
islet after kidney) (Figure 4.1, Table 4.1). Participants received a total of 20 islet 
transplants (single graft: n=5; two: n=6; three: n=1; median islet equivalents per 
kilogram (IEQ/kg) per recipient 11232 (IQR 8577-12267) IEQ/kg; per graft 5830 
(4943-7118) IEQ/kg). Median follow-up time was 18 (12-29) months post-transplant, 
and during this time participants underwent 5 (4-9) clinical assessments. Timing of 
clinical assessments during follow-up is shown in Figure 4.1. 
 
Restoration of C-peptide positivity was associated with recovery of hypoglycaemia 
awareness, resolution of recurrent severe hypoglycaemia and improvement in HbA1c 
(Table 4.1). One recipient achieved and maintained insulin independence, with the 
remainder continuing on reduced dose insulin therapy post-transplant (insulin 
requirement pre-transplant 0.60 (0.49-0.72) units/kg; post-transplant 0.42 (0.25-0.54) 
units/kg). 
 
74 CGM records were obtained, providing 7211 hours CGM data for analysis: 70 
records were paired with meal tolerance tests, with a further 4 records obtained between 
assessments. Records were obtained in recipients across a range of graft functions 
(Table 4.2): 19 records were obtained in 8 recipients at a time when graft function was 
‘low’ (<200 pmol/L, total group duration of CGM analysed 1608 hours, median 90 (58-
120) hours/recipient/visit) (Figure 4.3A); 15 records were obtained in 7 recipients when 
graft function was ‘moderate’ (200-500 pmol/L, total group duration of CGM analysed 
1487 hours, median CGM duration 108 (90-120) hours/recipient/visit) (Figure 4.3B); 17 
records were obtained in 7 recipients when function was ‘good’ (500-1000 pmol/L, total 
group duration of CGM analysed 1592 hours, median CGM duration of 96 (78-120) 
hours/recipient/visit) (Figure 4.3C) and 23 records were obtained in 4 recipients when 
function was ‘excellent’ (>1000 pmol/L, total group duration of CGM analysed 2524 
hours, median CGM duration 120 (96-120) hours/recipient/visit) (Figure 4.3D). 
 
4.3.2 Relationship of blood glucose control with endogenous C-peptide production 
There was a progressive reduction in mean glucose and standard deviation of blood 
glucose with higher levels of graft function. Duration of hypoglycaemia, 
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normoglycaemia, hyperglycaemia and measures of hypoglycaemia and hyperglycaemia 
risk all improved with increasing graft function (Jonckheere-Terpstra analysis, p<0.001) 
(Table 4.2, Figures 4.2, 4.3). Improvements in HbA1c and reduced insulin requirements 
were also associated with increasing levels of graft function (Table 4.2, Figure 4.4). 
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Figure 4.1 – Bar chart of islet graft function from time of first islet transplant in individual recipients, indicating timing of subsequent transplants. 
Endogenous C-peptide (median, range) and CGM hours analysed (median, range) from post-transplant assessments are also reported for each recipient. 
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Table 4.1 – Islet recipient pre-transplant characteristics and metabolic outcomes pre-transplant versus post-transplant
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Table 4.2 – Islet recipient pre-transplant characteristics and metabolic outcomes pre-transplant versus post-transplant
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Figure 4.2A & 4.2B Continuous glucose monitoring profiles recorded over 72 hours in 
islet recipients with low graft function (A), moderate graft function (B) 
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Figure 4.2C & 4.2D Continuous glucose monitoring profiles recorded over 72 hours in islet 
recipients with good graft function (C) and excellent graft function (D). 
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Figure 4.3 (next pages) - Box plots of time spent in normoglycaemic range (A), 
hyperglycaemic range (B), hypoglycaemic range (C), mean glucose (D), standard 
deviation of glucose (E), average daily risk ratio (F), high blood glucose index (G) and 
low blood glucose index (H) in islet recipients according to continuous glucose 
monitoring outcomes taken when graft function is low (n=19), moderate (n=15), good 
(n=17) and excellent (n=23). Box indicates median, upper quartile and lower quartile 
ranges. Whiskers plotted with the lowest datum within 1.5 times the interquartile range 
of the lower quartile and the highest datum within 1.5 times the interquartile range of 
the upper quartile. *P < 0.01 vs. low graft function, Mann-Whitney U-test.  
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Figure 4.4 - Box plots of HbA1c (A) and insulin dose (B) in islet recipients when graft 
function is low, moderate, good and excellent. Box indicates median, upper quartile and 
lower quartile ranges. Whiskers plotted with lowest datum within 1.5 times interquartile 
range of the lower quartile and highest datum within 1.5 times interquartile range of the 
upper quartile. *P < 0.01 vs. pre-transplant, Mann-Whitney U-test. 
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4.3.3 Relationship of endogenous C-peptide with proportion of time spent within 
glucose range 3.0 to 10.0 mmol/L, glucose variability, average daily risk ratio, 
hyperglycaemia and hypoglycaemia risk 
There was a strong association between C-peptide and time spent outside the normal 
glycaemic range, blood glucose standard deviation, average daily risk ratio and high 
blood glucose index. For each increase of 100 pmol/L in endogenous C-peptide, 
proportion of time spent outside a glucose range of 3.0 to 10.0 mmol/L reduced by 
12.9% (95% CI: 12.6% to 13.2%) (Figure 4.5A), standard deviation of blood glucose 
reduced by 4.92% (95% CI: 3.41%, 6.40%) (Figure 4.5B), average daily risk ratio 
reduced by 6.71% (95% CI: 4.33%, 9.02%) (Figure 4.5C), and mean high blood glucose 
index reduced by 9.52% (95% CI: 6.76%, 12.19%) (Figure 4.5D). 
 
Hypoglycaemia risk was reduced with increasing level of C-peptide (Figure 4.5E), 
although a random effects normal regression model provided no evidence of a 
significant linear association between the log transformed low blood glucose and C-
peptide.  
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Figure 4.5 (next pages) – Regression model plots showing relationship of endogenous 
C-peptide production with proportion of time glucose 3.0 to 10.0 mmol/L (A), blood 
glucose standard deviation (B), average daily risk ratio (C), high blood glucose index 
(D) and low blood glucose index (E). 
 
Figure Notes: 
The relationship between C-peptide and blood glucose control was investigated using a 
mixed Poisson regression model. The dependent variable in each analysis was the 
measure of blood glucose control, either fitted directly or after an appropriate 
transformation. Variation between patients and variation between observations within 
patients were included as a random effects; C-peptide was included as a fixed effect. 
 
The 95% confidence intervals for each plot are for the estimated population parameter. 
For example, in Figure 4.5A the mean proportion of time spent with glucose 3.0 to 10.0 
mmol/L corresponds to the value of C-peptide production given on the x-axis. At a 90 
minute C-peptide production of 200 pmol/L, it is 95% certain that in the population of 
patients from which this sample is drawn, the mean proportion of time spent with 
glucose 3.0 to 10.0 mmol/L will be between 41% and 64%. It is not implied that 95% of 
patients with this level of graft function will have observed levels of blood glucose that 
fall in this range; it is assumed that across all patients the proportion of time spent in 
the normal range will vary randomly about the population mean. The observations that 
correspond to values of C-peptide production provide a slope parameter of -0.0013799 
(with 95% CI: -0.0014134 to -0.0013465) on the exponential scale. The relationship 
suggests that for every increase of 100 pmol/L in C-peptide, the proportion of time spent 
outside glucose 3.0 to 10.0 mmol/L will be reduced by 12.9% (with 95% CI: 12.6% to 
13.2%). 
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4.4 Discussion 
4.4.1 Restoration of endogenous C-peptide production improves CGM outcomes 
This study used regular assessment of C-peptide and CGM outcomes in islet transplant 
recipients to demonstrate a continuous relationship between stimulated C-peptide and 
multiple clinical and metabolic parameters of blood glucose control. It provides clear 
evidence that restoration of C-peptide improves CGM outcomes, and quantifies how 
much improvement in blood glucose control might be expected with increases in 
endogenous C-peptide secretory capacity. 
 
CGM has been used to assess blood glucose control post-islet transplantation previously 
to demonstrate that duration of hypoglycaemia and hyperglycaemia is reduced 
following re-establishment of endogenous C-peptide production post-transplantation 
(Kessler et al., 2002, Vantyghem et al., 2012, Geiger et al., 2005, Paty et al., 2006, 
Faradji et al., 2006, Gorn et al., 2008). One group used the beta-score as measure of 
graft function and suggested that improvements in hypoglycaemia duration might be 
anticipated at lower levels of graft function before improvements in mean glucose, 
glucose variability and hyperglycaemia (Vantyghem et al., 2012, Ryan et al., 2005b).  
 
A greater understanding of the impact of endogenous C-peptide capacity on blood 
glucose parameters is now provided by application of the additional CGM analysis 
techniques used in this study. Stratification of outcomes according to endogenous C-
peptide production allowed initial assessment of the relationship between endogenous 
C-peptide and metabolic and clinical outcomes. It was noted that when measured level 
of endogenous C-peptide reduced in a recipient, paired CGM revealed a deterioration in 
blood glucose control parameters at the time of C-peptide assessment, even if excellent 
graft function and desirable glucose control outcomes had been achieved previously. 
Re-transplantation and increase in endogenous C-peptide production resulted in 
improvement in CGM outcomes once more, suggesting endogenous C-peptide was 
integral to clinical outcome. 
 
4.4.2 This study supports the original findings of the DCCT 
Eleven out of twelve recipients remained on insulin post-transplant to achieve the best 
possible level of blood glucose control. Increased C-peptide production was still 
associated with improved clinical outcomes, with less insulin required to achieve a 
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better HbA1c at higher endogenous C-peptide levels. The benefits of endogenous 
insulin production on blood glucose control were originally confirmed in the DCCT, in 
which the intensively treated group could be subdivided according to residual C-peptide 
secretion at entry into the trial: the subgroup with the highest stimulated C-peptide 
(>200 pmol/L) had a significantly lower HbA1c over the first four years of the study, 
50% less risk of progression of retinopathy and 65% less risk for severe hypoglycaemia 
with seizure or coma (The Diabetes Control and Complications Trial Research Group 
(1998)). Beyond outcomes from the DCCT, the evidence base for the advantages of 
maintained C-peptide production in individuals with type 1 diabetes has been scarce. 
The outcomes of this study support the original conclusions of the DCCT (Lachin et al., 
2013, Steffes et al., 2003): glycaemic control is improved and risk of hypoglycaemia is 
reduced with increasing levels of endogenous C-peptide production. 
 
4.4.3 Endogenous C-peptide has a continuous relationship with parameters of blood 
glucose control 
In our islet recipient cohort, endogenous C-peptide was subsequently found to have a 
continuous relationship with duration of blood glucose levels between 3.0 to 10.0 
mmol/L, blood glucose variability and hyperglycaemia / hypoglycaemia risk down to 
the lowest levels of detectable C-peptide. Subanalysis of data in assessments obtained 
only from individuals with a C-peptide of <200 pmol/L showed that the continuous 
relationship between these outcomes and measured levels of graft function was 
maintained. This supports the findings of a recently published study that used glucose 
clamps to assess functional beta-cell mass in islet recipients, and demonstrated a 
correlation between HbA1c, insulin dose and glycaemic variability even at very low 
levels of functional beta-cell mass (Gillard et al., 2013). Even low levels of endogenous 
C-peptide production may be of clinical benefit, supporting the hypothesis that 
glycaemic control might be easier in the ‘honeymoon period’ of type 1 diabetes, and 
providing a possible explanation as to why individuals who retain low levels of 
endogenous C-peptide may find blood glucose control easier than C-peptide negative 
individuals in the longer-term. 
 
Improvement in endogenous C-peptide may have immediate implications for 
predisposition to hypo or hyperglycaemia. LBGI and HBGI split overall glucose 
variation into two independent sections related to excursions into hypoglycaemia and 
hyperglycaemia, equalising the amplitude of the excursions with respect to the risk they 
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carry (Kovatchev et al., 2002). ADRR is designed to be equally sensitive to 
hypoglycaemia and hyperglycaemia risk (Kovatchev et al., 2006), taking into account 
the asymmetric nature of the blood glucose scale and providing a measure of event 
severity. At levels of excellent function (>1000 pmol/L), HBGI, LBGI and ADRR were 
reduced to low risk scores. Regression analysis in this study demonstrated that ADRR, 
HBGI and LBGI have a continuous relationship with endogenous C-peptide capacity, 
although higher levels of endogenous C-peptide production were required to influence 
LBGI significantly post-transplant and the risk reduction in LBGI achieved with an 
increase in endogenous C-peptide capacity was less predictable than that for HBGI or 
ADRR.  
 
4.4.4 Relationship between endogenous C-peptide secretion and incidence of severe 
hypoglycaemia is complex 
Prevention of severe hypoglycaemia may be more complex than simply re-establishing 
‘metabolic memory’ following a period of freedom from hypoglycaemia in islet 
transplant recipients. Improvement in HbA1c and insulin dose occurred with increasing 
graft function but although islet transplantation dramatically reduced the frequency of 
severe hypoglycaemia in the recipient cohort, a relationship between endogenous C-
peptide secretion and incidence of severe hypoglycaemia was more difficult to establish. 
Severe hypoglycaemia is an infrequent ‘all-or-nothing’ event that is often reported as an 
annualised rate; it is therefore difficult to establish a relationship with graft function, 
which might vary throughout the year. There remains the possibility that only a very 
low level of endogenous C-peptide is required to substantially reduce risk of severe 
hypoglycaemia.  
 
4.4.5 Precautions regarding CGM interpretation 
Caution must be applied to interpretation of this study’s results, given the small number 
of participants in the study and the limitations of current CGM sensors. The presence of 
a time lag between interstitial glucose values and actual plasma blood glucose must be 
accepted, and this has been reported to be 7.94+/-6.48 minutes for the iPro Enlite sensor 
worn in the abdominal area (Keenan et al., 2012). The MAD between the iPro Enlite 
sensor glucose and blood sample plasma glucose has been reported to be 13.86% in 
adults (Keenan et al., 2012). These inconsistencies have been shown to be increased 
outside of the normoglycaemic range, with clinical accuracy between actual interstitial 
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glucose and that recorded by the monitoring device as low as 62%, suggesting the error 
to be due to engineering rather than physiological difficulties (Clarke and Kovatchev, 
2007). Although CGM systems might generate statistically acceptable results, there is 
particular concern regarding their accuracy during the hypoglycaemic blood glucose 
range (Clarke et al., 1987, Zung and Zadik, 2002).  
 
CGM records that exceeded an MAD of 28% over a 24-hour period were excluded from 
statistical analysis but caution must remain with regards to the interpretation of our 
results, especially outside of the normoglycaemic range.  However, this study has 
analysed over 7,000 hours of CGM data before drawing its conclusions, and continuous 
measurement of interstitial glucose levels by CGM has allowed assessment of blood 
glucose variability, hyperglycaemia risk and hypoglycaemia risk in individuals with 
varying levels of endogenous C-peptide secretory capacity (Hill et al., 2011, Clarke and 
Kovatchev, 2009). 
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CHAPTER FIVE 
Quantitative assessment of  
hepatic steatosis in islet recipients 
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Chapter 5 - Quantitative assessment of hepatic steatosis by magnetic 
resonance imaging in islet recipients 
5.1 Introduction 
5.1.1 Hepatic steatosis may be a surrogate marker of graft function 
Islet graft function suffers attrition over time (Ryan et al., 2005a), and there is a need to 
develop techniques for monitoring graft function using surrogate markers of rejection. 
Accurate measurement of liver fat content would permit evaluation of steatosis post-
transplantation, and allow long-term assessment of whether its development does indeed 
impact on graft function. Steatosis seen in islet recipients is heterogeneous in 
distribution, and therefore the selected mode of investigation must assess the liver in its 
entirety. A non-invasive imaging modality that can be used to quantitatively assess the 
whole liver in post-transplant recipients is required, without unnecessarily exposing the 
assessed individual to ionizing radiation. 
 
5.1.2 Magnetic resonance imaging (MRI) for liver fat assessment 
MRI can be used to measure the difference in resonance frequencies between water and 
fat to obtain in-phase (water + fat signal) and opposed phase (water – fat signal) images: 
radiologists routinely use loss-of-signal on the opposed phase to interpret diffuse or 
focal steatosis. However, such methods cannot quantify liver fat owing to spatially 
varying imperfections in the magnetic and radiofrequency fields (Hu and Kan, 2013).  
 
Additional imaging using chemical shift based water-fat separation methods are 
required to overcome these problems (Reeder et al., 2011). This method separates MR 
signals from water and fat that can be used to produce water-only and fat-only images, 
corrected for inhomogeneities in the magnetic and radiofrequency fields; these images 
can be recombined to create a proton density fat signal fraction map. Unlike in and out-
of-phase imaging, full separation of water and fat signals permits a 0-100 % assessment 
of fat signal fraction. 
 
5.1.3 Study aims for hepatic steatosis in islet recipients 
Previous assessments of liver fat content in islet recipients have utilised imaging 
modalities to make qualitative measures of hepatic fat content. This study aimed to use 
MRI to make the first quantitative assessment of liver fat in islet recipients. A complex-
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based MR imaging technique was utilised, with magnitude and phase information from 
images acquired at echo times selected to achieve accurate separation of water and fat 
signals, so that a fat fraction estimate with a range of 0-100% (Yu et al., 2008) was 
provided.  
 
The specific aims of this study were: 
1) To develop a technique to accurately quantify hepatic fat content in islet transplant 
recipients, and to assess inter-user variability of this technique. 
 
2) To identify whether intra-hepatic islet transplantation results in morphological fatty 
change within the liver. 
 
3) To compare hepatic fat content in islet recipients with two control groups: 
individuals with a known diagnosis of NAFLD and adults with type 1 diabetes on 
continuous subcutaneous insulin infusions (CSII). 
 
4) To assess the impact of any hepatic fat changes in islet recipients on graft function. 
 
5.2 Methods 
See section 2.3 entitled ‘Hepatic steatosis assessment in islet recipients’ for a 
description of study methods (See also Appendix Three).
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5.3 Results 
5.3.1 Study recruitment and baseline characteristics 
Fifteen islet recipients, 15 patients with type 1 diabetes on CSII and 15 control patients 
with a previous clinical diagnosis of NAFLD were recruited to the study. Islet recipients 
were transplanted at NHS centres in Newcastle (11 recipients / 19 transplants), 
Manchester (2 recipients / 3 transplants), the Royal Free Hospital, London (1 recipient / 
2 transplants) and King’s College Hospital, London (1 recipient / 2 transplants) between 
September 2008 and November 2013. Islet graft mass per recipient was 10919 (5953-
12846) islet equivalents/kg (IEQ/kg). No steatosis was identified in any islet recipients 
on pre-transplant ultrasounds. Timing of MRI scans in the islet recipients is shown in 
Figure 5.1. 
 
Baseline characteristics (median, interquartile range) of islet recipients pre-transplant 
and post-transplant and the two control groups are given in Table 5.1. There was no 
significant difference in age, weight, BMI, waist circumference, insulin dose, alanine 
transaminase (ALT), total cholesterol, high density lipoprotein (HDL), low density 
lipoprotein (LDL) or triglycerides between islet recipients and CSII controls. NAFLD 
controls had a significantly greater weight, BMI, waist circumference and ALT and 
lower HDL than islet recipients (p<0.001, Mann-Whitney U-test). C-peptide was 
negative (<50 pmol/l) in all islet recipients prior to transplantation and all but one of the 
insulin pump controls (one patient random C-peptide = 357 pmol/l). 
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Figure 5.1 – Timing of MRI scans (black arrows) and additional islet transplants (unfilled arrows) up to 24 months post-transplant. 
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Abbreviations:  
NAFLD – non-alcoholic fatty liver disease, IQR – Interquartile range, M – male, F – female, BMI – Body Mass Index, HbA1c – glycated haemoglobin, ALT – alanine transaminase, 
C-cholesterol, HDL – high density lipoprotein, LDL – low density lipoprotein, Trigs – triglycerides, NA – result not available. 
¥P is Mann-Whitney test of significance versus islet recipient group at time of first scan post-transplant 
Table 5.1 - Baseline characteristics & hepatic fat quantification in islet recipients (pre and post-transplant) and CSII and NAFLD control groups
 M:F 
Age 
 (years) 
Weight 
(kg) 
BMI  
(kg/m2) 
Waist 
 (cm) 
Insulin  
(units/kg) 
HbA1c 
(%) 
ALT 
(IU) 
Lipid profile Hepatic Fat 
Quantificatio
n 
(%) 
Total C 
(mol/L) 
HDL 
(mol/L) 
LDL 
(mol/L) 
Trigs 
(mol/L) 
  
Islet 
recipients 
pre-
transplant 
(n=5) 
Median 
2:3 
52 72.4 25.8 NA 0.48 9.6 23 5.3 1.4 2.9 1.3 2.42 
IQR (47-55) (60.0-75.9) (23.4-26.8) NA (0.40-0.86) (8.0-11.4) (19-36) (4.0-6.1) (1.4-2.0) (2.0-3.8) (1.0-1.6) (2.05-4.41) 
  
Islet 
recipients 1st 
scan post-
transplant 
(n=15, 
median 
follow-up 
time 3 
months) 
Median 
4:11 
50 61.0 24.0 85 0.34 7.2 25 4.7 1.8 2.3 1.2 2.36 
IQR (48-57) (56.4-72.5) (22.2-25.3) (79-91) (0.21-0.56) (6.6-8.5) (16-30) (4.0-5.75) (1.5-1.9) (1.6-3.0) (0.9-1.8) (1.82-3.95) 
  
Continuous 
subcutaneous 
insulin 
infusion 
(n=15) 
Median 
7:8 
49 69.1 22.1 83 0.50 8.4 24 5.2 2.3 2.2 1.0 1.89 
IQR (26-61) (55.6-75.1) (20.6-75.1) (79-86) (0.43-0.78) (7.8-9.0) (12-33) (4.5-5.8) (1.8-2.9) (1.9-3.1) (0.6-1.3) (1.62-2.32) 
¥P  0.41 0.71 0.12 0.56 0.27 0.08 0.95 0.36 0.06 0.92 0.18 0.13 
  
Clinical 
Diagnosis of 
NAFLD 
(n=15) 
Median 
8:7 
54 101.1 34.7 106 NA 7.3 36 4.2 1.1 1.9 1.6 19.6 
IQR (42-57) 
(86.0-
110.1) 
(31.2-37.0) (97-113) NA (6.6-7.9) (29-56) (3.6-4.6) (1.0-1.4) (1.4-2.2) (1.2-3.4) (15.9-31.6) 
¥P  0.74 <0.001 <0.001 <0.001 NA 0.96 0.01 0.10 <0.001 0.20 0.13 <0.001 
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5.3.2 Hepatic fat assessment and precision of quantification  
Hepatic fat fraction was quantified in the islet recipients and both control groups (see 
Figures 5.2A and 5.2B, Table 5.1). 
 
Sixty-five paired MRI hepatic fat measurements were available for Bland-Altman 
analysis of hepatic fat quantification comparison between assessors AB and AA (see 
Figure 5.3). The correlation coefficient R value for AA’s values plotted against AB’s 
values was 0.997 (p<0.001). Mean difference between both sets of results was 
calculated at 0.081 %, with standard deviation of the differences 0.825 %. The 
coefficient of repeatability (twice the standard deviation) was 1.65 %, giving limits of 
agreement for the hepatic fat measurements by the two assessors to be -1.536 % to 
1.698 %. 
 
5.3.3 Comparison of hepatic fat in islet recipients versus control groups 
No difference in hepatic fat content was noted between islet recipients’ first post-
transplant scan (median time to scan post-transplant = 4 (1-12) months) and insulin 
pump controls (p=0.13, Mann-Whitney U-test) (Figure 5.4). Liver fat fraction was 
significantly greater in NAFLD patients compared to either of these groups (p<0.001 
versus islet recipients and CSII controls, Mann-Whitney U-test). 
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Figure 5.2 – ImageJ software screenshots showing ‘water-only’ (A) and ‘fat-only’ (B) 
signals from the liver. The region of interest for analysis (indicated by the dotted yellow 
line) was selected manually on water-only images initially, as these images highlight 
areas of vascularity, hepatic ducts, liver capsule and artefact which must be avoided for 
hepatic fat quantification (these areas alter signal intensity irrespective of fat content). 
Regions of interest were subsequently overlaid onto the corresponding fat-only image 
for hepatic fat quantification. 
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Figure 5.3 – Scatter plot showing correlation coefficient (A) and Bland-Altman plot (B) 
for comparison of inter-user variability for hepatic fat quantification by assessors AA 
and AB. 
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Figure 5.4 – Box plot showing comparison of hepatic fat content in insulin pump users 
(n=15), islet recipients post-transplant (n=15) and individuals with NAFLD (n=15). *P 
< 0.01 vs. islet recipients, Mann-Whitney U-test. 
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5.3.4 Variation in hepatic fat with time post-transplant in islet recipients 
Pre-transplant, mean liver fat fraction was 2.42 (2.05-4.41) % (n=5). No significant 
difference in liver fat fraction was noted pre-transplant compared to 1 month (2.16 
(1.85-3.99) %, n=6), 3 months (2.43 (1.77-3.04) %, n=6), 6 months (2.86 (1.41-3.62) %, 
n=4), 12 months (2.27 (1.41-3.62) %, n=6) and 24 months post-transplant (2.53 (1.95-
5.38) %, n=4) (p=0.94, Kruskal-Wallis test) (Figure 5.5). 
 
Of the 15 islet recipients, 10 had > 1 scan (Figure 1). 5 recipients had a pre-transplant 
and a post-transplant scan, whilst 5 recipients had sequential scans post-transplant. The 
median time between scans was 8.5 (3-15) months for all 10 recipients in the post-
transplant period. The median change in hepatic fat in islet recipients undergoing repeat 
scanning post-transplantation was 0.32 (-1.13-1.60) % between scans (Figure 5.6). 
 
5.3.5 Development of focal steatosis distribution 
Two islet recipients were noted to develop a focal steatosis distribution post-transplant 
(Figure 5.7). In the first recipient (NE014), hepatic fat fraction increased from 2.4 % 
pre-transplant to 5.7 % on a 1 month post-transplant scan showing the focal steatosis 
changes. This patient subsequently declined further MRI scanning. In the second 
recipient (NE010), hepatic fat fraction was quantified at 3.9 % on a 3 month post-
transplant scan showing the focal steatosis changes. This recipient went on to have a 
second islet transplant 6 months after the first, and resolution of the focal steatosis 
distribution was noted on a repeat MRI scan at 18 months from the first transplant: at no 
stage did this recipient have loss of graft function and liver fat fraction fell to 1.4 % on 
the follow-up scan. 
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Figure 5.5 – Box plot showing change in hepatic fat content in islet recipients pre-
transplant (n=5) and 1 (n=6), 3 (n=6), 6 (n=4), 12 (n=8) and 24 (n=5) months post-
transplant. 
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Figure 5.6 – Bar chart showing median change in hepatic fat in 10 islet recipients 
undergoing repeat scanning post-transplantation. 
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Figure 5.7 - ImageJ software screenshots showing ‘fat-only’ signals from the liver in islet 
recipient NE014, with fat signals highlighted in purple. Figure A displays fat signals pre-
transplant, Figure B displays fat signals one month post-transplant. 
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A heterogeneity index was calculated for both subjects with focal steatosis changes, and 
in two further control subjects with type 2 diabetes and a homogeneous hepatic fat 
distribution on their scans (study codes T2D01 and T2D02). Calculated heterogeneity 
indices were 2.34 for NE014 and 4.39 for NE010. Total hepatic fat content for T2D01 
and T2D02 was 4.85 % and 3.92 % respectively, with calculated heterogeneity indices 
of 1.29 and 1.52 respectively. 
 
5.3.6 Impact of hepatic fat content on graft outcome 
Median 90 minute C-peptide achieved during meal tolerance testing was 485 (68-882) 
pmol/L in islet recipients at 12 months post-transplant. Liver fat fraction on first scan 
undertaken post-transplant (median time of scan = 4 (1-12) months post-transplant) did 
not have a direct correlation with 90 minute C-peptide assessed by meal tolerance test at 
12 months post-transplant (R = +0.30, p=0.76 on regression analysis using Pearson’s 
Correlation Coefficient) (Figure 5.8). 
 
In the two recipients noted to have focal steatosis changes on MR scans, 90 minute C-
peptide was 794 pmol/l one month post-transplant in the first recipient (NE014) and 492 
pmol/l at the time of the changes three months post-transplant in the second recipient 
(NE010). 90 minute C-peptide achieved at a 12 month post-transplant meal tolerance 
test was 357 pmol/l in NE014 and 1003 pmol/l in NE010. The number of recipients 
with focal steatosis changes was too small to assess whether this had any impact on 
graft function at 12 months. 
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Figure 5.8 – Scatter plot showing relationship between hepatic fat fraction on first scan 
post-transplant (median 4 (1-12) months post-transplant) and 12 month graft function 
determined by 90 minute C-peptide during a meal tolerance test in islet recipients. 
 
 
 132 
5.4 Discussion 
5.4.1 Hepatic fat assessment in islet recipients 
This study is the first to describe a method of hepatic fat quantification utilising 
chemical shift based water-fat separation MRI in islet recipients. The technique has 
previously been used to quantify hepatic fat in individuals with NAFLD and type 2 
diabetes (Lim et al., 2011, Yokoo et al., 2011), where the steatosis distribution is diffuse 
and homogeneous. However, its use in islet recipients presents unique challenges due to 
the focal and patchy nature of hepatic fat distribution post-transplantation. Previous 
studies have shown that islets infused into the main portal vein at the time of 
transplantation embolize within branches of the portal venous system, which is 
predominantly located in the liver periphery (Sever et al., 1992). The paracrine action of 
insulin results in steatosis predominantly in perivenular regions and located peripherally 
in the liver. 
 
Earlier studies have attempted to assess hepatic fat in islet recipients but only a 
qualitative assessment has been previously reported. Ultrasound is the most commonly 
used imaging modality for the diagnosis of hepatic steatosis (Mishra and Younossi, 
2007) and has been used for assessment of steatosis after islet transplantation (Venturini 
et al., 2010). Although non-invasive and without radiation risk, the technique is operator 
and machine-dependent; and the outcomes are not reproducible on repeat testing 
(Saadeh et al., 2002). The sensitivity of ultrasound for diagnosing hepatic steatosis in 
islet recipients has been questioned when compared to MRI (Hu and Kan, 2013). 
Computed tomography (CT) can provide objective assessment of hepatic fat content 
(Kodama et al., 2007) but inaccuracies can be caused by oedema, fibrosis, glycogen, 
copper or iron, and CT has a low sensitivity for mild to moderate steatosis (Limanond et 
al., 2004). 
 
Non-targeted percutaneous liver biopsy with histological evaluation is considered to be 
the gold standard investigation for diagnosis of hepatic steatosis (Kleiner, 2005).  
However, biopsy is limited by sampling variability (Ratziu et al., 2005): a biopsy 
assesses a tissue sample 1/50,000th the overall size of the liver, and therefore is not 
representative of the whole organ. Biopsy assumes homogeneous distribution of 
steatosis within the liver – a major shortfall in the assessment of islet recipients as 
steatosis development is most likely to be heterogeneous in distribution. A biopsy study 
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in 16 islet recipients found localised steatosis in 8 patients (Toso et al., 2009), but 
emphasised the difficulties of using a liver biopsy as a diagnostic tool to assess 
transplanted islets, as islet tissue was found in only 31% of biopsies. In addition, liver 
biopsy has an associated risk of complications that can lead to hospitalisation (1-3%) 
and rarely death (1 in 10,000) (Bravo et al., 2001).  
 
This study’s chosen method of MRI utilises a non-invasive modality of investigation 
that does not expose the subject to ionizing radiation. To capture as much of the 
heterogeneous hepatic fat distribution as possible, images providing the largest possible 
area of liver for analysis on three different levels were assessed with ROIs that marked 
the largest possible area of liver. Our analysis technique did require that areas of 
vascularity were avoided when selecting the region of interest, so that calculation of 
hepatic fat content was not inappropriately influenced by fat content of vasculature. 
However, there remains the possibility that if steatosis distribution following islet 
transplantation is known to be predominantly perivenular, the described technique could 
have provided an underestimate of hepatic fat: this was avoided as much as possible by 
marking regions of interest as close as possible to blood vessels. In addition, the 
selected technique for this study volume-weights the fat measurements, and therefore 
extremely localised fat might be hard to detect in the 10 mm slices used for the fat map 
generation. 
 
5.4.2 Quantification of hepatic fat content in islet recipients 
It was necessary to check whether two individuals taught the described technique of 
hepatic fat quantification obtained comparable results, to verify that the technique 
described produced reliable and reproducible results and might be used by other 
scientific teams investigating hepatic fat changes in islet recipients. The two individuals 
(AA and AB) undertaking hepatic fat quantification were blinded to each other’s work 
and marked their own regions of interest for hepatic fat analysis on image sections 
selected independently from one another.  
 
Bland-Altman comparison of the two assessors’ measurements was undertaken. A plot 
of the difference in hepatic fat measurements against the mean hepatic value for both 
assessors’ measurements allowed investigation of the relationship between the 
assessors’ results. The true hepatic fat value for each obtained scan was unknown, and 
therefore the best available estimate for a true value was the mean of both assessors’ 
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measurements. The mean difference between both sets of results was calculated to be 
0.081 % fat, with a standard deviation of the differences of 0.825 %. This gave 
calculated limits of agreement for the assessors’ results of -1.536 % to 1.698 % (mean 
difference +/- two standard deviations). No previous quantitative data for hepatic fat in 
islet recipients has previously been reported to suggest what might be a clinically 
suitable limit of agreement. We believe that this is a sufficient limit of agreement given 
the range of fat fractions measured by the technique: mean values for hepatic fat from 
both assessors’ measurements ranged from 1.25 % to 51.08 %. However, many of the 
hepatic fat values were low fat fractions: it could be conceivably argued that the limit of 
agreement reported may not be sufficiently narrow to compare scans with low hepatic 
fat content values. Even so, the limits of agreement for the described technique suggest 
that two independent users should be capable of readily detecting shifts in hepatic fat 
content of >3 %, allowing investigation of whether islet transplantation produces 
sizeable shifts in hepatic fat content post-transplant. 
 
5.4.3 Hepatic fat outcomes after islet transplantation 
Hepatic fat in islet recipients did not differ from CSII controls. Both groups were well 
matched for BMI, so that detectable differences in hepatic fat content might be 
attributable to islet transplantation rather than body habitus (Gaba et al., 2012). NAFLD 
subjects had a substantially greater BMI and hepatic fat content than either of the other 
two groups.  
 
Hepatic fat content at time-points post-transplant did not change significantly from pre-
transplant values within the islet recipient group. These observations suggest that islet 
transplantation does not result in a marked increase in quantified hepatic fat content.  
 
Hepatic fat content has previously been correlated with body mass index (Gaba et al., 
2012). The islet recipients were not noted to have any significant change in weight 
compared to pre-transplant: a number of patients gained weight post-transplant, whilst a 
proportion lost weight; no correlation between recipient body mass index and hepatic 
fat assessment was identified. 
 
Our quantified hepatic fat content results for the CSII group are in keeping with 
previously calculated values in subjects with type 1 diabetes but perhaps closer to 
values previously calculated for a population without diabetes (Perseghin et al., 2005). 
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As hepatic insulin concentration is anticipated to be reduced in individuals with type 1 
diabetes, it has been suggested that the low glucagon to insulin ratio may result in 
abnormally low intrahepatic lipid oxidation. This combined with enhanced whole-body 
fat oxidation during the fasting state may contribute to a lower intrahepatic fat content 
in individuals with type 1 diabetes. 
 
Insulin secretion in islet transplant recipients is pulsatile, with glucose-induced 
stimulation of insulin secretion accomplished by amplification of insulin pulse size 
(Meier et al., 2006). This may optimise insulin signalling and insulin extraction by the 
liver, with pulsatile insulin release indirectly governing systemic insulin delivery 
because of preferential extraction of insulin bursts (Meier et al., 2005). Direct hepatic 
catheterisation studies have revealed that hepatic first-pass insulin extraction is similar 
in healthy control subjects and in patients who have undergone islet transplantation, 
implying that insulin secreted from islet grafts is delivered into hepatic sinusoids rather 
than into the hepatic central vein (Meier et al., 2006). If venous drainage was via the 
hepatic central vein, insulin secretion by intrahepatic transplanted islets would be 
systemic rather than portal and would have implications for hepatic insulin clearance, 
with a substantial risk of hyperinsulinaemia.  
 
Re-establishing a physiological route of intraportal insulin delivery might putatively 
expose hepatocytes to secreted insulin via fenestrated sinusoids, inducing lipid 
deposition by promoting esterification of free fatty acids within hepatocytes. However, 
it could equally be argued that the afore-mentioned findings suggest that insulin release 
from transplanted islets avoids hyperinsulinaemia, and insulin might not be present for 
sufficient time and in concentrations high enough in the liver parenchyma to induce 
localised fatty change. 
 
5.4.4 Hepatic fat fraction influence on graft function 
Hepatic fat fraction in islet recipients calculated from scans taken 4 (1-12) months post-
transplant did not correlate with C-peptide achieved during a meal tolerance test at 12 
months post-transplant, suggesting that hepatic fat fraction measured soon after 
transplantation is unlikely to be a surrogate marker for future graft function. This is in 
keeping with the findings of another recent study that found no relationship between 
qualitative assessment of hepatic fat content and graft survival (Jackson et al., 2013). 
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5.4.5 Development of focal steatosis and significance in islet recipients 
Although no significant increase in hepatic fat content was found post-transplantation in 
the islet population as a whole, two islet recipients did develop focal steatosis changes 
post-transplant. This focal steatosis pattern in islet recipients has been identified by 
other groups (Markmann et al., 2003, Bhargava et al., 2004, Venturini et al., 2010, Hu 
and Kan, 2013), although the onset of steatosis post-transplant in this study (1 month 
and 3 months post-transplant) was considerably quicker than that reported previously. 
 
One of the two subjects with focal changes (NE014) had a pre-transplant MRI and 
hepatic fat was quantified at 2.42% pre-transplant. This increased to 5.71% on an MRI 
showing the focal steatosis pattern 1 month post-transplant. Unfortunately, this subject 
declined further imaging. In the second subject (NE010), focal steatosis changes were 
noted on a scan taken 3 months post-transplant. This subject received a second islet 
transplant 6 months after the first transplant to improve endogenous insulin production, 
and islet graft function improved (90 minute MTT C-peptide was 492 pmol/l at 3 
months and 1003 pmol/l at 12 months post-first transplant). At no stage did this 
recipient have loss of graft function but on a repeat scan undertaken at 18 months post-
transplant, the focal steatosis changes had resolved, and liver fat fraction fell from 
3.95% to 1.39%.  
 
Previously, it has been noted that localised focal steatosis patterns resolve with loss of 
graft function (Bhargava et al., 2004, Venturini et al., 2010), and steatosis development 
has been associated with a higher proportion of islet recipients requiring exogenous 
insulin compared to those without steatosis. Stimulated C-peptide production has been 
reported to be significantly lower in patients with positive ultrasound findings for 
steatosis compared to those with no fatty changes (Venturini et al., 2010). Transplanted 
islets with a chronic exposure to a uniquely high lipid environment and high glucose 
levels may become victim to combined glucolipotoxicity, and it can be hypothesised 
that development of localised hepatic steatosis may reflect islet graft stress and dying 
islets. β cell apoptosis in the presence of high fatty acid concentrations could result in 
residual functioning islets having to produce excessive insulin to maintain blood sugar 
levels within the normal range. Hypersecretion of insulin might therefore promote an 
environment of glucolipotoxicity that results in further islet death, and localised hepatic 
steatosis may therefore be a harbinger of graft failure.  
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This study showed resolution of steatosis with an improvement in graft function 
following repeat transplantation, suggesting acute lipotoxicity may be reversible with 
improved blood glucose control using insulin or repeat transplantation. Identification of 
localised steatosis by MRI scanning may theoretically be used to time medical 
intervention, such as recommencement of insulin therapy or re-transplantation. 
However, a recent study in islet recipients with a median follow-up time of 8 years has 
found no clear relationship between additional islet infusions and the development or 
resolution of steatosis (Jackson et al., 2013). It is equally possible that only a subgroup 
of islet recipients have a genetic predisposition to developing localised steatosis post-
transplantation, and only a proportion of these patients may experience complications 
from the finding. Studies utilising MR analysis in a larger number of post-transplant 
recipients are required before further conclusions and recommendations can be made. 
 
5.4.6 The heterogeneity index as a method of identifying recipients with focal 
steatosis changes 
A measure that might be used to assess whether recipients have developed focal 
steatosis changes is the heterogeneity index. This measure utilises the heterogeneity of 
the steatosis distribution identified in islet recipients developing the focal changes. 
Values of 4.39 and 2.34 were reported in islet recipients, versus 1.29 and 1.52 in control 
subjects subjectively identified as having homogeneous fatty changes. The results 
suggest that an index of >2 might be initially used as a measure of whether islet 
recipients have developed focal steatosis. The index calculation relies on subjectivity in 
the selection of areas of high and low fat concentration but it does attempt to quantify 
the heterogeneity seen in recipients developing focal changes. The measure needs to be 
applied to a larger number of scans from islet recipients before it can be validated as a 
true measure of whether an individual has developed focal steatosis post-transplant.  
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Chapter 6 - De novo donor specific antibody development in islet 
recipients and impact on graft function 
6.1 Introduction 
6.1.1 The role of the humoral immune system in graft rejection 
Islet graft function has been noted to suffer attrition with time, with 14% of recipients 
maintaining insulin independence and 30% of recipients experiencing graft failure two 
years post-transplant in an international trial (Shapiro et al., 2006). Assessments of 
metabolic function have been used to define when graft failure has occurred but 
surrogate markers might allow prediction of graft failure, allowing interventions that 
maintain endogenous insulin production (Lacotte et al., 2011). 
 
6.1.2 HLA matching pre-islet transplantation 
Pre-transplant sensitisation to donor HLA has previously been associated with rapid loss 
of islet graft function (Mohanakumar et al., 2006). Ideally, HLA matching would be 
performed to prevent sensitisation and problems associated with the immune response 
to transplanted islets. However, a limited pool of donors and suitable recipients makes 
allocation of HLA matched donor organs to recipients unworkable. Islets are allocated 
primarily on ABO compatability and a sufficient number of islet equivalents based on 
recipient weight. Multiple infusions of islets from different donor organs are generally 
required to reach adequate transplanted islet mass to attain insulin independence. 
Recipients usually have multiple mismatches with donor epitopes, and each HLA 
mismatch may result in the development of de novo antibodies to donor tissue and 
previously mismatched HLA antigens. It has been shown that de novo HLA antibodies 
act differently to preformed antibodies and - as they are not present at the time of 
infusion - do not result in hyperacute rejection. However, their presence may be 
associated with gradual injury and repair steps that might lead to graft failure (Terasaki 
and Mizutani, 2006). 
  
6.1.3 HLA antibody and DSA detection 
Historically, detection of HLA antibodies was performed using complement-dependent 
cytotoxicity (CDC). However, this relatively insensitive method underestimates the 
presence of circulating antibodies (Christiaans et al., 2000, Muro et al., 2005a). The 
molecular structure of HLA was identified in 1987 (Bjorkman et al., 1987), and it 
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became possible to make recombinant lines containing only a single HLA specificity. 
Current methods for the detection of HLA antibodies utilise newer methods such as the 
use of the Luminex® assay. This assay is the most sensitive test currently available and 
detects both complement fixing and non-complement fixing antibodies using either 
soluble or recombined HLA molecules bound to polystyrene beads. Beads are mixed 
with patient serum in order to allow for antibody binding, then a second anti-human 
antibody linked to a fluorescent reporter molecule is added. Binding of alloantibodies to 
the beads is then detected by a dual laser flow cytometer, increasing both sensitivity and 
accuracy of HLA antibody detection (Tambur et al., 2000, El-Awar et al., 2005). This 
allows a semi-quantitative interpretation of the level of antibody binding present using 
Median Fluorescence Intensity (MFI). Single antigen Luminex tests can be used to 
determine reactions against specific HLA antigens. 
 
6.1.4 The role of the autoimmune response in graft rejection 
The autoimmune response may also have a significant role in islet graft rejection. Type 
1 diabetes is an autoimmune disease characterised by T cell mediated destruction of β 
cells, in which T helper cells seem to play a pivotal role (Roep, 2003). Transplantation 
in recipients with type 1 diabetes is performed in the presence of an active or memory 
autoimmune response to islet autoantigens that could theoretically contribute to 
rejection. In SPK recipients, a rise in autoantibody titre and T cell response post-
transplant has been correlated with subsequent pancreas graft failure (Braghi et al., 
2000). The presence of autoreactive T cells in the failed allografts of pancreas transplant 
alone (PTA) recipients lends further support to the hypothesis that autoimmunity may 
play a significant role in graft failure (Vendrame et al., 2010). 
 
In this study, islet graft function was assessed in parallel with DSA screening to 
compare graft function in recipients developing DSA against those without DSA 
development. At each clinical follow-up, blood was taken to assess alloimmune and 
autoimmune response in order to explore the temporal relationship between antibody 
onset and graft failure in islet recipients followed up for 12 months post-transplant.  
 
Available donor information (age, body mass index, HLA match, pancreas condition, 
harvesting and cold ischaemia time) was retrospectively reviewed to see if there was 
any influence on the characteristics of the isolated islets (islet yield and total number 
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transplanted, islet purity and viability), and whether this in turn had a correlation with 
DSA formation and duration of graft function.  
 
This study assessed the impact of alloantibody and autoantibody development on graft 
outcome. The aim of the work was to identify potential surrogate markers that might 
predict islet graft failure, with particular emphasis on whether DSA formation in islet 
recipients might be used as a prognostic tool for predicting future islet transplant 
function. 
 
6.2 Methods 
See section 2.4 entitled ‘De novo donor specific antibody assessment in islet recipients 
and assessment of impact on graft function’ for a description of study methods. 
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6.3 Results 
6.3.1 Islet recipient population 
Fourteen individuals (12 females and 2 males; 9 islet transplant alone, 3 islet after 
kidney) followed up for 12 months post-first transplant received a total of 23 islet 
transplants (single graft: n=6; two: n=7; three: n=1) between October 2008 and March 
2013 at Newcastle-upon-Tyne Hospitals NHS Foundation Trust. Recipient age (median 
[IQR]) was 51.5 (48.3-54.0) years with diabetes duration 38.5 (33.5-42) years and 
weight 59.8 (54.3-70.1) kg at time of first transplant. Total transplant mass per recipient 
was 11232 (6222-12802) IEQ/kg, per graft was 6032 (4872-7186) IEQ/kg (Table 6.1). 
 
6.3.2 DSA response to individual grafts 
DSA was detected following transplantation in 5 / 23 (21.7%) grafts, with median time 
to DSA onset of 1 (1-2) month post-transplant of the provoking graft (Figure 6.1). In 
three cases, DSA class I antibodies alone were identified; in two cases both class I and 
class II DSA were detected simultaneously in recipient serum. 
 
6.3.3 Impact of DSA presence on graft outcome 
All five grafts associated with a DSA positive response failed within eight months post-
transplantation, with three grafts failing within two months of DSA detection (Figures 
6.1, 6.2). Stimulated C-peptide at 3 months post-transplant was significantly less in 
recipients developing DSA to a graft compared to recipients who remained DSA 
negative (Table 6.1, Figures 6.2, 6.3, 6.4).
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  DSA negative grafts  DSA positive grafts  
*P 
DSA positive vs 
DSA negative 
n 
 
18 
 
5 
 
 
Donor Age (years) 48.0 (37.5-53.3) 53.0 (43.0-58.0) 0.33 
Donor BMI (kg/m2) 31.9 (29.2-35.0) 30.6 (28.4-31.1) 0.17 
Donor creatinine (μmol/L) 78 (68-94) 63 (48-111) 0.64 
Donor ALT (U/L) 20 (16-45) 41 (38-41) 0.15 
Donor amylase (U/L) 47 (29-72) 89 (40-184) 0.21 
Donor ventilation duration (hours) 29 (25-61) 39 (35-215) 0.12 
Cold ischaemia time (minutes) 320 (446-560) 254 (199-341) 0.01 
Transplant mass (IEQ/kg) 6106 (4704-7457) 5556 (4856-8532) 0.91 
    
HLA-A mismatch  1 (1-2)  1 (1-2)  0.69 
HLA-B mismatch  2 (1-2)  1 (1-2)  0.40 
HLA-DR mismatch  1 (1-2)  1 (1-2)  0.45 
Total number of HLA mismatches  4 (4-5)  4 (3-5)  0.54 
       
Islet viability on release (%)  90 (90-90)  90 (90-92)  0.69 
Islet purity on release (%)  73 (60-86)  75 (55-88)  0.97 
       
MTT90 C-peptide at 3 months (pmol/L)  551 (289-841)  106 (34-235)  0.004 
Table values given as median (interquartile range). 
*Comparison of 12 month outcomes in DSA positive grafts vs DSA negative grafts, Mann-Whitney test used for statistical analysis. 
Abbreviations: ALT – alanine transaminase,, BMI - Body mass index, DBD – donors after brain death, DCD – donors after circulatory death, DSA – Donor specific antibody, HLA - 
Human Leukocyte Antigen, ICH – intracranial haemorrhage, IEQ/kg - islet equivalents/kilogram recipient weight, MTT90 C-peptide - stimulated C-peptide at 90 minutes in meal 
tolerance test. 
Table 6.1 – Comparison of clinical characteristics of grafts provoking DSA negative and DSA positive responses. 
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Figure 6.1 Bar graph of graft function post-transplant, indicating DSA formation in islet recipients and temporal relationship with graft failure. All 
DSA positive recipients developed graft failure within 12 months follow-up, one of nine DSA negative recipients developed graft failure.  
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Figure 6.2 Line graph showing time course of graft function (as determined by 90 minute C-peptide during a meal tolerance test) in recipients 
developing DSA up to 12 months following first transplant 
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Figure 6.3 Line graph showing time course of graft function (as determined by 90 minute C-peptide during a meal tolerance test) in recipients without 
DSA up to 12 months following first transplant.
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Figure 6.4 Box plot of stimulated C-peptide (pmol/L) at 90 minutes during a meal 
tolerance test three months post-transplant for islet grafts provoking a DSA negative 
(n=18) versus a DSA positive response (n=5). Boxes indicate median, upper quartile 
and lower quartile ranges. Whiskers plotted with the lowest datum within 1.5 times the 
interquartile range of the lower quartile and the highest datum within 1.5 times the 
interquartile range of the upper quartile. *P < 0.01 vs. DSA negative grafts, Mann-
Whitney U-test.  
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6.3.4 Factors associated with DSA development 
The clinical characteristics of donors and recipients in grafts developing DSA were 
compared to grafts with a DSA negative response (Table 6.1). 
 
There were 22 donors after brain death (DBD) and one donor after circulatory death 
(DCD), with the DCD donor associated with later DSA formation. Intracranial 
haemorrhage was the cause of death in 20 of the 23 donors. 
 
No difference was noted in donor age, BMI, renal function, liver function tests, 
amylase, duration of ventilation, HLA A / B / DR / total mismatches, HLA C / DP / DQ 
mismatches, IEQ received, pre-transplant islet viability or purity between grafts that 
subsequently developed DSA and those that did not (Table 6.1). Cold ischaemia time 
was shorter in grafts that subsequently developed DSA (p<0.05).  
 
6.3.5 Induction immunosuppression 
In grafts developing a DSA response, induction was with alemtuzumab (n=2), 
basiliximab (n=2) or daclizumab (n=1). In grafts with no DSA formation, induction was 
with alemtuzumab (n=11) or basiliximab (n=7).  
 
6.3.6 Autoantibody assessment 
Pre-transplant, five recipients were GAD positive only, one recipient was IA-2A 
antibody positive only, one recipient was GAD positive and ICA positive, and the 
remaining recipients were autoantibody negative. There was no difference in three 
month post-transplant graft function according to pre-transplant autoantibody status 
(p=0.61). 
 
A weakly positive ICA response was detected following two of the graft 
transplantations at three months post-transplant but this was not sustained and ICA 
response was negative at 12 months. Follow-up of each graft with an ICA response 
indicated that one developed DSA and subsequent graft failure (MTT90 12 months = 7 
pmol/L), whilst the second remained DSA negative and achieved insulin independence 
(MTT90 12 months = 2254 pmol/L). IA-2A positivity developed in a third graft at one 
month post-transplant; this recipient did not develop DSA and good graft function was 
maintained post-transplant (MTT90 6 months = 692 pmol/L). GAD positivity developed 
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following four transplants but was sustained to 12 months post-transplant in only two 
cases. Of these cases, one patient with a sustained rise in GAD antibodies and one 
patient with a temporary rise in GAD antibodies developed graft failure; in both cases 
DSA formation preceded GAD positivity. In the remaining two recipients with GAD 
positivity, DSA remained negative and graft function was maintained at 12 months 
post-transplant (MTT90 12 months = 1003 pmol/L and 357 pmol/L).  
 
There was no difference in three month graft function when comparing post-transplant 
autoantibody positive versus post-transplant autoantibody negative grafts (p=0.61), and 
no difference in graft function outcomes when comparing transplants that resulted in a 
change in autoantibody status (n=7) versus those that did not (n=16) (p=0.53). 
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6.4 Discussion 
In this study, de novo DSA formation occurred following 21.7% grafts. Formation 
occurred soon after transplantation and was associated with rapid graft failure, occurring 
within two months in three out of five cases. Little change in autoantibody levels 
occurred post-transplant, and no association with graft function was found. 
 
6.4.1 Measured DSA rate is comparable to other forms of organ transplant 
The de novo DSA rate of 21.7% to individual islet grafts is comparable to other reports 
in solid organ transplantation: DSA rates are usually below 25% after several years in 
renal transplant populations (Everly et al., 2013). However, our study differs from these 
previous studies in that eight of our recipient population received more than one 
transplant, making the DSA rate in the recipient population 35.7% (5 / 14). All five 
recipients who developed DSA remained on maintenance immunosuppression at the 
time of antibody detection, with regular monitoring of tacrolimus levels and full blood 
counts to ensure that adequate immunosuppression with tacrolimus and mycophenolate 
was achieved. A previous study has reported a comparable DSA incidence of 30% in 98 
islet recipients (Campbell et al., 2007b), with the majority of recipients remaining on 
immunosuppression at the time of DSA detection. It has been suggested that solid organ 
transplants may adsorb antibodies, preventing their detection on peripheral blood 
sampling (Adeyi et al., 2005). Islet tissue mass is likely to be insufficient to adsorb 
antibody and therefore DSA will be detectable if present in the blood. Biopsy of islet 
transplant tissue to confirm this hypothesis is difficult due to the heterogeneous nature 
of liver architecture post-islet transplantation (Toso et al., 2009). 
 
6.4.2 Association of DSA with graft failure 
In this study, DSA onset was rapid in grafts stimulating DSA formation, with detection 
within two months of transplantation in all five cases. Their presence was associated 
with rapid graft failure and significantly reduced graft function at three months post-
transplant, with subsequent graft failure within eight months of DSA detection. 
 
The impact of DSA on islet graft outcome is debatable: not all studies demonstrate an 
association between DSA detection and graft failure. Pre-transplant DSA has been 
detected in 49% of islet recipients in a recent study, and this was associated with 
improved graft outcomes (Piemonti et al., 2013). However, the same study also reported 
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that graft function was reduced in recipients developing de novo DSA post-transplant. 
Resynthesis of DSA has been reported to have no impact on graft function (Cardani et 
al., 2007), although it has also been shown that outcome for islet recipients is poorer 
when HLA antibody formation is detected both pre and post-transplant (Campbell et al., 
2007a, Campbell et al., 2007b). In keeping with our findings, the largest available 
database for islet transplantation reported that de novo HLA antibody (class I) formation 
was associated with subsequent graft failure (Naziruddin et al., 2012). 
 
6.4.3 Factors influencing DSA development  
On assessment of donor characteristics, cold ischaemia time was found to be 
significantly shorter in grafts that subsequently demonstrated DSA. This is unexpected 
and contradicts previously published literature, which suggests that an increased 
incidence of DSA formation is associated with increased cold ischaemia times 
(Lebranchu et al., Abu-Elmagd et al., Gilligan et al., 2004). An extended cold ischaemia 
time might have been expected to impact on islet purity or viability, and reduced islet 
purity has been suggested to be a possible risk factor for DSA formation as it may lead 
to increased presentation of donor material to host antigen presenting cells (Hilbrands et 
al., 2013). However, in our patient population no difference in pre-transplant purity or 
viability was identified between DSA positive and DSA negative recipients. Although 
cold ischaemia time was prolonged in DSA negative recipients, the increased duration 
may not have been sufficient to impact on islet isolate quality (median 320 minutes 
versus 254 minutes), and the role of cold ischaemia time in influencing graft outcomes 
in this study remains questionable. Whether reduced cold ischaemia time might 
conceivably be responsible for DSA formation remains uncertain, and caution must be 
taken in interpreting results from this small study reporting on outcomes on 23 grafts in 
14 recipients.  
 
There was no difference in recipient characteristics in the DSA positive group when 
compared to the DSA negative group. When comparing HLA mismatches, the median 
number of total mismatches was five per recipient and four per graft, again with no 
difference found for recipients developing DSA. Other studies have reported a higher 
median number of mismatches per recipient (Campbell et al., 2007b, Piemonti et al., 
2013) but these studies failed to show a significant relationship with the development of 
DSA. 
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Reduced islet purity has been suggested as a possible risk factor for DSA formation, as 
it may lead to increased presentation of donor material to host antigen presenting cells 
(Hilbrands et al., 2013). However, no difference in pre-transplant purity or viability was 
identified between DSA positive and DSA negative recipients in this study. 
 
6.4.4 No relationship between graft outcome and autoimmune antibody levels 
identified 
Two recipients temporarily became ICA positive at three months post-transplant, four 
recipients became GAD positive (one of which was also one of the recipients 
developing ICA positivity) and a further recipient developed IA-2A positivity. 
However, no temporal relationship with subsequent graft function was identified, and 
only in individuals developing DSA was graft function later compromised, regardless of 
autoantibody status. 
 
Previous studies have suggested that autoantibody status might influence islet graft 
function. Autoantibody and DSA response was recently assessed in 59 islet recipients 
and an increase in autoantibody or DSA was associated with graft loss, with a hazard 
ratio five times that of recipients developing no antibodies (Piemonti et al., 2013). 
Although our autoantibody tests were negative, the findings do not completely rule out 
that an autoimmune response occurred post-transplantation: we did not measure ZnT8 
antibody response, and this was the only autoantibody to increase in five recipients in 
the afore-mentioned study. In addition, our autoantibody findings do not rule out that an 
autoimmune response occurred post-transplantation. A cytotoxic T lymphocyte 
precursor assay has allowed the development of T cell studies to assess the autoimmune 
response to transplantation (Bouma et al., 1992). Poor outcome has been associated with 
the presence of pre-transplant autoreactive T cells, with no influence observed regarding 
pre-transplant or post-transplant autoantibody status (Roep et al., 1999, Huurman et al., 
2008). Whilst our study agrees with the finding that autoimmune antibody levels might 
not be a surrogate marker of graft failure, the practical aspects of monitoring T cell 
mediated autoimmunity remain challenging; evidence suggests that cellular reactivity to 
autoantigens and alloantigens following transplantation might not correlate with future 
graft function (Huurman et al., 2008). 
 
 
 155 
6.4.5 DSA detection might guide therapeutic intervention 
DSA development might reflect inadequate induction immunotherapy. Improved islet 
transplant outcomes have been reported with newer lymphocyte depleting agents (Cai 
and Terasaki, 2010, Bellin et al., 2012), with an insulin independence rate of 50% at 
five years approaching that of pancreas transplant alone recipients (Bellin et al., 2012). 
In this study, DSA was detected following grafts where campath (n=2), basiliximab 
(n=2) and daclizumab (n=1) were used at induction. DSA formation therefore occurred 
in recipients receiving both lymphocyte depleting agents and the older anti-CD25 
agents. Tacrolimus and mycophenolate mofetil were used as maintenance 
immunosuppression in all recipients, and therefore no difference in regimen was 
implicated in DSA susceptibility. Mycophenolate targets de novo purine biosynthesis, 
and therefore can inhibit human T and B lymphocytes more efficiently to reduce 
allograft rejection episodes (Cai and Terasaki, 2005). 
 
All our recipients developing DSA experienced graft failure within 8 months. If DSA is 
a genuine surrogate marker for future graft rejection, therapeutic interventions that 
might improve outcome upon its detection should be considered. Steroids are often used 
as the first line drug upon detection of organ rejection in transplant medicine and they 
can inhibit production of alloantibodies (Planey and Litwack, 2000); however, they 
cannot be used in islet transplant recipients as they are detrimental to islet graft function 
(Kaufman et al., 1991). Rituximab – a chimeric mouse / human monoclonal antibody - 
specifically targets B cell surface marker CD20 and induces B cell lysis. Anecdotal 
reports suggest that its use might prevent humoral rejection (Garrett et al., 2002). In an 
islet transplant recipient who developed DSA and lost insulin independence, insulin 
independence was restored following treatment with rituximab and intravenous 
immunoglobulin (Kessler et al., 2009). Bortezomib - a proteasome inhibitor that affects 
plasma cells – has been shown to reduce antibody levels and improve graft function in 
renal transplant recipients developing DSA (Walsh et al., 2010). High dose intravenous 
immunoglobulin acts by blocking HLA antibody activity and inhibiting complement, as 
well as inducing significant B cell and T cell apoptosis to prevent the mechanisms 
underlying transplant rejection (Toyoda et al., 2003). Intravenous immunoglobulin used 
in conjunction with plasmapharesis has been used to reverse established antibody 
mediated rejection in renal recipients (Rocha et al., 2003), and could potentially reverse 
established antibody mediated rejection in islet recipients. However, intensive, 
prolonged immunosuppression interventions do not always successfully prevent graft 
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rejection in the presence of DSA (Hodges et al., 2012), and there are risks associated 
with their use. In addition, outcomes from this study suggest that DSA detection might 
be subsequently followed by loss of graft function that is too rapid to allow these 
interventions to be clinically effective. If this is the case, alternative strategies need to 
be contemplated.   
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Chapter 7 - Concluding Remarks 
7.1 The UK islet transplant program has achieved its primary outcome goals 
The primary goals of the UK islet transplantation program were to prevent recurrent 
life-threatening hypoglycaemia and restore optimal glycaemic control in islet recipients, 
and this study has shown that these goals have been attained up to 36 months post-
transplant. 
 
Islet transplantation has often been perceived as an experimental procedure which is 
prohibitively costly - both financially and in terms of deceased donor pancreas usage - 
and which cannot deliver sustainable insulin independence (Khan and Harlan, 2009). 
The UK program shows how integration of a limited number of isolation facilities with 
satellite centres providing all aspects of assessment, transplantation and post-transplant 
follow-up can be achieved without the major costs of establishing and maintaining their 
own isolation teams and facilities.  
 
Clinical success has been confirmed in the UK islet transplant program in tandem with 
avoidance of multiple transplants. This has underpinned sharing of donor organs 
between isolated islet and solid organ recipients listed according to congruent criteria, 
providing a platform for further innovation and definitive comparison of outcomes. The 
therapeutic goal of preventing recurrent severe hypoglycaemia in those at highest risk in 
combination with restoration of glycaemic control to a level proven to prevent long-
term hyperglycaemic complications (The Diabetes Control and Complications Trial 
Research Group (1993)) has been realised. 
 
7.2 Assessment of long-term outcomes is now required for islet transplantation 
This study has shown that islet transplantation achieves short-term goals for diabetes 
care by improving glycaemic control and reducing the incidence of severe 
hypoglycaemia. Further studies assessing islet transplantation must now determine the 
intervention’s impact on microvascular and macrovascular complications that are 
attributed to the long-standing hyperglycaemia associated with diabetes. Islet 
transplantation has only achieved widespread recognition as an acceptable intervention 
for the management of recurrent severe hypoglycaemia in patients with type 1 diabetes 
since the landmark Edmonton study of 2000 (Shapiro et al., 2000); time is therefore 
required before conclusions can be drawn about the procedure’s long-term outcomes.  
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The Collaborative Islet Transplant Registry (CITR) has been compiling a 
comprehensive international database for islet transplantation from 27 North American, 
European and Australian centres since 1999, including outcomes for retinopathy, 
nephropathy, neuropathy and macrovascular disease. CITR have recently published data 
on outcomes for islet transplantation in 677 ITA and IAK recipients receiving 1375 islet 
infusions between 1999 and 2010 (Barton et al., 2012). The study focused on five 
primary efficacy outcomes that are not dissimilar to the clinical outcomes reported in 
this study: assessment of graft function, (with C-peptide 0.3 ng/ml indicative of 
sustained graft function), reduction in HbA1c, resolution of severe hypoglycaemia, 
fasting blood glucose stabilisation and insulin independence rate. Graft function was 
retained for longer in the most recent era of islet transplantation from 2007-2010: graft 
survival was 92% at 1 year and 83% at 3 years, with duration of insulin independence 
66% at 1 year and 44% at 3 years. However, to date CITR have not formally published 
long-term outcome data for microvascular and macrovascular outcomes following islet 
transplantation. 
 
Islet transplantation has been shown to improve microvascular disease outcomes in 
small-scale short-term studies by the Edmonton islet transplant team (Thompson et al., 
2011, Warnock et al., 2008). These studies demonstrated that rate of decline of 
glomerular filtration rate and progression of retinopathy were slower following islet 
transplantation in comparison to individuals receiving intensive medical therapy for 
management of type 1 diabetes; these studies also found a non-significant trend for 
improvement in nerve conduction velocity after islet transplantation.  
 
The comorbidities associated with long-term immunosuppression therapy must also be 
taken into consideration when assessing long-term outcomes from transplantation 
therapies. Transplant recipients receiving immunotherapy to reduce the potential for 
graft rejection have a substantially increased lifetime incidence of lymphoproliferative 
disorders (Singavi et al., 2015) and skin cancer (Stoff et al., 2010). Squamous cell 
cancer relative risk is increased 100-fold compared to the non-transplanted population, 
whilst basal cell carcinoma relative risk is increased 10-16 times in renal transplant 
recipients. Following a diagnosis of skin cancer, early preventative and aggressive 
therapeutic interventions are required in transplant recipients to reduce mortality risk 
(Martinez et al., 2003). 
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Reduced renal function is common following solid organ transplantation as a 
consequence of immunosuppression nephrotoxicity, predominantly from the use of 
calcineurin inhibitors. The steroid free immunosuppression regimen used by the 
Edmonton team to achieve insulin independence in islet recipients included the use of 
the calcineurin inhibitor tacrolimus: this medication remains a recommended 
maintenance immunosuppressant following islet transplantation and was regularly used 
in the UK cohort of islet recipients reported in this study. No decline in renal function 
was seen in our recipients but long-term follow-up of the UK cohort is required to 
assess the impact of immunosuppression therapy on renal function following islet 
transplantation. 
 
A second immunosuppressant originally recommended by the Edmonton team was 
sirolimus, which suppresses the immune system’s IL-2 response by its action as an 
mTOR (mechanistic Target Of Rapamycin) inhibitor. Sirolimus also has adverse effects 
on renal function and has been implicated in the development of proteinuria in a cohort 
of 41 islet recipients (Senior et al., 2007, Senior et al., 2005). Median glomerular 
filtration rate decline was 0.39 ml/min/1.73m2/month at a median of 29.8 months 
follow-up. Substantial inter-individual variation was noted, although in the majority of 
individuals, glomerular filtration rate was lower at 24 months post- transplantation. 
Albuminuria progressed in 10 individuals, with regression of microalbuminuria in only 
one recipient despite improved glycaemic control post-transplant. Rate of decline of 
glomerular filtration rate and progression of albuminuria was very difficult to predict, 
and proteinuria was reversed on withdrawal of sirolimus (Senior et al., 2005). 
Symptomatic small bowel ulceration was also noted to resolve on stopping sirolimus 
therapy (Molinari et al., 2005).  
 
Sirolimus has now been dropped as a maintenance immunosuppressant of choice for 
islet transplant recipients following the Edmonton team’s findings and replaced by 
mycophenolate mofetil, which was used in the majority of this study’s UK islet 
recipients as the second maintenance immunosuppressant alongside tacrolimus. ITA is 
now only considered in individuals with an isotopic glomerular filtration rate of >60 
ml/min/1.73m2 with no evidence of macroalbuminuria. The Edmonton team’s reported 
experiences with sirolimus highlight the need for caution when contemplating the 
potential consequences of immunosuppression therapy, and underline the need for 
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thorough counselling when obtaining consent from patients prior to transplant 
interventions. 
 
Islet transplantation is an intervention where the short-term risks of the procedure are 
low, and short-term outcomes for the management of patients with type 1 diabetes have 
now been demonstrated by this study. However, given the potential associated risks of 
immunotherapy, islet transplantation should only be used as an intervention for those 
most at risk of harm from recurrent severe hypoglycaemia, where the intervention can 
bring about an immediate improvement in quality of life and reduce mortality risk such 
that this outweighs any potential long-term risks from immunosuppression therapy.  
 
Similarly, it should be acknowledged that type 1 diabetes is a disease that can result in 
long-term complications that have a substantial impact on quality of life, and 
assessment of any intervention that might improve long-term clinical outcomes should 
be supported so that the potential risks and benefits of the intervention can be 
established prior to a decision on its place in routine clinical practice. Following this 
study’s reported findings for the first three years of the UK islet transplant programme, 
commissioning of multicentre, randomised trials should be considered to assess the 
impact of islet transplantation on long-term clinical outcomes in individuals with type 1 
diabetes. 
 
7.3 Endogenous C-peptide secretory capacity has a continuous relationship with 
clinical outcome measures of blood glucose control and might determine long-term 
outcomes in individuals with type 1 diabetes 
CGM analysis techniques used in this study have provided a greater understanding of 
the impact of endogenous C-peptide secretory capacity on blood glucose control, 
demonstrating a continuous relationship between stimulated C-peptide and multiple 
clinical and metabolic parameters including blood glucose variability, hyperglycaemia 
risk and hypoglycaemia risk. Work undertaken during this research has quantified just 
how much each of these parameters might improve with increases in endogenous C-
peptide secretory capacity. 
 
This study’s results go beyond the original conclusions of the DCCT by showing that 
these relationships are maintained at levels of endogenous C-peptide well below the 200 
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pmol/L cut-off originally quoted in the DCCT. Even low levels of endogenous C-
peptide production might provide clinical benefits. 
 
Ultra-sensitive assays capable of detecting C-peptide under 5 pmol/l now allow very 
low levels of C-peptide to be detected using an electrochemiluminescence assay, and a 
recent study in 74 volunteers with diabetes (median duration 30 (19-41) years) has 
suggested that individuals with long-standing diabetes may be insulin microsecretors 
with functioning beta cells (Oram et al., 2014). Absolute C-peptide levels were reported 
to fall with increasing disease duration, although prevalence of detectable C-peptide 
remained high (68% in 25/37 volunteers with >30 years disease duration). A mixed 
meal tolerance test was administered to study participants, and C-peptide increased in 
80% of those with detectable C-peptide, suggesting the presence of functional beta cells. 
This finding of residual endogenous C-peptide secretion in individuals with long-
standing diabetes has subsequently been repeated in a larger cohort study of 924 
individuals using urine C-peptide to creatinine ratio assessment, where 80% of study 
participants were defined as insulin microsecretors (Oram et al., 2015). 
 
The techniques described for CGM interpretation in this study could be applied to the 
microsecretor population to assess what benefits might be attained from retaining low 
levels of endogenous insulin production. CGM could be utilised in this population to 
establish whether the relationship between outcome measures of glycaemic control and 
endogenous C-peptide secretory capacity is maintained in subjects with extremely low 
levels of endogenous C-peptide production. It might then be possible to elucidate 
whether factors other than those assessing overall glycaemic control - such as the degree 
of glucose variability or hyperglycaemia / hypoglycaemia risk - have any determination 
on the subsequent risk of developing long-term microvascular and macrovascular 
complications associated with diabetes. Findings from such a proposed study and this 
study’s reported findings of a continuous relationship between C-peptide secretory 
capacity and outcome measures of glycaemic control will establish the benefits of 
residual endogenous insulin secretion, and may have substantial implications for present 
and future therapeutic interventions aimed at maintaining or restoring endogenous 
insulin production in individuals with type 1 diabetes. 
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7.4 Hepatic fat content quantified for the first time in islet recipients and future 
studies for the assessment of localised hepatic steatosis in islet recipients  
This study is the first to demonstrate how a quantitative assessment of hepatic fat 
content might be made in islet recipients by use of chemical shift based water-fat 
separation MRI. For centres with access to this technique, MRI settings can be readily 
recreated at different sites to standardise the hepatic images produced. If it is agreed that 
the method of hepatic fat quantification from obtained images in islet recipients is 
reproducible, centres at different geographical locations might be able to adopt the same 
analysis techniques to quantify hepatic fat in their own islet recipient cohorts.  
 
Scan analysis has shown that islet recipients do not have a significantly increased level 
of hepatic fat compared to individuals with type 1 diabetes on CSII therapy, and levels 
of hepatic fat are substantially less than that seen in individuals with NAFLD. 
 
A focal steatosis pattern that develops in a subgroup of islet recipients post-
transplantation has been identified. In the presence of this change, hepatic fat 
quantification has shown that these recipients appear to have increased levels of hepatic 
fat. Resolution of steatosis occurred with improvement in graft function following 
repeat transplantation in one of our recipients, suggesting acute lipotoxicity may be 
reversible with improved blood glucose control. Identification of focal steatosis on MRI 
may therefore have a role in determining time of re-transplantation. A heterogeneity 
index might be used as a measure of focal steatosis, although its use for the assessment 
of heterogeneous hepatic fat changes requires validation in larger studies. 
 
Ultimately, one of the requirements of islet monitoring tests should be that they allow a 
clinical intervention to be made if there is concern that the graft might be failing. Novel 
markers of islet graft stress at an early stage may allow early rescue therapies or repeat 
transplantation to prevent total graft failure. The initial work of this study has not shown 
a relationship between hepatic fat content and graft function measured at 12 months 
post-transplant, suggesting that quantification of hepatic fat may not be a novel marker 
for islet graft failure. However, the causation and significance of focal steatosis warrants 
further investigation in larger scale studies before further conclusions and 
recommendations can be made regarding the use of MRI in islet recipients to assess 
hepatic fat. 
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7.5 Strategies to prevent DSA formation could be key in improving islet graft 
outcomes, with focus on early inflammatory responses following transplantation 
All islet recipients developing DSA in this study experienced graft failure within 8 
months of its detection, suggesting that DSA may be a genuine prognostic marker for 
future graft rejection, and that strategies should be implemented to prevent its formation 
post-transplantation. 
 
Investigation of factors that promote DSA formation in the peri-transplant period could 
be key in improving islet graft outcomes. During islet isolation, tissue digestion of the 
donor pancreas leads to disruption of the extracellular matrix and loss of cell adhesion 
molecules, reducing islet function and survival (Hammar et al., 2004). Isolation 
requiring tissue digestion at ‘high’ temperatures adds another level of injury to the islets 
(Noguchi et al., 2010). Notably, injured islets undergo shedding of donor antigens, 
which may contribute to the first steps of initiating an adaptive immune response.  
 
Islets constitutively express HLA class I antigens but it has been demonstrated that they 
can be induced to express HLA class II molecules following stimulation with 
inflammatory markers tumour necrosis factor alpha (TNFα) and interferon gamma 
(IFNγ) (Jackson et al., 2009); this might precede HLA class II DSA formation and play 
a critical role in islet allograft rejection. Studies assessing allograft specific cytokine 
profiles by IFNγ:IL-10 ratio have shown that when the profile is skewed towards a TH2 
T helper cell profile with raised concentrations of IL-10, post-transplant insulin 
independence rates are higher than recipients with a TH1 T helper cell profile (Huurman 
et al., 2009). IL-10 stimulates regulatory T cells and is inversely correlated with the 
proliferation of alloreactive cytotoxic T cell precursors; it also restricts the antigen 
presenting functions of dendritic cells, and IL-10 modified dendritic cells might induce 
transplant tolerance (Lai et al., 2009). Therefore, interventions encouraging a TH2 T 
helper cell response and increased IL-10 concentrations might reduce the risk of DSA 
formation and subsequent graft failure. 
 
T cell studies measure T cell response to transplant alloimmune and diabetes-related 
autoimmune antigens, and these responses may provide an earlier view of the 
pathogenic processes underlying transplant rejection prior to DSA and autoantibody 
formation. Lymphopenia that follows induction immunosuppression has been associated 
with increased IL-7 and IL-15 release: IL-7 expands the CD4+ helper T cell population; 
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IL-15 expands the number of CD8+ cytotoxic T cells, including highly enriched GAD-
65 specific autoreactive T cell clone populations. The presence of autoreactive T cells 
proliferating after incubation with islet-specific autoantigens has been shown to be 
predictive of post-transplant insulin independence (Huurman et al., 2008), and it has 
been suggested that T cell studies might be used to measure autoreactive effector T cell 
IFNγ production pre-transplant as a prognostic tool for determining future islet 
transplant outcomes (Van Belle and von Herrath, 2008). An increase in alloreactive 
cytotoxic T cell lymphocyte precursors has also been associated with poorer islet 
transplant outcomes (Roep et al., 1999), and it may be this response that precedes DSA 
formation and might be used as an earlier prognostic marker of future graft dysfunction. 
However, the challenge of using T cell studies to predict future clinical outcomes are 
that they are time consuming and notoriously difficult to undertake, being reliant on the 
provision of substantial blood samples (typically 50 mls) for processing by expertly 
trained staff prior to interpretation. 
 
Initial inflammatory challenges might result in antigen exposure that leaves islet cells 
susceptible to secondary immunological responses, provoking allogeneic rejection. 
Future studies should therefore focus on the mechanisms that underlie early islet 
damage following transplantation, as it may be that these are the initial steps that later 
provoke DSA formation and subsequent islet graft loss. Animal studies with 
radiolabelled islets have utilised positron emission tomography and computed 
tomography techniques to demonstrate that half the transplant mass is lost within the 
first minutes to hours post-transplant, with <50 % of transplanted islets engrafting two 
hours after intraportal infusion (Eich et al., 2007, Eriksson et al., 2009). Early losses are 
primarily non-specifically immunological within the liver, secondary to ischaemia-
reperfusion injury and non-specific inflammatory phenomena, such as the instant blood 
mediated inflammatory reaction (IBMIR) (Barshes et al., 2005, Tjernberg et al., 2008, 
Lai et al., 2009, Grotting et al., 1978).  
 
The IBMIR is triggered by naturally occurring IgG and IgM, with islets subjected to a 
double-peak attack: rapid complement activation induced by naturally occurring 
antibodies is followed by a slower coagulation reaction triggered by Tissue Factor (TF) 
(Tjernberg et al., 2008). TF is a transmembrane glycoprotein expressed by islets that 
initiates the extrinsic coagulation system (Dahlback, 2000) and binds factor VIIa to 
cause inflammation (Versteeg et al., 2001). Innate defence cells trigger the IBMIR in 
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the presence of TF, with release of IL-1B, TNFα, and IFNγ (Gysemans et al., 2008). 
Activated platelets bind islet surfaces for assembly of coagulation factors (Ozmen et al., 
2002), with subsequent macrophage and neutrophil stimulation mediated by TF and 
monocyte chemoattractant protein-1 (MCP-1). Heparin is now administered in the 
immediate post-transplant period in islet recipients in an attempt to reduce the severity 
of this early inflammatory response.  
 
TF might be a potential target for improving islet transplant outcomes given its role in 
initiating the IBMIR, and use of humanised anti-TF monoclonal antibodies (CNTO 859) 
has been shown to enhance engrafted islet mass and function (Berman et al., 2007). 
Other potential inflammatory marker targets for improving islet transplant outcomes 
include macrophage migration inhibitory factor (MIF). MIF inhibits macrophage 
migration and mediates cellular immunity, inducing macrophages to produce TNFα and 
IL-1B; high levels of MIF have been associated with subsequent graft loss in SIK 
patients (Pfleger et al., 2011). Recently, efforts have focused on the encapsulation of 
islets in protective barriers to reduce harm from early inflammatory responses but to 
date these strategies have largely failed due to the size of the protective capsules and the 
materials used to encase islet isolates (Scharp and Marchetti, 2014). 
 
Inflammatory changes identified in islet isolate preparations pre-transplant might also 
predict future DSA formation and islet graft function. MCP-1, TNFα, IL-1 and IFNγ 
have been reported to be released by islets following isolation from a donor pancreas 
(Lai et al., 2009). MCP-1 is produced by multiple cell types in response to pro-
inflammatory stimuli, and it is produced constitutively in human islet preparations. High 
levels of isolate MCP-1 pre-transplant (measured by mRNA expression using 
polymerase chain reaction) have been associated with poor clinical outcomes following 
transplantation, with increased coagulation and inflammation in the immediate post-
transplant period (Piemonti et al., 2002, Melzi et al., 2010). MCP-1 assessment might 
therefore be a useful tool for preselecting islet preparations for engraftment success, and 
it has been suggested that pre-transplant exposure of isolated islets to nicotinamide 
might reduce TF and MCP-1 expression and improve islet recipient outcomes (Moberg 
et al., 2003). 
 
Rejection of islet transplants is multifactorial but identification of markers predictive of 
graft success or failure will allow interventions to be made that improve outcome. This 
 168 
study has shown that routine screening for DSA in recipients might predict future graft 
failure, suggesting that elimination of DSA might improve clinical outcome. However, 
the rapidity with which graft function was lost on detection of DSA and the inability of 
current treatments to selectively eliminate alloantibody indicates that alternative 
therapeutic strategies might need to be considered in the peri-transplant period to 
improve islet graft outcomes in the longer term.  
 
Assessment of inflammatory markers in the peri-transplant period is likely to be the 
next crucial step in the search for prognostic markers of graft function, with the goal 
being identification of a marker that will also be amenable to medical interventions that 
improve clinical outcomes for future islet recipients. Identification and management of 
the correct inflammatory marker may start even before the point of transplantation, with 
assessment and treatment of islet isolates pre-transplant. 
TNFα is known to be cytotoxic to human islets in culture (Rabinovitch et al., 1990), and 
the use of etanercept – a TNFα inhibitor – in the peri-transplant period has been 
associated with improved long-term insulin independence (Bellin et al., 2012); it 
remains to be seen whether etanercept use might reduce DSA formation post-transplant. 
Future studies should identify which inflammatory markers in the immediate post-
transplant period are associated with graft dysfunction, and investigate the means by 
which these responses might be suppressed to improve graft outcomes. 
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Appendix One 
 
Islet transplantation: Service specifications 
(Non-Research Requirements) 
 
The National Commissioning Group (NCG) requirements for islet transplantation list 
the investigations and follow-up that must be arranged for all patients undergoing 
islet cell transplantation, regardless of whether they are participating in additional 
research studies. 
 
 
Indications for referral for islet transplantation 
 
The overall aim of the islet transplantation service is to provide patients with freedom 
from episodes of recurrent severe hypoglycaemia. Referral is anticipated from 
secondary care but can come directly from primary care. Post-transplant follow up 
necessitating regular outpatient attendance will be undertaken by the multidisciplinary 
team at each transplant site.  Patients to be considered for referral: 
 
1. Recurrent severe hypoglycaemia in patients with type 1 diabetes who have 
persistent hypoglycaemia despite full education and multidisciplinary team 
intervention. 
 
2. Patients with type 1 diabetes who are already immunosuppressed following renal 
transplantation and continue to have problematic blood glucose control. 
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Attendance at first outpatient appointment 
 
Patient selection criteria 
 
Acceptable indications for listing for islet transplantation: 
 
1. Patients experiencing ≥1 episode of severe hypoglycaemia requiring third party 
intervention per year AND ≥2 episodes of severe hypoglycaemia within the last 2 
years or 1 episode in the last year. 
 
Usually the rate of severe hypoglycaemia will be higher but this criterion is used to 
allow inclusion of patients who begin to experience recurrence of severe hypoglycaemia 
having previously obtained benefit from optimization of therapy and in those who have 
relaxed control in an attempt to avoid hypoglycaemia. 
 
2. Evidence of impaired awareness of hypoglycaemia.  
 
3. Marked glycaemic lability as defined by the Ryan Lability Index or continuous 
subcutaneous glucose monitoring profiles. 
 
 
Requirements for patients being listed for islet transplantation 
 
1. Established C-peptide negative diabetes (Type 1 diabetes; monogenic diabetes; 
post-pancreatectomy) 
a. Male and female patients aged 18 years or older 
b. Insulin dependence for at least 5 years 
c. Negative C-peptide (below the limit of detection on local assays in the 
absence of hypoglycaemia – blood glucose ≥ 4 mmol/l) 
 
Note: Children will not ordinarily be considered for transplant given the potential long-
term complications of immunosuppression. 
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2. Intensive diabetes management 
a. Evidence of compliance with expert medical advice 
b. Glucose testing 3 or more times daily 
c. Evidence of diabetes self-management and re-education 
d. Optimized insulin regimens – this would usually include a trial of continuous 
subcutaneous insulin infusion (CSII) via an insulin pump 
 
3. Absence of insulin resistance 
a. Insulin requirement of <0.7 units/kg body weight per day to achieve an 
HbA1c <9%. 
b. BMI <28 kg/m2 
 
(Maximum insulin dose usually < 55 units/day and weight usually <80 kg) 
 
4. Absence of contraindications to the use of the immunosuppressants 
a. Impaired renal function 
i. Isotopic GFR <60 mls/min/1.73m2 (unless previous renal transplant, 
GFR 60-90 mls/min/1.73m2 to be discussed with nephrologist) 
or 
ii. Macroalbuminuria (AER >300 mg/24hr) or overt proteinuria (unless 
previous renal transplant))  
b. Uncontrolled hypertension 
c. Uncontrolled dyslipidaemia 
d. Active infection including HBV, HCV, HIV, TB or aspergillus within 
previous year 
e. Any history of malignancy except completely resected squamous or basal 
cell carcinoma of skin 
f. High index of suspicion of non-compliance with conventional therapy 
g. Pregnancy or plans for pregnancy (including fatherhood) 
 
5. Absence of contraindications to surgery 
a. Untreated proliferative retinopathy 
b. Recent myocardial infarction or uncorrected myocardial ischaemia 
c. Portal hypertension, gall stones or liver haemangioma on baseline ultrasound 
d. Anaemia / leucopenia / thrombocytopenia; coagulopathy 
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e. On anticoagulants (excluding aspirin) 
f. Active gastric or duodenal ulcer; pancreatitis 
g. Abnormal liver function tests (persistently >1.5 x upper limit of normal) 
 
6. Other contraindications 
a. Addison’s disease (untreated) 
b. Malabsorptive disease (untreated) 
c. Evidence of alcohol excess or other drug abuse 
d. Concomitant conditions requiring steroid therapy (>15 mg prednisolone 
daily) 
 
 
NOTE: Indications for pancreas transplant alone versus islet transplant alone 
 
The indications for pancreas transplant alone (PTA) are the same as those for islet 
transplant alone (ITA).  PTA may be considered in patients with a low cardiovascular 
risk and in patients who are fit for major surgery, especially if insulin independence is 
the desired primary outcome of intervention over and above that of the achievement of 
freedom from severe hypoglycaemia.  The morbidity and mortality risk from PTA is 
much higher than that from ITA, and these risks must be weighed up against the 
likelihood and benefits of achieving / maintaining insulin independence post-
intervention. 
 
Requirements in individuals with sub-optimal control despite a functional renal graft 
(Islet After Kidney [IAK] transplantation)  
 
Patients should have a functional renal transplant and be clinically stable on 
immunosuppression (with prednisolone dose ≤5mg daily).  
 
There are no absolute renal contraindications to listing for islet after kidney transplant, 
but caution if GFR <40 ml/min/1.73m / serum creatinine >175µmol/L. 
The following renal transplant recipients would be eligible for islet transplantation: 
 
1. Severe hypoglycaemia or altered hypoglycaemia awareness 
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or 
 
2. HbA1c >7% (>53 mmol/mol) 
 
or 
 
3. Evidence of marked glycaemic lability 
 
This group of patients may also be considered for pancreas after kidney transplantation 
provided they do not have a high cardiovascular risk precluding the more major whole 
organ transplant procedure. 
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Patient assessment for islet transplantation 
 
Patients fulfilling selection criteria are put through a series of investigations designed to 
assess suitability for the procedure.  
 
1. Hypoglycaemia assessments: standardised recording of number and impact of 
severe hypoglycaemic events 
a. Nature and number of severe hypoglycaemia events requiring third party 
assistance over last 12 months should be recorded 
b. Visits should be preceded by one month’s glucose diary, minimum of 4 point 
day profile and a single 8 point profile with a complete log of all glucose 
levels <4 and/or hypo episodes per month 
c. Modified Clarke & Gold impaired hypoglycaemia awareness assessments 
d. Completion of Ryan Hypo Score / Lability Index (optional) 
e. Performance of 3 to 7 day continuous sub-cutaneous glucose monitoring 
profile 
 
2. Blood tests: to exclude concurrent pathology and characterise diabetes 
control/complication 
a. Full biochemistry profile to include 
i. Renal profile –inc eGFR 
ii. Bone profile 
iii. Liver profile 
iv. Bicarbonate 
v. CRP  
vi. Immunoglobulins 
vii. Glucose 
viii. HbA1C 
ix. Lipid profile 
x. Thyroid function 
xi. Addison’s assessment of serum cortisol ± short synacthen test 
xii. Coeliac screen 
xiii. Ferritin, B12 and folate 
xiv. PSA (if male) 
xv. β-HCG (if female of reproductive age) 
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b. Haematology 
i. Full blood count 
ii. Clotting screen 
c. Assessment of residual β-cell function 
i. Undetectable C-peptide (below the limit of detection on local 
assays in the absence of hypoglycaemia – blood glucose ≥ 4 
mmol/l) 
d. Microbiology and serology 
i. Toxoplasmosis 
ii. VDRL 
e. Virology 
i. Hepatitis B 
ii. Hepatitis C 
iii. HIV 
iv. VZV 
v. CMV 
vi. EBV 
vii. HSV 
f. Islet auto-immunity 
i. GAD antibodies 
ii. IA-2 antibodies 
iii. Islet cell antibodies 
g. Studies of activated T cells (Tim Tree / Mark Peakman, KCH) 
h. Blood bank 
i. Group and save serum 
i. Tissue typing 
i. Tissue type 
ii. PRA and HLA specific antibodies 
 
3. Renal workup   
a. Serum creatinine 
b. 24 hour proteinuria collection 
c. Isotopic GFR 
 
4. Dental health (assessed by qualified dental practitioner) 
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5. Ensure no history of previous malignancy 
a. Breast examination; in women >40 yrs mammography required 
b. Cervical smear will be required 
 
6. Psychological evaluation 
Includes semi-structured interview with a clinical psychiatrist or psychologist to 
assess understanding of risks / benefits of and suitability for transplantation.   
 
Patient reported psychosocial outcomes are critical in the evaluation of islet 
transplantation.  If the patient consents to the Biomedical and Quality of life study, a 
Psychosocial questionnaire pack should be provided to the patient for completion 
(see islet transplant research protocol).  The answers to these questionnaires will be 
received and collated by the Applied Health Psychology team for a psychological 
evaluation that meets NCG requirements.  
 
7. Cardiac evaluation: history of cardiovascular; peripheral vascular; cerebrovascular 
disease 
a. ECG 
b. Stress echocardiography or stress isotope perfusion scan 
c. Where indicated, coronary angiogram. This is not costed in the programme: 
if indicated by earlier investigations, needs to be undertaken independent of 
any transplantation plans 
 
8. Lung Function assessment 
a. Chest x-ray 
 
9. Liver ultrasound 
a. Exclude hepatic pathology 
b. Confirm patency of and direction of flow in portal vein 
c. Exclude vascular malformations 
 
10. Eye evaluation: 
a. Arrange dilated 4 field retinal photography 
b. Consider obtaining opinion on retinopathy from ophthalmologist 
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11. Clinical assessment of autonomic function & peripheral neuropathy.  
Recommend quantitative assessment through: 
a. Biothesiometry  
and  
b. Autonomic function tests 
Note:  Nerve conduction studies are costed into NCG budget but have not been 
routinely undertaken to date 
 
12. Clinical assessment of diabetic foot disease 
Acute ulceration / infection / ischaemia / Charcot foot will require suspension from 
the transplant waiting list until resolution.  
 
 
Multi-disciplinary team meeting for listing for islet transplantation 
 
After physical and psychological assessment a clinical consensus is reached by the 
multi-disciplinary transplant team of a patient’s suitability for transplantation. 
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Listing Visit for islet transplantation 
 
The patient will be required to attend for a listing visit to discuss the outcome of 
investigations and an MDT meeting will be required before a final decision on whether 
to proceed to islet transplantation is made. 
 
All assessment investigations will be reviewed with the patient at the listing visit with 
confirmation of understanding of risks / benefits and desire to proceed. 
 
Fulfilment of listing criteria will be reconfirmed and it is recommended that a 4 week 
blood glucose diary is specifically completed before this visit. 
 
Standardised recording of the number and impact of severe hypoglycaemic events 
should be made. The nature and number of severe hypoglycaemia events requiring third 
party assistance over last 12 months must be documented, and a pre-transplant Clarke 
and Gold hypoglycaemia score recorded. 
 
If the decision is to pursue transplantation, the patient is listed locally for islet 
transplantation: 
 
1. Complete NHS blood and transplant kidney/pancreas/islet recipient registration 
(including the supplementary form) at time of listing 
 
2. On-line registration for transplantation at ODT 
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6 monthly follow-up visits 
 
If no transplant is undertaken within 6 months, then 6 monthly review is required to 
assess ongoing suitability for islet transplantation.  At each visit the following must be 
provided by the patient: 
 
1. One month blood glucose diary readings.  A minimum of 4 day profiles, a 
single 8 point profile and a complete log of all glucose levels <4 and/or hypo 
episodes per month should be recorded. 
 
 
2. 3 to 7 day CGM download 
 
 
3. Modified Clarke & Gold impaired hypoglycaemia awareness 
assessments 
 
 
At each review, an assessment must be made as to whether any investigations must be 
repeated to assess a patient’s fitness for islet transplantation. 
 
 
At each 6 monthly visit, MDT to review that patient remains suitable to remain on 
islet transplant waiting list. 
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Admission for transplant 
 
On being made aware of a donor for islet transplantation, the patient should attend the 
islet transplant unit for bloods whilst islet isolation is being undertaken.   
 
Bloods include:  
H&I Crossmatch, FBC, U&E, LFTs, TFTs, clotting, HbA1C, glucose 
 
Discuss cross-match with Histopathology & Immunocytogenetics prior to 
transplantation.   
 
Pre and post-transplant, follow local islet transplant protocols for peri-operative 
management. 
 
NCG requirements at the time of transplantation: 
Ensure the following documentation is completed during the admission: 
1. Standard hospital consent for transplantation (NICE requirement for audit purposes) 
 
2. Obtain and record donor UKT / ODT Number (found on islet infusion bag). 
NHSBT donor pancreas form is completed by the isolation labs and returned to ODT. 
 
3. Return Product Release Form to the isolation centre after filing a copy in the local 
patient records. 
 
4. Complete NHSBT transplant form for recipient.   
Return form to NHSBT at ODT Data services, NHS Blood and Transplant, Fox Den 
Road, Stoke Gifford, Bristol. BS34 8RR  
 
5. Ensure HTA B form completed & signed and sent to ODT. 
Return form to ODT Data services, NHS Blood and Transplant, Fox Den Road, 
Stoke Gifford, Bristol. BS34 8RR  
 
At the time of transplantation, ensure a donor islet sample is sent for Gram stain and 
culture both from the islet isolation centre and the transplantation centre.  Regular 
liaison with the microbiology teams at the site of isolation and the site of transplantation 
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must occur in the peri-transplant period to identify whether any additional treatments 
are required in the event of positive culture results from any of the samples at each 
centre. 
 
It is anticipated that patients will remain in hospital for 3 days following each 
transplant, with close monitoring of blood glucose levels, adjustment of insulin doses 
and immunosuppressant medications, measurement of C-peptide and monitoring for 
bleeding following portal vein cannulation (including a liver ultrasound on day +1). 
 
It is imperative that a standard discharge summary is sent to the patient’s GP to inform 
them of the patient’s treatment and medications on discharge (especially 
immunosuppressant therapy).  On discharge, arrange appointment to see patient for next 
blood test and to review immunosuppressant levels and dose. 
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Immediate post-discharge management  
 
Regular structured review should be organized, including monitoring of 
immunosuppression levels and assessment for complications over the first 3 months. 
Following discharge, a UKITC glucose diary should be given to the patient to complete. 
 
Suggested blood test schedule post discharge:  
 
Day 7 
FBC, U&E, LFT, TFT, CRP, Tacrolimus level 
Random glucose & C-peptide 
 
Day 10 
FBC, U&E, LFT, Tacrolimus level 
CRP if previous result not within normal range 
 
Day 14 
FBC, U&E, LFT, Tacrolimus level 
CRP if previous result not within normal range 
 
Day 21 
FBC, LFT, U&E, Tacrolimus level 
CRP if previous result not within normal range 
 
Day 28 
FBC, LFT, U&E, Tacrolimus level 
CRP if previous result not within normal range 
Fasting glucose and C-peptide, HbA1C 
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1 month post-transplant: 
 
Patient to receive clinical review by managing team 
 
This visit will allow a review of the patient’s progress post-transplantation, an 
assessment of their insulin dosing and adjustment of their immunosuppression if 
required. 
 
1 month – 3months 
Review every 2 weeks up to 3 month post-transplant 
HbA1c, FBC, U&E, Tacrolimus level to be checked at each review visit 
CRP and LFT should be checked at review visits if the previous results have not been 
within normal range 
 
In addition, at 3 month visit:  
Fasting glucose & C-peptide, HbA1c, antibody testing for ICA, anti-GAD and IA-2, 
fasting lipid profile & TFTs 
 
Month 3 – Month 6 
Review every 4 weeks 
FBC, U&E, Tacrolimus level to be checked at each review visit 
CRP and LFT should be checked at review visits if the previous results have not been 
within normal range 
 
In addition, at 6 month visit: 
Fasting glucose & C-peptide, HbA1c, antibody testing for ICA, anti-GAD and IA-2, 
fasting lipid profile & TFTs 
 
Month 6 onwards 
Review every 6 weeks  
FBC, U&E, Tacrolimus level to be checked at each review visit 
CRP and LFT should be checked at review visits if the previous results have not been 
within normal range 
Fasting glucose & C-peptide, HbA1c, fasting lipid profile & TFT at 6 monthly visit 
 
 186 
Scheduled follow-up assessment at 3, 6 and 12 months 
 
NCG requirements specify that follow-up and review should at least be organized for 3, 
6 and 12 months post-transplant.  If a patient has a further transplant, an extra 
follow-up one month after discharge must be organized for an additional patient 
review. 
 
At each scheduled follow-up: 
1. Complete NHSBT forms at the each timepoint.  
Return form to NHSBT at ODT Data services, NHS Blood and Transplant, Fox Den 
Road, Stoke Gifford, Bristol. BS34 8RR  
 
2. Hypoglycaemia assessments at 3, 6 and 12 months 
 
a. Standardised recording of number and impact of severe hypoglycaemic 
events. Visits should be preceded by one month’s glucose diary, minimum of 
4 point day profile and a single 8 point profile with a complete log of all 
glucose levels<4 and/or hypo episodes per month 
b. Continuous glucose monitoring assessment (CGMS) at 3, 6, 12 months. 
CGMS device should be attached to patient 7 days before each review.  1 
single 8 point profile to be completed while wearing the CGMS sensor 
 
3. Urine albumin-creatinine ratio assessment 
 
4. Retinal screening assessment – dilated 4-field retinal photography 
 
5. Clinical assessment of peripheral neuropathy and foot risk - quantitative assessment 
with nerve conduction studies and autonomic nerve function tests should be 
considered at each review 
 
6. T cell studies – autoreactive T cell profiles may be a predictive marker for graft 
function and loss and they are thus a clinical requirement in all islet transplant 
patients.  This assessment is dependent on the provision of a service that can 
undertake T cell study analysis, and this is currently provided by Tim Tree at King’s 
Hospital. 
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After 12 months, follow-up should be arranged on a 6 monthly basis for ongoing review 
of the patient post-transplantation. 
 
Secondary endpoints: to be determined at 3 months post-transplant and then 
annually.   
 
1. Insulin independence / insulin requirement 
 
2. HbA1c 
 
3. Clarke survey / Hypo Score / Lability Index 
 
4. Measurement of glucose, insulin and C-peptide. Consider patient for standardised 
meal tolerance test with fasting and 90 minute values. 
 
5. Serum creatinine / urinary protein estimation 
 
6. Dilated 4 field Retinal photography 
 
7. Detailed clinical assessment of diabetes / immunosuppressant complications status 
 
8. Quality of life and health status questionnaires – alternative arrangements for 
psychological assessment must be made if the patient is not participating in the 
Biomedical and Quality of Life research study and completing the Psychosocial 
questionnaire packs (see research protocol). 
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Appendix Two 
 
Islet transplant research manual: Research summary for patients 
undergoing islet transplantation 
 
 
Pre transplant 
 
 
First clinic visit 
 
Please see NCG requirements section for work-up and required investigations pre-
transplant; these assessments will take place in all patients being considered for islet 
transplantation, whether they consent to research or not.   
 
After the first clinic visit and when all investigations are available, a multi-disciplinary 
team (MDT) meeting will take place and a decision on whether to offer to list the 
patient for islet transplantation will then be made.  The patient will then return to 
outpatients for their listing visit to be informed of the outcome of the MDT meeting and 
make their final decision. 
 
Listing Visit 
 
If the patient is listed for an islet transplant, the following should be arranged: 
 
1. The opportunity to participate in research should be offered to the patient and they 
should be provided with the participant information sheet for biomedical and 
quality of life research in islet transplantation. 
 
2. Arrange research visit. 
 
 The research visit can be at the same time as the listing visit, depending on the 
preferences of the patient and the local islet transplant team.   
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 The aim of the Research Visit is an opportunity for the transplant team to 
explain and consent patients for research projects associated with islet 
transplantation.  
 
 The patient is at liberty not to consent for research projects but must understand 
that some investigations are still required as part of the service specific 
requirements for islet transplantation (National Commissioning Group [NCG] 
requirement. A screening log entry of the patient’s decision not to participate in 
research should be made locally. 
 
 
Research Visit 
 
The research visit is to allow the patient to discuss the aims of the research and ask any 
questions regarding research, prior to signing consent forms.  Patients do not have to 
undertake all aspects of the available research. 
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Study Consent Forms 
 
1. Biomedical and quality of life consent form - Consenting to completion of adult 
healthcare psychology questionnaire pack for centralized analysis and analysis of 
their collated biomedical data for research presentations / publication.  
2. Islet function assessment consent form - Includes mixed meal tolerance testing 
[MMTT] post transplant.  Covers blood samples sent for metabolic and 
inflammatory marker analysis at Cambridge and King’s, and urine C-peptide 
analysis at Exeter. 
3. Liver Magnetic Resonance Imaging (MRI) scan consent form.  If consent is 
given for MRI scanning, send a letter to the patient’s GP informing them of 
participation in the study.  
 
At the research visit, if patients have consented to participate in studies, please ensure 
the following: 
 
1. Assign patient a Study Number 
2. Pre-transplant Case Report Forms (CRF) – History, examination, investigation 
forms.  Return copies to Ruth Wood at Newcastle Clinical Trials Unit, Human 
Nutrition Research Centre, Room M1 151, 1st Floor William Leech Building, 
Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH 
3. Psychosocial questionnaire pack. Add the study number to the packs before giving 
to the participant.  Participants return these in the reply paid envelope direct to 
Applied Health Psychology (AHP) Research.  Ensure that study participant returns 
it to: UKITC Project, AHP Research, 16 Walden Way, Hornchurch, Essex RM11 
2LB 
4. Modified Clarke & Edinburgh (includes Gold score) Hypoglycaemia 
questionnaire.  These are an NCG requirement but please ensure that a copy of the 
completed questionnaire is returned to Ruth Wood at Newcastle Clinical Trials Unit.  
Human Nutrition Research Centre, Room M1 151, 1st Floor William Leech 
Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH 
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5. Arrange for patient to have pre-transplant MRI of liver if they consent to the 
liver MRI study 
6. Patient to have a further 50 ml blood sample taken on two separate occasions for T-
cell studies – sample must be taken on a Monday and sent to Shereen Sabbah at 
Guy’s Hospital via DX Drop box delivery system.  Using DX delivery system, 
ensure samples are sent to Dr Shereen Sabbah, Central Specimen Reception, 4th 
Floor, Guy's Hospital Southwark Wing, London SE1 9RT (DX number 6571004, 
DX Exchange 6571000) 
7. Collection of a sample for urine C-peptide.  This is a research urine sample to 
assess endogenous insulin production by a patient prior to islet transplantation.  A 
urine ‘pack’ can be supplied by Richard Oram at the Royal Devon & Exeter 
Hospital.  All samples to be returned to address Clinical Biochemistry, Area A2, 
Royal Devon & Exeter Hospital NHS Foundation Trust, Barrack Road, Exeter, 
Devon EX2 5DW 
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If no transplant after 6 months – 
6 monthly assessments required from date of listing visit 
 
A 6 monthly research assessment visit is required whilst awaiting transplantation.  
This could take place alongside the 6 monthly assessment that is an NCG requirement 
in patients on the waiting list for transplantation. 
 
At each appointment: 
 
1. Complete CRF forms – Subsequent history, examination and investigations. 
Return copies to Ruth Wood at Newcastle Clinical Trials Unit, Human Nutrition 
Research Centre, Room M1 151, 1st Floor William Leech Building, Medical School, 
Framlington Place, Newcastle upon Tyne, NE2 4HH 
 
2. Give out Psychosocial questionnaire pack.  Participants return these in the reply 
paid envelope direct to AHP Research.  Ensure that study participant returns the 
form to: UKITC Project, AHP Research, 16 Walden Way, Hornchurch, Essex 
RM11 2LB 
 
3. Further 50 ml blood sample taken for T-cell studies – sample must be taken on a 
Monday and sent to Shereen Sabbah at King’s College London via DX Drop box 
delivery system.  Using DX delivery system, ensure samples are sent to Dr Shereen 
Sabbah, Central Specimen Reception, 4th Floor, Guy's Hospital Southwark Wing, 
London SE1 9RT (DX number 6571004, DX Exchange 6571000) 
 
4. Modified Clarke & Edinburgh (includes Gold score) Hypoglycaemia 
questionnaire. A copy of the completed questionnaire is returned to Ruth Wood at 
Newcastle Clinical Trials Unit, Human Nutrition Research Centre, Room M1 151, 
1st Floor William Leech Building, Medical School, Framlington Place, Newcastle 
upon Tyne, NE2 4HH 
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Admission for transplant  
 
Please follow NCG requirements for all patients admitted for transplantation.  See 
NCG section. 
 
For all patients participating in research, please ensure the following: 
 
1. Complete CRF forms – Subsequent History, examination, investigations.  Return 
copies to Ruth Wood at Newcastle Clinical Trials Unit, Human Nutrition Research 
Centre, Room M1 151, 1st Floor William Leech Building, Medical School, 
Framlington Place, Newcastle upon Tyne, NE2 4HH 
2. On discharge: 
a. Complete the CRF Discharge Summary. Donor ODT number must be 
recorded on the CRF sheet. Return a copy to Ruth Wood at Newcastle 
Clinical Trials Unit, Human Nutrition Research Centre, Room M1 151, 1st 
Floor William Leech Building, Medical School, Framlington Place, 
Newcastle upon Tyne, NE2 4HH 
b. Enter the UKT recipient number on the CRF discharge summary form 
c. On discharge, give the patient an appointment time and date for their one 
month post-transplant Meal Tolerance Test 
d. Arrange Liver MRI for one month post-transplant if participating in MRI 
study 
 
 
Early post-transplant 
 
1. For research patients, please ensure that Research samples for C-peptide are 
taken peri-transplant and most importantly at 7 days post-transplant.  These 
are stored and then sent to Cambridge as a batch on dry ice for C-peptide analysis.   
(Consent for transporting these to Cambridge is taken as part of the islet function 
assessment.  Samples can be stored, but not shipped until consent has been given).  
 
Ensure that blood form has relevant Cambridge labelling prior to being sent to 
local laboratory to ensure Cambridge receive sample. Cambridge Address for 
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samples: Clinical Biochemistry, Box 232, Cambridge University Hospitals NHS 
Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 
0QQ 
 
2. Collection of samples for urine C-peptide following discharge should be started 
one week after transplant.  Once a week, patients should provide a urine specimen 
on waking (first void of the day) followed by a second sample two hours after 
breakfast. Ensure patient has sufficient supply of urine ‘packs’ until one month meal 
tolerance test and samples are returned to Richard Oram at Royal Devon & Exeter 
Hospital. All samples to be returned to address Clinical Biochemistry, Area A2, 
Royal Devon & Exeter Hospital NHS Foundation Trust, Barrack Road, Exeter, Devon EX2 
5DW 
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1 month post first transplant 
 
NOTE: 
 The 1 month follow-up is a research requirement 
 
 Patients should have a one month research follow-up after any second / 
subsequent transplant and then revert back to 3 / 6 / 12 monthly follow-up 
from first transplant 
 
 The NCG specifies that scheduled follow-up of islet transplant patients should 
be at 3, 6 and 12 months.  Please ensure that all NCG requirements are met at 
each follow-up appointment (see NCG section) 
 
 
 
At the one month research follow-up, please ensure the following are undertaken: 
 
1. Completion of 1 month post-transplant CRF forms – Subsequent History, 
examination, investigation.  Return copies to Ruth Wood at Newcastle Clinical 
Trials Unit, Human Nutrition Research Centre, Room M1 151, 1st Floor William 
Leech Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 
4HH 
 
2. The visit should be preceded by one month’s glucose diary. A minimum of 4 day 
profiles, a single 8 point profile and a complete log of all glucose levels <4 and/or 
hypo episodes per month should be recorded. 
 
3. The visit should be preceded by a 1 week CGMS download 
 
4. Modified Clarke/Edinburgh Hypoglycaemia questionnaire.  A copy of the 
completed questionnaire is returned to Ruth Wood at Newcastle Clinical Trials Unit, 
Human Nutrition Research Centre, Room M1 151, 1st Floor William Leech 
Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH 
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5. Give out the Psychosocial questionnaire pack.  Participants return these in the 
reply paid envelope direct to AHP Research. Ensure that study participant returns 
the form to: UKITC Project, AHP Research, 16 Walden Way, Hornchurch, Essex 
RM11 2LB 
 
6. Attend for 1 month post-transplant Meal Tolerance Test. Samples are separated, 
stored, batched and sent to Cambridge for analysis in line with the Cambridge SOP 
(Cambridge finally send aliquots to King's for cytokine analysis). Cambridge 
address for samples: Clinical Biochemistry, Box 232, Cambridge University 
Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, 
Cambridge CB2 0QQ 
 
7. Collection of samples for urine C-peptide.  Ensure patient has sufficient supply of 
urine ‘packs’ until next meal tolerance test and samples returned to Richard Oram at 
Royal Devon & Exeter Hospital. All samples to be returned to address Clinical 
Biochemistry, Area A2, Royal Devon & Exeter Hospital NHS Foundation Trust, 
Barrack Road, Exeter, Devon EX2 5DW 
 
8. Liver MRI if participating in MRI study. Arrange MRI visit for three months, six 
months and twelve months post-transplant, if consented to this part of study.   
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3 months post transplant  
 
NOTE: 
 Please ensure that all NCG requirements are met at each follow-up 
appointment (see NCG section)  
 
 
The NCG specify that the following are required at 3 months: 
 
1. The visit should be preceded by one month’s glucose diary. A minimum of 4 day 
profiles, a single 8 point profile and a complete log of all glucose levels <4 and/or 
hypo episodes per month should be recorded. 
 
2. The visit should be preceded by 1 week CGMS download recorded. 
 
3. Modified Clarke/Edinburgh Hypoglycaemia questionnaire.  A copy of the 
completed questionnaire is returned to Ruth Wood at Newcastle Clinical Trials Unit, 
Human Nutrition Research Centre, Room M1 151, 1st Floor William Leech 
Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH 
 
Research patients will also require: 
 
1. Complete CRF forms – Subsequent History, examination, investigation.  Return 
copies to Ruth Wood at Newcastle Clinical Trials Unit, Human Nutrition Research 
Centre, Room M1 151, 1st Floor William Leech Building, Medical School, 
Framlington Place, Newcastle upon Tyne, NE2 4HH 
 
2. Attend for 3 month post-transplant Meal Tolerance Test. Samples are then 
batched and sent to Cambridge for analysis in line with the Cambridge SOP 
(Cambridge finally send aliquots to King's for cytokine analysis). Cambridge 
address for samples: Clinical Biochemistry, Box 232, Cambridge University 
Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, 
Cambridge CB2 0QQ 
 
 199 
3. Patient to have a further 50 ml blood sample for T-cell studies – sample must be 
taken on a Monday and sent to Shereen Sabbah at Guy’s Hospital via DX Drop 
box delivery system. Using DX delivery system, ensure samples are sent to Dr 
Shereen Sabbah, Central Specimen Reception, 4th Floor, Guy's Hospital Southwark 
Wing, London SE1 9RT (DX number 6571004, DX Exchange 6571000) 
 
4. Review weekly urine C-peptide completion.  Ensure patient has sufficient supply 
of urine ‘packs’ until next meal tolerance test and samples returned to Richard Oram 
at Royal Devon & Exeter Hospital. All samples to be returned to address Clinical 
Biochemistry, Area A2, Royal Devon & Exeter Hospital NHS Foundation Trust, 
Barrack Road, Exeter, Devon EX2 5DW  
 
5. Liver MRI if participating in MRI study 
 
 
No psychosocial questionnaire pack at 3 months 
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6 months post transplant  
 
NOTE: 
 Please ensure that all NCG requirements are met at each follow-up 
appointment (see NCG section) 
 
 
The NCG specify that the following are required at 6 months: 
 
1. The visit should be preceded by one month’s glucose diary. A minimum of 4 day 
profiles, a single 8 point profile and a complete log of all glucose levels <4 and/or 
hypo episodes per month should be recorded. 
 
2. The visit should be preceded by 1 week CGMS download recorded. 
 
3. Modified Clarke/Edinburgh Hypoglycaemia questionnaire.  A copy of the 
completed questionnaire is returned to Ruth Wood at Newcastle Clinical Trials Unit, 
Human Nutrition Research Centre, Room M1 151, 1st Floor William Leech 
Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH 
 
Research patients will also require: 
 
1. Complete CRF forms – Subsequent History, examination, investigation. Return 
copies to Ruth Wood at Newcastle Clinical Trials Unit, Human Nutrition Research 
Centre, Room M1 151, 1st Floor William Leech Building, Medical School, 
Framlington Place, Newcastle upon Tyne, NE2 4HH 
 
2. Attend for 6 month post-transplant Meal Tolerance Test. Samples are then 
batched and sent to Cambridge for analysis in line with the Cambridge SOP 
(Cambridge finally send aliquots to King's for cytokine analysis).  Cambridge 
address for samples: Clinical Biochemistry, Box 232, Cambridge University 
Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, 
Cambridge CB2 0QQ 
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3. Patient to have a further 50 ml blood sample for T-cell studies – sample must be 
taken on a Monday and sent to Shereen Sabbah at Guy’s Hospital via DX Drop 
box delivery system. Using DX delivery system, ensure samples are sent to Dr 
Shereen Sabbah, Central Specimen Reception, 4th Floor, Guy's Hospital Southwark 
Wing, London SE1 9RT (DX number 6571004, DX Exchange 6571000) 
 
4. Review weekly urine C-peptide completion.  Ensure patient has sufficient supply 
of urine ‘packs’ until next meal tolerance test and samples returned to Richard Oram 
at Royal Devon & Exeter Hospital. All samples to be returned to address Clinical 
Biochemistry, Area A2, Royal Devon & Exeter Hospital NHS Foundation Trust, 
Barrack Road, Exeter, Devon EX2 5DW  
 
5. Give out Psychosocial questionnaire pack.  Participants return these in the reply 
paid envelope direct to AHP Research.  Ensure that study participant returns it to: 
UKITC Project, AHP Research, 16 Walden Way, Hornchurch, Essex RM11 2LB 
 
6. Liver MRI if participating in MRI study 
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12 months post transplant 
 
NOTE: 
 Please ensure that all NCG requirements are met at each follow-up 
appointment (see NCG section)  
 
The NCG specify that the following are required at 12 months: 
 
1. The visit should be preceded by one month’s glucose diary. A minimum of 4 day 
profiles, a single 8 point profile and a complete log of all glucose levels <4 and/or 
hypo episodes per month should be recorded. 
 
2. The visit should be preceded by 1 week  CGMS download recorded. 
 
3. Modified Clarke/Edinburgh Hypoglycaemia questionnaire.  A copy of the 
completed questionnaire is returned to Ruth Wood at Newcastle Clinical Trials Unit, 
Human Nutrition Research Centre, Room M1 151, 1st Floor William Leech 
Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH 
 
Research patients will also require: 
 
1. Complete CRF forms – Subsequent History, examination, investigation. Return 
copies to Ruth Wood at Newcastle Clinical Trials Unit, Human Nutrition Research 
Centre, Room M1 151, 1st Floor William Leech Building, Medical School, 
Framlington Place, Newcastle upon Tyne, NE2 4HH 
 
2. Attend for 12 month post-transplant Meal Tolerance Test. Samples are then 
batched and sent to Cambridge for analysis in line with the Cambridge SOP 
(Cambridge finally send aliquots to King's for cytokine analysis). Cambridge 
address for samples: Clinical Biochemistry, Box 232, Cambridge University 
Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, 
Cambridge CB2 0QQ 
 
3. Patient to have a further 50 ml blood sample for T-cell studies – sample must be 
taken on a Monday and sent to Shereen Sabbah at Guy’s Hospital via DX Drop 
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box delivery system. Using DX delivery system, ensure samples are sent to Dr 
Shereen Sabbah, Central Specimen Reception, 4th Floor, Guy's Hospital Southwark 
Wing, London SE1 9RT (DX number 6571004, DX Exchange 6571000) 
 
4. Review weekly urine C-peptide completion.  Ensure patient has sufficient supply 
of urine ‘packs’ until next meal tolerance test and samples returned to Richard Oram 
at Royal Devon & Exeter Hospital. All samples to be returned to address Clinical 
Biochemistry, Area A2, Royal Devon & Exeter Hospital NHS Foundation Trust, 
Barrack Road, Exeter, Devon EX2 5DW  
 
5. Give out Psychosocial questionnaire pack.  Participants return these in the reply 
paid envelope direct to AHP Research.  Ensure that study participant returns it to: 
UKITC Project, AHP Research, 16 Walden Way, Hornchurch, Essex RM11 2LB 
 
6. MRI at 12 months to be done at local centre if participating in MRI study 
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More than 12 months post transplant  
 
Patients should continue to be followed up 3 monthly if the local team have the capacity 
to do so.  Otherwise, 6 monthly full research follow-up visits are acceptable to remain a 
participating centre for the Diabetes UK research study.  
 
Psychosocial questionnaire packs should be completed every 6 months. 
 
Ensure all NCG requirements are completed at each 6 month appointment. 
 
Research patients should continue to have 6 monthly testing as listed in the previous 
sections whilst they are considered to have ongoing graft function by the lead clinician 
(detectable serum C-peptide >50 pmol/l). 
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Appendix Three 
 
Protocol for MRI analysis in islet recipients 
 
A) Conversion of Original Scans into “fat” and “water’ files 
 
From University Login: 
1) Open ‘MATLAB 2011a’ in Scientific Software File 
2) In ‘Current Directory”, select “X:\” or “Z:\” (as appropriate according to “T1Tx“ 
location) 
3) Select ‘Analysis Program’ – Right click – select ‘Add to Path’ – select ‘Folders and 
subfolders’ 
4) In command window, type ‘fatcalc’ 
5) Select ‘3’ PAR files for analysis 
6) Select MRI file for analysis, then pick 3 files in order of ‘inferior, middle, superior’ 
or ‘3, 2, 1’ 
7) Analyse 
8) Look for abdominal fat in fat window to ensure correct analysis (x3) 
9) File conversion complete 
 
 
B) Fat analysis of converted files 
 
From University Login 
1) Open ‘Image J’ 
2) Select subfile for analysis ending in’fatPC.hdr’ 
NB: For water images (& to be blinded to fat content but to see vessels) use 
‘water.hdr’ file 
3) Check image to ensure has been converted from original scan appropriately (check 
no inversion) 
4) Select 3 of 18 files with largest liver surface are available for analysis 
5) Mark Region Of Interest (ROI) for analysis: using water file, choose rhomboid 
symbol and draw area for analysis, avoiding: 
a. Liver Capsule 
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b. Vessels (where possible) 
6) Avoid kidney / other organs  
7) Press “T” – Save file with name denoting ‘Subject/Time post-Tx/Slice No’ 
8) Check ROI transfers okay to fat image to make sure not over artefacts (ENSURE 
SLICE NUMBERS MATCH UP FOR WATER AND FAT FILES) 
9) Save ROI outline: 
a. Press “Ctrl” 
b. Select all 
c. Right click 
d. Save in relevant T1Tx file labelled “Gus ROI” or “Afsara ROI” as 
appropriate  
10) Analyse fat slice: 
a. If desired, change view to ‘Fire’ to see liver more clearly 
i. On Image J title menu, select ‘Image’ then ‘Lookup Tables’ 
ii. Select ‘Fire’ view 
b. Image J – select ‘analyze’, then ‘measure’ 
c. Gives mean/min/max values 
11) Repeat entire process for total of 3 slices 
12)  In results box, select ‘edit’ then ‘summarise’ – this will give mean / min / max / SD 
for all 3 slices analysed 
13)  Save ‘1, 2, 3, Mean, SD’ by ‘Copy’, ‘Documents’, ‘T1Tx’, ‘Afsara outputs summer 
2012 legacy’, ‘Templates’, ‘Mean/histogram templates’ – 
a. This file contains tabs with ‘Sheet 1 / Slice 1 / Slice 2 / Slice 3 / Mean 20 bin 
/ Mean 100 bin’ 
b. Paste ‘1, 2, 3, mean, SD’ into sheet 1 
c. Rename Slice Numbers 
14)  For Histograms: 
a. Press ‘H’ whilst analysing fat file 
b. On menu, type in ‘100 bins’ , unclick ‘min/max’, X min ‘0’, X max ‘100’, Y 
max ‘Auto’ 
c. Copy down SD into Xcel file ‘Sheet 1’ 
d. Copy Histogram to Xcel file for relevant slice 
i. Paste data on ‘0’ for 100 bin histogram – this gives you 100 bin and 
20 bin data automatically 
ii. Rename Slice tab 
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iii. Repeat for next 2 slices 
e. On ‘Mean 20 bin tab’, paste 20 bin values (include all values >0 only) for 
each slice, pasting ‘123 paste option’ 
i. Rename all columns appropriately 
ii. Empty boxes need to be zero (affects mean column values) 
f. Repeat step ‘e.’ for ‘Mean 100 bin tab’ and repeat for all 3 slices 
i. 3 x columns 
ii. Empty boxes need to be zero (affects mean column values) 
15)  On ‘islet’ and ‘Pump patient’ Xcel tabs, entered values will produce graphs 
16)  Xcel file for scan analysis now complete for selected T1Tx file 
17)  Before finishing, copy data to reference table file for all data 
a. On “Summary Sheet” “Sheet 1” of file, copy ‘Slice file values (eg 11, 12, 
13), mean & SD’, ‘Copy’ 
b. Open ‘T1Tx’ 
c. Select ‘Afsara_outputs_summer_2012_legacy’ 
d. Select ‘Tables’ 
e. Copy Means & SD in 3 slices fat PC into appropriate ‘Gus’ or ‘Afsara’ file 
 
 
C) Converting T1Tx files to ‘In and out phase’ files 
 
Looks at difference between fat and water phases to highlight areas of fat 
Allows identification of fat pattern quickly 
 
From University Login: 
1) Need to reimage in Matlab 
2) Choose appropriate ‘X’ or ‘Z’ drive 
3) Select ‘Analysis NMRC 20’, Right click and select ‘Folders and subfolders’ 
4) In command window, type ‘out of phase’ 
5) Choose ‘3’ files for analysis 
6) Select files in order of inferior, middle and superior 
7) This will give you 2 ‘out of phase’ images and 1 ‘in phase’ image in “Image J’: 
a. Select appropriate patient file: 
i. Choose ‘inphase.hdr’ / ‘outofphase.hdr’ / ‘outofphase2.hdr’ 
ii. Black lines are more clear on ‘out of phase’ images 
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8) Looking for exclusive fat pattern on ‘out of phase’ images that are not present on ‘in 
phase’ images 
a. Note decision of ‘yes’ or ‘no’ for whether exclusive fat pattern is present 
b. Record yes/no decision in appropriate Xcel file tab of ‘Gus’ or ‘Afsara’ file 
 
 
D) Altering Colour % on files to enhance fatty contrast on fat files 
 
From University Login: 
1) Open Matlab, select appropriate drive and then file 
2) Select ‘Analysis Program NMRC 20’ 
3) Select ‘Afsara_read’ 
4) Look for numbers in brackets (eg ‘[1,25]’), and set values as desired, then save 
5) Type ‘Afsara_read’ in command menu, then select ‘fatPC.hdr’ file for analysis 
6) This program gives 1-18 slices with altered % contrasts in image J 
a. Select the same 3 slices that were used for analysis 
b. Save images as ‘jpeg’ file in ‘image file’ appropriate T1Tx file 
i. In name of file, include Slice No / Min % / Max % (Lower 
percentage and upper percentage  borders for colour range) 
ii. Select to save as ‘jpeg’ file 
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